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Abstract 
Maturity-onset diabetes of the young (MODY) and congenital hyperinsulinism (CHI) 
are monogenic disorders of glucose-stimulated insulin secretion. MODY is the 
commonest form of monogenic diabetes and results from a heterozygous mutation in 
one of thirteen identified genes. It is estimated that up to 90% of cases of MODY are 
not diagnosed, possibly due to the insufficient awareness of or access to genetic 
screening. CHI is the commonest cause of persistent hypoglycemia in infancy and 
childhood, for which there are ten identified genes (mutation-positive disease found 
in 45% of all CHI, and 88% of diazoxide-unresponsive cases). 
Genetic confirmation of MODY and CHI traditionally involved Sanger sequencing of 
each exon of each gene individually; however, the development of massively parallel 
sequencing (MPS) allows simultaneous sequencing of multiple target regions 
efficiently and cost-effectively. This thesis assessed two forms of MPS - whole 
exome sequencing and targeted sequencing, in population and small family cohorts. 
An entire paediatric diabetes clinic underwent targeted MPS for MODY genes, which 
showed the prevalence of pathogenic/likely pathogenic MODY variants to be 2.1%. 
Based on these results, a cost-effectiveness analysis was performed, demonstrating 
that routine MPS screening for MODY in all paediatric cases with presumed type 1 
diabetes was cost-saving. 
The utility of WES was evaluated in MODY and CHI in a proof-of-concept study. 
Subjects with known mutations in MODY and CHI genes were re-sequenced using 
two “off-the-shelf” WES capture technologies. All mutations were confirmed; 
however, the study showed the importance of careful selection of appropriate 
capture technology to ensure targeting of relevant genes and the use of 
bioinformatics tools appropriate to mutation type.  
Seven probands diagnosed with MODY but without a previously identified mutation 
were also assessed using WES. Three novel variants in known MODY genes were 
identified by WES, which variants segregated with diabetes in the families. A 
potential novel MODY gene was also identified through sequencing of one extended 
family.  
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Six probands with CHI but without a known mutation were also sequenced. Two 
probands and their affected family members had the same variant in a potential 
novel CHI gene. 
MPS is an extremely useful addition to the diagnostic workup for paediatric cases of 
diabetes overall, in addition to its utility in screening clinically diagnosed MODY/CHI 
cases. Additionally, MPS can lead to novel gene identification for these conditions. 
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1.0   Introduction 
1.1   Glucose-stimulated insulin secretion 
The main function of the pancreatic beta cell is to synthesize and secrete insulin. 
Pancreatic beta cells sense blood glucose levels and adjust their insulin secretion 
accordingly. There are many stimulatory and inhibitory factors controlling the release 
of insulin, of which glucose is the most important. Any alteration in insulin secretion 
in response to glucose can lead to either hypoglycaemia (from excessive secretion 
relative to glucose levels) or hyperglycaemia and diabetes (insufficient secretion). 
There is a sigmoidal relationship between plasma glucose and insulin release [1], 
with a Km for glucose of 8mM, underlying the dependence of the beta cell insulin 
secretory response to glucose in the physiological range [2].  
In mammals, expression of the insulin gene and insulin biosynthesis occurs 
exclusively in the pancreatic beta cell (aside from the yolk sac and liver during foetal 
life) [3, 4]. The primary function of the pancreatic beta cell is the synthesis, storage 
and secretion of insulin. Insulin synthesis in the pancreatic beta cell is complex. 
Preproinsulin is the first translational product of INS. It consists of an A-chain, C-
peptide B-chain and signal peptide domain. Preproinsulin is translocated across the 
endoplasmic reticulum (ER) membrane, after which proteolytic cleavage of the signal 
peptide results in proinsulin. Within the ER, proinsulin undergoes oxidative folding 
forming three disulphide bonds, allowing exit from the ER into the Golgi apparatus. 
Proinsulin subsequently undergoes further cleavage to produce C-peptide and 
mature insulin, which are stored in secretory granules, which are released on 
demand. 
Glucose-stimulated insulin secretion (GSIS) involves the coupling of electrical activity 
with insulin secretion. Briefly, glucose enters the beta call via facilitated diffusion 
through the GLUT2 glucose transporter. Coupled with glucokinase (GCK), GLUT2 is 
thought to be part of the glucose-sensing mechanism responsible for GSIS. GCK is a 
hexokinase enzyme involved in modulating GSIS. Thus GCK is frequently referred to 
as the “glucose-sensor”. GCK phosphorylates glucose to glucose-6-phosphate 
(G6P) within the beta cell. Activating GCK mutations result in insulin secretion at 
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lower glucose levels - as in GCK-hyperinsulinism [5]. Inactivating mutations result in 
insulin secretion at higher glucose levels, as in GCK- MODY [6]. G6P undergoes 
further glycolysis to form pyruvate, which enters the mitochondria, where it is 
oxidised via the tricarboxylic acid (TCA) cycle. This ultimately results in the 
production of ATP from ADP, and other second messengers. 
Insulin secretion can also be stimulated by amino acids. Glutamate is oxidised to α-
ketoglutarate which also enters the TCA cycle to produce an increase in ATP. This 
reaction is catalysed by glutamate dehydrogenase (GDH), which itself is stimulated 
by leucine and ADP and inhibited by GTP. 
 KATP channels couple cell metabolism to membrane potential by regulating 
potassium (K+) fluxes. The KATP channel of the beta cell is an octomeric complex of 
four Kir6.2 subunits (encoded by KCNJ11) and four SUR1 subunits (encoded by 
ABCC8). The four Kir6.2 subunits form the inner pore; the outer sulphonylurea 
receptor (SUR) functions as the regulatory subunit. The SUR is sensitive to 
magnesium (Mg) nucleotides; can be activated by sulphonylurea medications; and is 
inhibited by KATP channel opener drugs (e.g. diazoxide). Binding of intracellular ATP 
to Kir6.2 closes the channel, whereas binding of ADP to SUR1 opens the channel. 
Thus the state of the channel is determined by the ATP/ADP ratio. Closure of the 
KATP channel allows depolarisation of the cell membrane. This activates voltage-
sensitive Ca2+ channels, resulting in an increase in intracellular Ca2+. The 
intracellular calcium activates insulin granule exocytosis.  
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Figure 1.1   Mechanism of insulin secretion by the pancreatic beta cell  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Green arrows indicate stimulation, red arrows indicate inhibition. 
αKG = alpha-ketoglutarate; SUR = sulphonylurea receptor; G6P = glucose-6-
phosphate; ATP = adenosine triphosphate; ADP = adenosine diphosphate; GTP = 
guanine triphosphate; GDH = glutamate dehydrogenase; GCK = glucokinase; 
SCHAD = short chain 3-OH acyl-CoA dehydrogenase 
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Monogenic disorders of insulin secretion illustrate the physiology of insulin secretion. 
Two such conditions are congenital hyperinsulinism (CHI) and maturity-onset 
diabetes of the young (MODY). 
 
1.2   Maturity-onset diabetes of the young (MODY) 
1.2.1   Definition 
The term MODY, short for “maturity-onset diabetes of the young”, is somewhat of a 
misnomer. The original description in the 1960s was of a “milder” form of diabetes in 
the young, which was characterised by fasting hyperglycaemia without evidence of 
ketonuria [7-10]. With advances in molecular genetics in the last 20 years, it has 
become clear that MODY is a separate genetic entity and not a subtype of type 2 
diabetes mellitus (T2DM).  
Monogenic diabetes results from the inheritance of a mutation or mutations in a 
single gene. Monogenic diabetes includes MODY, neonatal diabetes and syndromic 
diabetes. MODY, the most common form of monogenic diabetes, with individuals 
having a mutation in one of thirteen confirmed genes (with two potential additional 
genes recently reported). Affected individuals typically have diabetes with autosomal 
dominant inheritance, maintenance of endogenous insulin secretion, disease onset 
usually before 25 years of age, and a primary pancreatic beta-cell defect [11, 12].  
 
1.2.2   Prevalence of MODY 
The proportion of paediatric diabetes cases identified as MODY has been estimated 
as 0.14-2.5% [13-16]. The criteria for classifying MODY varies between studies and 
possibly account for the variance in prevalence data. In early studies (discussed in 
detail below), a diagnosis of MODY was based solely on clinical criteria (e.g. 
antibody-negative diabetes, family history, low/no insulin requirement and/or young 
age of onset). Later studies performed Sanger sequencing on a limited number of 
5 
 
genes. Given the number of causative genes and the time and cost of sequencing all 
currently identified genes using traditional Sanger sequencing, until recently no study 
had sequenced all MODY genes in an entire diabetes population, paediatric or adult. 
More recently, with the advent of massively parallel sequencing (MPS), studies have 
been able to sequence all known MODY genes (discussed below). But to date no 
study has sequenced an entire diabetes population; rather, only antibody-negative 
individuals have been sequenced.  
The first studies of MODY prevalence were performed in Germany and based on 
clinical criteria of young age of onset and no insulin requirement for at least 5 years. 
This suggested 0.14% of the paediatric diabetes population (0.007% of the general 
population) had MODY [17]. A second study from a district in Germany was based 
on clinical features alone, those being a diagnosis <25 years, autosomal dominant 
inheritance and successfully treated with oral hypoglycaemics for five years. By this 
definition, they claimed 1.8% of diabetes individuals had MODY, which would 
presumably also include many individuals with young-onset type 2 diabetes [13].  
A paediatric survey from Germany and Austria of 40,757 individuals diagnosed with 
diabetes before 20 years of age identified 0.65% as MODY, confirmed by genetic 
testing, after selecting patients for genetic testing based on the current clinical 
criteria [18]. Previous whole population-based study of people with diabetes (from 
Norway) reported a prevalence of 2.2 % based on clinical criteria (autosomal 
dominant inheritance and GAD antibody negative), with 0.4% confirmed with HNF1A 
mutations (the only gene sequenced in this study) [15]. 
A more recent study in Oxfordshire revealed a prevalence of genetically-confirmed 
MODY of 0.18% of those with diabetes (0.005% of the general population) [19]. The 
inclusion criteria for this study was glutamic acid decarboxylase (GAD) antibody 
negative individuals with evidence of endogenous insulin secretion (fasting C-peptide 
≥0.1 nmol/l) and either diagnosed at ≤30 years or ≤45 years with absence of 
metabolic syndrome. There were separate criteria for suspected GCK mutations. 
Despite screening 3280 people with diabetes, only six cases of HNF1A-MODY were 
detected and no HNF4A or GCK-MODY were found. No other MODY genes were 
screened.  
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Alternatively, one report of prevalence data was based on referrals for genetic 
testing, rather than a population-based strategy [20]. The largest study of MODY 
prevalence based on referrals for testing revealed an estimated minimum prevalence 
of 0.011% of the general population of the UK [20]. It is noteworthy that these were 
only genetically-confirmed cases. The greatest prevalence was noted in the region of 
Exeter; whose university is responsible for much of the research into MODY. There 
was a five-fold variation in rates of MODY within UK regions, which also correlated 
with the number of referrals, indicating that at least some of the variation results from 
unequal use of genetic testing. Consistent with this, the population of the UK has 
been demonstrated to have very little population stratification [21].  
Only one study of MODY prevalence has been performed in a paediatric Australian 
population [22]. 470 patients with presumed type 1 diabetes at a tertiary hospital 
were screened for antibody status. Nineteen remained persistently antibody 
negative; and were screened for HNF1A, HNF4A, KCNJ11, ABCC8 and INS 
mutations. One was found to have a mutation in HNF1A, suggesting 0.2% of this 
paediatric diabetes population had MODY. 
In 2016, Shepherd et al. recruited individuals from six diabetes clinics. Those who 
were antibody negative and had a urinary C-peptide creatinine ratio ≥0.2 nmol/mmol 
underwent targeted MPS for known monogenic diabetes genes [23]. The prevalence 
of monogenic diabetes (including MODY) in this population was 2.5%. 
 
1.2.3   Clinical Diagnosis of MODY and its implications 
The international society for paediatric and adolescent diabetes (ISPAD) has 
guidelines for the diagnosis and management of monogenic diabetes in children and 
adolescents [24]. It recommends screening for MODY in cases with: 
• A family history of diabetes in one parent and a first degree relative, and 
• Lack the characteristics of T1DM (no islet antibodies, low/no insulin 
requirement 5 years from diagnosis), and 
• Lack the characteristics of T2DM (marked obesity, acanthosis nigricans) 
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Separate criteria exist for GCK-MODY: mild stable fasting hyperglycaemia. 
Many subtypes of MODY (HNF4A, HNF1A, ABCC8 and KCNJ11) can often be 
treated with a sulphonylurea. Sulphonylurea use has been shown to be much more 
cost effective than insulin in neonatal diabetes caused by mutations in KATP channel 
genes [25]. Moreover, there is a lower risk of severe hypoglycaemia, potential for 
improved glycaemic control and greater quality of life compared to insulin therapy 
[26-29]. Thus the diagnosis of a MODY subtype may enable the patient to cease 
insulin which can be life-changing.  
Yet MODY is frequently misdiagnosed as Type 1 diabetes (T1DM) or T2DM. There 
is no definitive test to categorise diabetes as T1DM or T2DM, whereas there is (or 
could be) for MODY.  
 
1.2.4   Subtypes of MODY 
Since the identification of the first MODY gene, GCK, in 1993, there have been 13 
confirmed MODY genes characterised, the last KCNJ11 identified in 2012 [30-42]. 
Many of these genes have also been described in other disorders of insulin 
secretion, namely neonatal diabetes or congenital hyperinsulinism [43-46]. MODY 2 
(GCK) and MODY 3 (HNF1A) account for the majority of MODY [18, 20]. In most 
studies these two genes account for 80% of all diagnosed cases. However, the 
proportions of each appear to vary depending on the referral base. The largest 
published clinical cohort, reported by the Exeter group, found 52% of confirmed 
cases to be HNF1A, 32% GCK, 10% HNF4A, 6% HNF1B and the remainder INS or 
NEUROD1 [20]. In contrast, in continental Europe the ratios of the two most common 
genes are reversed, with 62% GCK, 31% HNF1A, 4% HNF4A and only 3% 
undiagnosed [18]  (noting that this study only sequenced  the three listed genes). 
These results may be determined by the criteria for referral at the differing 
sequencing centres rather than true population differences. For example, GCK 
mutations are more common in many mainland European countries who test glucose 
in asymptomatic individuals, whereas HNF1A is more common in the UK where 
random blood glucose testing is less common [47] 
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The features of each of the thirteen confirmed MODY subtype are summarised in 
Table 1.1. 
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Table 1.1 Characteristics of Maturity-Onset Diabetes of the Young (MODY) subtypes 
Gene Frequency 
 
[18, 20] 
Age at 
diagnosis 
Clinical features Mechanism of diabetes 
MODY1 
HNF4A 
[31, 48-58] 
4-10% Early 
adolescence 
onwards 
Can have LGA and hypoglycaemia as neonate 
Causes diazoxide-responsive hyperinsulinism, often with 
diabetes presenting later in same individual and/or family 
members  
SU sensitive 
Risk of microvascular disease high, related to glycaemic control 
Lower levels of lipoprotein A2 and HDL 
R76W have associated Fanconi renotubular syndrome 
Transcription factor for 
beta cell function and 
pancreatic development  
MODY2 
GCK 
[1, 33, 44, 59-65] 
32-63% Any age from 
neonate 
Usually mild, asymptomatic 
Elevated fasting glucose, with minimal glucose rise on OGTT 
SGA in heterozygous infants with an unaffected mother 
LGA infant if mother heterozygous, and infant not heterozygous 
No treatment usually required 
Non-progressive with a lack of microvascular complications 
Glucose-sensor 
MODY3 
HNF1A 
[26, 32, 66-74] 
31-52% Average 17-
22 years 
Risk of microvascular disease high, related to glycaemic control 
SU sensitive  
Progressive beta cell defect 
Glycosuria precedes diabetes 
Reduced first-phase insulin release 
Transcription factor for 
beta cell function 
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Recently identified in CHI, can occur in same family or individual 
as MODY 
MODY4 
PDX1 
[34, 37, 75-79] 
Rare 
(5 families with 
MODY) 
Post-pubertal Milder phenotype than HNF1A 
Same variants causing MODY can cause T2DM in older 
individuals 
Reduced first phase insulin release 
Pancreatic agenesis in homozygote patients 
Reduced beta cell number 
 
MODY5 
HNF1B 
[80-85] 
6% Post pubertal RACD – “renal cysts and Diabetes” 
Dysplastic kidneys, renal cysts, 
Mullerian structural abnormalities – absent or bicornuate uterus 
Liver function abnormalities, hypomagnesaemia 
Pancreatic hypoplasia, with mild exocrine abnormalities 
Role in early pancreatic 
development and 
differentiation 
MODY6 
NEUROD1 
[36, 86-91] 
Rare 
(11 probands) 
Variable Generally mild phenotype with one report of ketosis 
Variable penetrance. Four families with segregation through 
extended pedigrees 
Reduced insulin secretion 
Homozygous mutations cause NDM with cerebellar hypoplasia, 
learning difficulties and visual/hearing impairment 
Regulator of insulin gene 
expression and endocrine 
pancreatic development 
MODY7 
KLF11 
[38, 92, 93] 
Rare 
(3 probands) 
Variable Mild phenotype 
Reduced post-prandial insulin production 
One single report of KLF11 segregating with four-generation 
family with diabetes; and two unrelated families, one with 
possible phenocopies 
Pancreas development 
and beta cell insulin gene 
expression 
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MODY8 
CEL 
[39, 94-97] 
Rare 
(3 families) 
Ave 36yrs Endocrine and exocrine pancreatic abnormalities, including 
cysts 
Functional studies suggest the deletion mutation in MODY 
results in intracellular aggregates that increase ER stress and 
beta cell apoptosis 
Elevated fasting and postprandial glucose with reduced insulin 
Significant microvascular complications described in one family 
Role in exocrine and 
endocrine pancreas 
development 
MODY9 
PAX4 
[40, 98-101]
 
Rare 
(3 families) 
Post-pubertal Diabetes mild but significant microvascular complications 
described in one family 
No segregation in large pedigrees demonstrated 
Promotes β and δ cell 
expression from endocrine 
progenitors  
MODY10 
INS 
114, 156-158 
Rare Variable Variable phenotype, from mild to ketosis-prone. 
Same mutation can be seen in neonatal diabetes and in MODY 
Can have hyperproinsulinaemia, hyperinsulinemia or insulin 
deficiency 
Insulin deficiency from protein mis-folding and endoplasmic 
reticulum stress with beta cell apoptosis. Insulin resistance can 
develop from abnormal insulin receptor binding 
Encodes pro-insulin, 
precursor of insulin 
MODY11 
BLK 
[42, 92] 
Rare 
(3 families) 
Ave 30yrs Variable phenotype – penetrance higher with greater BMI 
Elevated fasting and postprandial glucose 
Based on a single report 
Upregulated transcription 
factors stimulating insulin 
synthesis and secretion 
MODY12 
ABCC8 
[26, 28, 30, 70] 
Rare Variable Variable phenotype – same mutations can present with MODY, 
NDM and CHI , even in same family 
SU sensitive 
Failure to close KATP 
channel 
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MODY13 
KCNJ11 
[46, 102, 103] 
Rare Variable Variable phenotype – can present with NDM – permanent or 
transient and/or MODY or asymptomatic 
SU sensitive 
Failure to close KATP 
channel 
MODY 14 
APPL1* 
[104] 
 
Rare 
(2 families) 
Over 20 
years 
Variable penetrance. 
Family 1: 20 individuals with APPL1 – 10 with diabetes, 
Family 2: 4 individuals with APPL1 mutations – 3 with diabetes; 
plus 2 with diabetes without APPL1   
Increased AKT2 activation 
and insulin secretion,  
MODY 15 
RFX6* 
[105-110] 
Rare 
(9 individuals) 
Median age 
15y 
Recessive inheritance results in Mitchell-Riley syndrome – 
absence of pancreatic islets, intestinal atresia, gallbladder 
hypoplasia and intractable diarrhoea 
Dominant mutations have diabetes alone with reduced 
penetrance (27% by 25 years) and not SU responsive 
Modulates insulin 
expression and secretion 
by effect on calcium 
channel expression  
SU, sulphonylurea; CHI, congenital hyperinsulinism; SGA, small for gestational age; LGA, large for gestational age; BMI, body 
mass index; HDL high density lipoprotein ; NDM, neonatal diabetes mellitus; OGTT, oral glucose tolerance test. 
Genes marked with an asterisk were not known at the commencement of this PhD and have been identified during the course of 
these doctoral studies. 
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1.3   Congenital hyperinsulinism 
1.3.1   Overview 
Hyperinsulinism (HI) can result in dangerously low blood glucose levels. It can 
present in the neonatal period, and can be either permanent or transient. It can also 
be an acquired condition, presenting in infancy through to adulthood. 
Hyperinsulinaemic hypoglycaemia is the most common cause of neonatal 
hypoglycaemia and if untreated can result in permanent brain injury [111]. It results 
from dysregulated insulin secretion from pancreatic beta cells. Congenital 
hyperinsulinism (CHI) is caused by mutations in one of ten known genes: ABCC8 
and KCNJ11 [112, 113], which encode the two subunits of the KATP channel; and 
GLUD1 [114], CGK [115], HADH [116], UCP2 [117], SLC16A1 [118], HNF4A [57], 
HNF1A [119] and HK1 [120], which fall under the category of metabolopathies 
(“metabolopathies” refers to conditions which alter the concentration of intracellular 
signalling molecules of intermediary metabolites). HI may also occur in the context of 
various syndromes or in association with perinatal stress [121]. These are beyond 
the scope of this study, which will focus on the isolated CHI syndromes.  
CHI was traditionally classified as responsive or non-responsive to medical 
therapies, namely diazoxide. Initially KATP channelopathies were all thought to be 
diazoxide-unresponsive and all other forms diazoxide-responsive. With more 
detailed investigation of genotype-phenotype correlations, this pragmatic approach 
to classification has been deemed overly simplistic. Ultimately a classification of CHI 
based upon genetic analysis should enable a greater understanding of this complex 
condition.  
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1.3.2   Clinical description 
Prevalence 
CHI is a heterogeneous condition in terms of clinical presentation, histological 
subgroups and molecular biology [122]. Both sporadic and familial forms of CHI 
exist, with sporadic form relatively uncommon (incidence 1 case per 40,000−50,000 
live births) and familial forms relatively common in some populations (about 1 case 
per 2,500 in communities with high rates of consanguinity) [123-126] . 
 
Clinical features 
CHI is the result of dysregulated insulin secretion from the beta cell of the pancreas 
in relation to prevailing blood glucose. Inappropriately elevated insulin causes 
increased glucose uptake in insulin-sensitive tissues (e.g. skeletal muscle, adipose 
tissue and liver) and inhibits glucose production (i.e. gluconeogenesis and 
glycolysis). Together, these processes cause profound hypoglycaemia particularly 
whilst fasting, after exercise, and/or post-prandially after ingestion of a protein-rich 
meal [127] . Increased insulin secretion also inhibits lipolysis and ketogenesis. The 
combination of hypoglycaemia and lack of ketones places infants at high risk of 
neurological damage [128]. Thus rapid diagnosis and appropriate management are 
critical to prevent poor neurodevelopmental outcomes [129]. 
CHI most commonly presents in the newborn period, but can occur in infancy or 
childhood [111, 122]. Hypoglycaemia can induce non-specific symptoms such as 
lethargy or poor feeding through to apnoeas, seizure and coma. As a result of foetal 
hyperinsulinism, some children (especially those with an HNF4A mutation) are born 
macrosomic, although the absence of macrosomia does not exclude hyperinsulinism 
[130]. They can also present with hepatomegaly, muscle hypertrophy and 
hypertrophic cardiomyopathy as a result of increased glycogen stores and, possibly, 
the growth factor-like properties of insulin [57, 131, 132]. Hypoglycaemia may occur 
after a relatively short period of fasting, while patients with hyperinsulinism and 
hyperammonaemia may present with hypoglycaemia following a protein/leucine load 
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[133, 134]. Those with exercise-induced CHI typically develop hypoglycaemia after 
exercise [118, 135, 136].  
 
1.3.3   Diagnosis 
Early diagnosis and treatment is essential to prevent the devastating consequences 
of neonatal hypoglycaemia and hypo-ketonaemia [129]. The primary biochemical 
feature of CHI is an inappropriately normal or elevated insulin level in the context of 
hypoglycaemia. The metabolic effects of insulin will also result in suppressed plasma 
β-hydroxybutyrate and free fatty-acid levels. An exaggerated glycaemic response to 
glucagon at the time of hypoglycaemia is also consistent with excess insulin action 
and is useful for confirming the diagnosis [137]. An important clue to the presence of 
dysregulated insulin secretion is an increased glucose requirement to achieve 
normoglycaemia – a glucose infusion rate of >8mmol/kg/min (normal 4-6mg/kg/min) 
is virtually diagnostic of CHI [138]. Additional laboratory tests for specific forms of 
CHI include plasma ammonia levels (increased in GLUD1 mutations) and a plasma 
acyl-carnitine profile (3-hydroxybutyrylcarnitine) and urine organic acids (3-
hydroxyglutarate) (both of which are increased in HADH mutations) [139]. In patients 
with CHI resulting from GLUD1 mutations, a leucine provocation test may be 
required to demonstrate CHI. Similarly patients with SLC16A1mutations may 
demonstrate hypoglycaemia following an exercise test.  
 
1.3.4   Management of CHI 
Medical management 
The aim of treatment is to correct episodes of hypoglycaemia rapidly and avoid 
recurrent hypoglycaemia to prevent the risk of severe neurological abnormalities. 
Initial treatment usually requires intravenous dextrose, often in high concentrations 
that necessitate central venous access [138]. In addition long term enteral 
carbohydrate may be best delivered by nasogastric or gastrostomy feeding, 
particularly for overnight maintenance of normoglycaemia. Management of patients 
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with protein-sensitive hypoglycaemia may also involve specialised feeding regimens 
to provide glucose-rich, protein-free feeds. Simple dietary manipulation alone, 
however, is rarely sufficient to ensure normoglycaemia in these patients and a 
number of medical therapies employed in managing patients with CHI are discussed 
below. 
Diazoxide: This is the first-line medical therapy for patients with hyperinsulinism. 
Diazoxide binds to the SUR1 component of the KATP channel. It acts by maintaining 
the KATP channel in an open position, preventing depolarisation of the beta-cell 
membrane and insulin secretion.  
In order for diazoxide to be effective, a functional KATP channel is necessary. Thus 
many patients with mutations in ABCC8 or KCNJ11 (especially recessive mutations) 
do not respond to diazoxide. However, there are some dominant forms of KATP 
channelopathies that are responsive to diazoxide [140]. Conversely, there are 
reports of patients with GCK mutations unresponsive to diazoxide [44]. Patients who 
are classified as diazoxide-unresponsive often require pancreatic resection or more 
intensive medical management. 
Sirolimus: In 2014 the use of the mTOR inhibitor, sirolimus in the treatment of 
diazoxide-unresponsive cases of CHI was reported [141]. It was hoped this would 
revolutionise the management of diazoxide-unresponsive CHI and obviate the need 
for surgery, with all its inherent long-term complications. A number of short-term 
case reports followed with cases of CHI either avoiding operation or a second 
operation with the use of sirolimus [142-144]. A subsequent paper on the use of 
sirolimus in ten individuals, reported an efficacy of only 30%, with significant side-
effect profile: elevated triglycerides, anaemia requiring bloods transfusion, stomatitis, 
sepsis, gut dysmotility with exocrine pancreatic insufficiency [145]. Thus a trial of 
sirolimus is only recommended in severe cases of CHI and should be used with 
caution.  
Octreotide: Octreotide is a somatostatin analogue, used as a second-line agent in 
diazoxide unresponsive CHI. Octreotide has an insulin-inhibitory effect, in addition to 
exerting multiple effects on the gastrointestinal tract, the majority of which result from 
a reduced mesenteric blood flow  [146]. In a study of 28 subjects with CHI, 43% 
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avoided surgery with octreotide and manipulation of feeds [147]. However, a number 
of individuals experienced significant side-effects, including elevated liver enzymes, 
gall bladder pathology, necrotising enterocolitis [148] and a case of long QT 
syndrome [149]. Octreotide is administered with multiple subcutaneous injections per 
day, or by continuous subcutaneous infusion. More recently long acting somatostatin 
analogues (LAR octreotide [Sandostatin LP, Novartis] or Lanreotide [Ipsen, Paris]) 
have shown efficacy in managing CHI and can improve quality of life by reducing the 
number of injection from 3-4 per day to 1 per month [150, 151].  
Surgical management 
The management of children who do not respond to diazoxide has changed 
dramatically in the past few years due to advances in molecular genetics, 
radiological techniques, surgical and medical management. It is important to 
differentiate those with a focal lesion, who can be essentially “cured” with a limited 
pancreatectomy, from those with diffuse disease, who require more extensive 
surgery with considerable risk of diabetes and pancreatic exocrine dysfunction [129, 
152, 153]. Ideally this distinction should be made quickly as the neurological 
outcome in these children is improved if surgery is not delayed [129].  
The distinction between focal and diffuse disease is aided by a genetic diagnosis. 
Homozygous or compound heterozygous ABCC8 or KCNJ11 mutations and GLUD1, 
CGK, HADH, UCP2, SLC16A1 and HNF4A mutations are associated with diffuse 
disease. Patients with only a paternal mutation in ABCC8 or KCNJ11 or no 
detectable mutation may have focal disease and could be potentially cured by 
surgery.  
18
 F-DOPA PET in distinguishing focal from diffuse disease 
The major advancement in the management of CHI in the last decade has been the 
introduction of preoperative fluorine-18-L-3,4- dihydroxyphenylalanine positron 
emission tomography–computed tomography (18 F- DOPA PET-CT) scanning. This 
is generally reserved for patients unresponsive to medical therapy who may require 
pancreatectomy. The aim of 18 F- DOPA PET-CT scanning is to distinguish diffuse 
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from focal CHI pre-operatively, and direct surgery accordingly. Infants with genetics 
suggesting diffuse disease may not require further imaging 
The dopamine localization provided by PET-CT correlates with the 
immunohistochemical positivity for DOPA decarboxylase, proinsulin, and insulin in 
pathological foci. At present 18F-DOPA PET scanning is available in a limited number 
of centres, one of which is Brisbane, Australia. As transferring children with unstable 
blood glucose levels is not without risks, it is currently reserved for patients with a 
genetic diagnosis suggestive of focal disease (or not suggestive of diffuse disease). 
This highlights the importance of a rapid, accurate genetic analysis for these 
patients. There has been one report of a focal lesion in a diazoxide-responsive 
patient [124]; which raises the possibility of expanding the indication for 18F-DOPA 
PET scans to include diazoxide-responsive patients. 
 
1.3.5   Genetics 
CHI is a heterogeneous disease in which mutations of ten different genes have been 
described (ABCC8, KCNJ11, GLUD1, GCK, HADH, UCP2, SLC16A1, HNF4A, 
HNF1A and HK1). Mutations in the genes for the KATP channels of the beta cell 
(ABCC8 and KCNJ11) are the most common, accounting for 40-45% of cases. 
Mutations in the other eight genes account for 5-10% of cases. Approximately 45-
55% of cases have no identifiable genetic basis [154].  
Flanagan et al. reported a KATP channel mutation in 88% of their diazoxide-
unresponsive cohort; no mutation (in KATP or other genes) was detected in the 
remaining 12%. Of the diazoxide responsive cohort, 73% had no identifiable 
mutation – it is not clear how many genes were screened in each patient [154]. 
CHI has traditionally been described as diazoxide responsive or unresponsive, which 
was thought to correspond to the metabolopathies and channelopathies respectively. 
However, with the advances in molecular genetics in the last decade, it has become 
clear that this distinction is not so simple; as there are diazoxide-responsive 
channelopathies and unresponsive GCK mutations [140, 155, 156].  
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KATP channel mutations 
The most common cause of CHI are mutations in ABCC8 and KCNJ11 (encoding 
the two subunits of the beta cell KATP channel, SUR1 and Kir6.2). ABCC8 and 
KCNJ11 are co-localised genes on chromosome 11p15 [157]. 
Diffuse disease  
Diffuse lesions can be divided into: 
1. Autosomal recessive 
2. Autosomal dominant – diazoxide unresponsive 
3. Autosomal dominant – diazoxide responsive. 
Groups 1 and 2 are clinically indistinguishable except for family history. Affected 
children are frequently large for gestational age due to foetal hyperinsulinaemia, 
typically present within hours of birth, and fail to respond to diazoxide [158].  
Autosomal recessive mutations are the most common forms of KATP channel 
mutations, and the most common form of CHI in general [154]. The carrier frequency 
of any KATP channel mutations in the general population is around 1:150 [159]. The 
frequency of a KATP mutations is much higher in some populations (up to 1:50), due 
to founder mutations (e.g. V187D in the Finish population and p.delPhe1388 among 
the Ashkenazi Jewish population [124, 125]). Carriers have normal glucose 
tolerance.  
Dominant mutations are much less common than recessive mutations. Phenotypic 
expression can vary, even with the same genotype; some carriers have diazoxide-
responsive CHI, one has been reported with diazoxide-unresponsive CHI, some 
have diabetes and others are completely asymptomatic [140].  
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Focal disease 
The ability to detect focal lesions either by genetics or imaging has been a major 
advance in the management of CHI. These children can be “cured” with a limited 
pancreatectomy. 30-60% of diazoxide-unresponsive CHI cases are focal [152, 160, 
161]. Focal disease is caused by paternal inheritance of a recessive ABCC8 or 
KCNJ11 mutation with somatic loss of heterozygosity in the distal portion of the short 
arm of the maternal chromosome 11 (11p15, a region including 11p15.1 which 
includes the non-imprinted genes, ABCC8 and KCNJ11 and 11p15.5, which include 
the imprinted genes discussed below) [162]. The loss of heterozygosity unmasks the 
paternally inherited KATP channel mutation and alters the expression of a range of 
imprinted genes - including the maternal tumour suppressor genes H19 and 
CDKN1C and the paternally expressed growth factor IGF-2, at 11p15.5. The overall 
effect of this alteration of gene expression is the promotion of cell growth [163, 164]. 
The risk of focal-CHI is 1:540 per pregnancy in offspring of carrier fathers [125]. 
Typically focal disease does not respond to diazoxide therapy, although one case of 
focal diazoxide-responsive CHI has been reported in the literature [165]. These 
patients could be “cured” with a limited pancreatic resection and avoid both a lifetime 
of diazoxide exposure and insulin-dependent diabetes. Thus, it is important to 
investigate the diazoxide-responsive cohort for a genetic and radiological diagnosis 
suggestive of focal disease. 
 
The Metabolopathies 
GLUD1-CHI: Activating mutations of glutamate dehydrogenase are due to a 
heterozygous mutation in GLUD1 and result in hyperammonaemic hyperinsulinism 
(HI/HA) syndrome [114, 133]. It is the second most common form of CHI, after the 
KATP channel defects, accounting for 6% of patients with diazoxide-responsive CHI 
[130]. The majority of these mutations occur de novo. However, 30% are inherited in 
an autosomal dominant fashion [166]. Affected children are typically of normal birth 
weight and present aged 4-12 months with protein-sensitive hypoglycaemia, 
responsive to diazoxide. Plasma ammonia levels are typically 3-5 times the normal 
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range. They have a high rate of neurodevelopmental delay and seizures, unrelated 
to episodes of hypoglycaemia. Some carriers may be asymptomatic, or present as 
an adult with hypoglycaemia and/or seizures [167]. The mechanism of the CNS 
disorder in HI/HA is unknown. 
HADH-CHI: Deficiency of the enzyme short 3-hydroxyacyl-CoA dehydrogenase 
(HADH, previously known as SCHAD) is a rare autosomal recessive form of 
congenital hyperinsulinism caused by mutations in HADH. HADH is a mitochondrial 
enzyme, that catalyses the conversion of medium- and short-chain L-3-hydroxyacyl-
CoA’s to long-chain acyl-CoA and is the penultimate reaction in the β-oxidation of 
medium and short-chain fatty acids [139]. In addition to abnormal carnitine profile, 
many of these patients display protein-sensitive insulin secretion, similar to GLUD1-
CHI. Flanagan et al. reported a rate of HADH mutations of 10% in patients with 
diazoxide-responsive CHI after exclusion of the more common genes (ABCC8, 
KCNJ11, GCK and HNF4A) [168]. These patients have a similar biochemical profile 
to GLUD1-CHI. 
GCK-CHI: Activating mutations of GCK were the third mutation found to cause CHI 
in infants, after GLUD1-CHI and the KATP channel mutations [115]. GCK mutations in 
CHI are inherited in an autosomal dominant manner (76%) or as de novo mutations 
[156]. The frequency of GCK mutations in CHI varies from 0.9% to 6.9%, depending 
on the population sampled [5, 130]. It was generally thought that GCK-CHI was a 
mild disease and responsive to diazoxide [44, 115, 169]. However, some patients 
with GCK mutations have failed to respond to diazoxide, and required 
pancreatectomy [156].  
HNF4A-CHI: Hepatocyte nuclear factor 4-alpha (HNF4A) was the first transcription 
factor to be described in MODY (MODY 1). In 2007 a study examined the rates of 
hypoglycaemia and foetal macrosomia in offspring of families with MODY 1 [57]. 
Heterozygous carriers have a substantial (790g) increase in birth-weight and 
transient hyperinsulinism was noted in 8/54 carriers [130]. HNF4A-CHI usually 
presents within the first week of life (median day 1) and is diazoxide-responsive. 
Infants may require diazoxide for a few months; however, one eight-year-old child 
has been described still requiring diazoxide. Mutations in HNF4A account for 5% of 
the infants with diazoxide-responsive CHI. There is currently no established 
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genotype-phenotype correlation: within the same family, some carriers will remain 
unaffected, some will develop CHI, some develop diabetes and yet others will have 
CHI as an infant and develop diabetes as an adult [45, 57, 130].  
SLC16A1-CHI: Exercise-induced hyperinsulinism is a rare disorder that has been 
described in three index cases: once as an isolated case, and twice in individual 
families with an autosomal dominant inheritance [135, 136, 170]. Affected cases 
present with hyperinsulinaemic hypoglycaemia, usually within 30 minutes of intense 
anaerobic exercise. These patients are frequently sensitive to diazoxide. However, 
they are frequently asymptomatic with avoidance of intense exercise [118]. 
UCP2-CHI: The mitochondrial uncoupling protein 2 (UCP2) is a member of the UCP 
family, expressed in a variety of tissues including pancreatic islets and is suspected 
to attenuate insulin secretion by decreasing the ATP/ADP ratio or modulating the 
production of reactive oxygen species [171]. In 2008, Gonzalez-Barroso identified a 
heterozygous mutation in UCP2 in two of ten children with CHI with no previously 
identified mutation in known CHI genes [117]. Functional assays in yeast and in 
insulin-secreting cells revealed an impaired activity of UCP2 mutants. 
HNF1A-CHI: Recently HNF1A was identified as a CHI gene [119]. Loss of function 
of HNF1α has been identified in macrosomic neonates and neonates and infants 
presenting with diazoxide-responsive CHI. As with HNF4A-CHI, HNF1A-CHI often 
has reduced penetrance, with some heterozygotes carriers having diabetes and 
some are asymptomatic. Affected children are at risk of developing diabetes 
themselves in their second or third decade; the diabetes is usually responsive to 
sulphonylurea. The mechanism for the hyperinsulinism followed by insulin deficiency 
is not known.  
HK1-CHI: To date there is only a single report of an association between HK1 and 
CHI. In 2013 Pinney et al. identified a dominant form of CHI that mapped to HK1 
locus [172]. A large pedigree of 25 affected individuals were identified with 
hyperinsulinism. The clinical presentation even within this family was variable. 
Clinical data from 15 individuals with CHI was available: age of presentation was 3-
17 months, 12 individuals were diazoxide responsive, and two required 
pancreatectomy. A further five individuals were identified as obligate carriers. DNA 
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from 31 individuals were used for the linkage analysis, but only one for whole 
genome sequencing and gene capture. Three variants were identified, all of which 
were intronic. This dominant gain-of-function mutation is predicted to cause 
expression of HK1 which is usually silenced in the pancreatic beta cell. Henquin et 
al. reported somatic overexpression of HK1 in beta cells from focal CHI samples, but 
no somatic HK1 mutations were identified [173].  
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1.4   Massively parallel sequencing technology  
In the decade since the initial publication of the reference human genome [174, 175], 
there has been a fundamental shift in the approach to genetic sequencing and 
analysis. This has been brought about by the completion of the first draft of the 
human genome project in 2001 and the development of new technologies and 
statistical approaches [176]. The introduction of massively parallel sequencing 
([MPS], also known as next generation sequencing, [NGS]) has revolutionised 
genomic sequencing, making it possible to sequence large amounts of DNA in a 
faster and more cost-effective manner. 
There are multiple platforms in use for MPS. The common feature of these methods 
is that they are ‘massively parallel’, meaning that the number of sequence reads 
from a single experiment is vastly greater than the single read per sample well 
obtained with modern capillary electrophoresis-based Sanger sequencers. My 
project uses Illumina platforms, which I will discuss below. (For a description of other 
sequencing platforms, see excellent review articles [177-179]) 
The massively parallel genome analyser system developed by Illumina is based on 
sequencing by synthesis. Bases of small fragments of genomic DNA are sequentially 
identified from signals emitted as each fragment is re-synthesized from a DNA 
template strand. MPS technology is not limited to sequencing genomic DNA and can 
also be used for transcriptomes and epigenomes [180]. In addition to genomes, this 
technology can be used for whole exomes or a limited number of exons using 
targeted sequencing (also known as panel sequencing). When sequencing smaller 
regions, there is the opportunity to use a lower output instrument and process a 
smaller number of samples per run, or to process a large number of samples by 
multiplexing on a small or high-throughput instrument. Multiplexing enables large 
sample numbers to be sequenced simultaneously during a single experiment. To 
accomplish this, individual “barcode” sequences are added to each sample so they 
can be differentiated during subsequent data analysis.  
The following is a description of the process of WES specifically, although the 
process is broadly similar for panel sequencing and whole genome sequencing 
(WGS). Input DNA is fragmented enzymatically or by focused ultrasonication to 
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generate a smear of fragments peaking at approximately 200bp. The fragments are 
blunt ended and phosphorylated, and a single ‘A’ nucleotide is added to the 3’-ends 
of the fragments. Then DNA fragments are ligated at both ends to adapters and to 
“barcode” sequences for multiplexing samples. The library is amplified by PCR and 
then hybridised to a pool of biotinylated oligonucleotides specific for the desired 
sequence (“baits”), either targeting all the exome (approx. 200,000 exons) or 
selected exons for targeted sequencing. Streptavidin magnetic beads are used to 
separate genomic-bait hybrids, thus creating a library of DNA fragments, which is 
further amplified and sequenced in flow cells. 
DNA fragments are immobilized at one end on a solid support-flow cell. The surface 
of the support is coated densely with the adapters and the complementary adapters. 
Each single-stranded fragment, immobilised at one end on the surface, creates a 
‘bridge’ structure by hybridising with its free end to the complementary adapter on 
the surface of the support. In the mixture containing the PCR amplification reagents, 
the adapters on the surface act as templates for the following PCR amplification. The 
tethered fragments are then replicated using several rounds of PCR to form a very 
dense cluster. After amplification, sequencing begins with the addition of 
fluorescently labelled reversible dNTP terminators to the nucleic acid chain. After the 
corresponding complementary base has been incorporated into the first position, the 
unincorporated reagents are washed away, a laser is used to excite the bound 
fluorescent labels, and the signal is recorded. The fluorescent label and the 
terminating group attached to the incorporated base are then removed, allowing for 
further extension of the DNA fragment. The DNA extension reaction is reinitiated by 
adding more labelled dNTPs and DNA polymerase to extend the growing fragment 
by one modified base. The reagents are washed away and the second position is 
interrogated by laser excitation of the fluorophore. The process is then repeated for 
multiple cycles, depending on the library being sequenced. The Illumina HiSeq 2500 
is capable of read lengths of up to 150bp. In addition, the reported throughput for this 
instrument can be up to 600Gb per run, taking 10-14 days, or as little as 27 hours for 
run generating 120GB of data. The newest platforms have optical modifications 
enabling analysis of higher cluster densities. Illumina and other MPS technologies 
have devised strategies to sequence both ends of template molecules. Such “paired-
end” sequencing provides positional information that facilitates alignment and 
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assembly, especially for short reads. The approximate interval between the 
sequence read from one end and the other is known (because the approximate DNA 
fragment length is known in advance). This makes paired end reads easier to map 
against the reference sequence during data analysis. 
 
1.4.1   Whole exome sequencing  
The exome represents about 1% of the human genome with approximately 30 million 
base pairs [181] but accounts for over 85% of all mutations identified in Mendelian 
disorders [182]. As a result, exome sequencing is currently an attractive and 
practical approach for investigation of coding variations, as it affords lower 
sequencing costs and higher sample throughput compared with sequencing the 
whole genome. Exome capture allows an investigation of the complete protein-
coding regions in the genome. The goal of this approach is to identify the functional 
variation that is responsible for diseases without the high costs associated with 
whole-genome sequencing while maintaining high coverage in sequence depth.  
 
1.4.2   Targeted sequencing 
Targeted sequencing offers a cheaper and efficient alternative to WES. Panels can 
be customised for regions of interest. This generated a much smaller amount of data 
for subsequent analysis and storage. As the total area to be sequenced is smaller 
than with WES, it can be sequenced to greater depth and generally multiplexed in 
greater numbers to reduce costs. The downside of panel sequencing is the inability 
to re-analyse data in light of new gene discoveries and the need to design new 
panels in this instance.  
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1.4.3   Limitations 
Some of the limitations of MPS are similar to other technologies e.g. the need to 
confirm a new variant is pathogenic. However, MPS gives rise to its own challenges. 
MPS experiments generate unprecedented volumes of data, which present 
challenges for data management, storage, and, most importantly, analysis  [183]. 
DNA sequences (‘reads’) produced by the new technologies are much shorter than 
sequences produced by capillary sequencers. The shorter read lengths mean that 
alignment and assembly are substantially more difficult for MPS data than for Sanger 
data. One limitation of short-read alignment and assembly is the inability to align 
large portions of a read set uniquely when the read length becomes too short. 
Similarly, the probability of repetitive sequences reduces the ability to align reads. 
Error rates for individual MPS reads are higher than for Sanger sequencing, and 
these errors were not random throughout the read. One study using the Illumina 
platforms found an error rate of 0.3% at the beginning of the read and 3.8% at the 
end of the read. There was also a difference in the base transversions with A>C the 
most common and C>G the least frequent [184].  
Accuracy in MPS is achieved by sequencing a given region multiple times, enabled 
by the massively parallel process, with each sequence contributing to “coverage” 
depth. Through this process, a “consensus” sequence is derived. To assemble, 
align, and analyse MPS data requires an adequate number of overlapping reads, or 
coverage. Beyond sequence errors, inadequate coverage can cause failure to detect 
actual nucleotide variation, leading to false-negative results for heterozygotes. For 
the Illumina system, higher coverage depths (50- to 60-fold) have been used in an 
effort to improve short-read alignment, assembly, and accuracy, although coverage 
in the 20- to 30-fold range may be sufficient for certain resequencing applications 
[184]. Coverage is determined by the number of bases able to be sequenced per run 
and the size of the region (i.e. number of bases) to be sequenced. 
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1.5   Evolution of genetic sequencing technology for new 
gene discovery (using MODY as an example) 
For the majority of the twentieth century, linkage was the main tool to elucidate the 
genetics of Mendelian disorders. Linkage relies upon the co-segregation of a genetic 
locus with a disease phenotype within a family. Many rare disorders are amenable to 
linkage analysis – those with a clear Mendelian inheritance, that are highly 
penetrant, and that occur in sufficiently large pedigrees with multiple meiosis. Some 
conditions are less well suited to linkage: those with few affected individuals will 
result in underpowered analysis. Similarly, conditions likely to undergo selection, 
either with early lethality or low reproductive fitness, will reduce the number of 
available individuals for analysis.  
Substantial progress has been made in human genetic and genomic research since 
the publication of the human genome and the advent of MPS. In particular, MPS has 
greatly facilitated discovery of causative genes in Mendelian conditions, in which 
traditional linkage analysis has failed. Genetic discoveries can be made by 
sequencing fewer individuals, including small families or unrelated cases, or even a 
single proband for some recessive conditions [185]. 
MODY was originally identified by Cammidge in 1928 as a mild familial form of 
diabetes [186]. While the familial nature of diabetes was known, it was not until 1974 
that its autosomal dominant inheritance was recognised [187]. It took nearly 50 years 
from identifying and genotyping the first MODY pedigree (RW pedigree) of over 300 
subjects, to identifying the genetic cause in this pedigree [31, 49]. Although the 
majority of MODY genes have been identified to date using linkage approaches, 
nowadays, this could be performed more efficiently and cost-effectively by 
interrogating fewer subjects using MPS, as was the case with KCNJ11-MODY 
(discussed below). 
This chapter will explain the progression from traditional linkage studies through to 
gene discovery using newer sequencing technologies, particularly with relevance to 
MODY research.  
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1.5.1   Linkage analysis 
DNA sequences of any two individuals are believed to be 99.9% identical [188]. 
However, linkage studies are based on utilising the variability in the genome. Genetic 
material is encoded from maternal- and paternal-donated chromosomes. During 
meiosis, chromosome pairs exchange material during their first cell division; the 
process of crossing over is called recombination. Recombination is more likely to 
occur between two loci that are far apart on a chromosome. Hence loci that are 
closely located on a chromosomal strand are more likely to be inherited together. 
These loci that are co-inherited are “linked”.  
Markers, typically single nucleotide polymorphisms (SNPs) (but can be tandem 
repeats, insertions or deletions, or restriction fragment length polymorphisms) can be 
genotyped. Linkage analysis tracks the genetic markers and DNA segments as they 
are transmitted between family members. Linkage studies detect co-segregation of 
the marker allele with the disease phenotype within a family (demonstrated in Figure 
1.2). The size of the disease-causing region within the family is determined by the 
number of recombination events i.e. number of meioses. Recombination frequencies 
can be converted to a genetic distance as measured by Morgans. One centiMorgan 
is equivalent to a 1% chance of recombination. 
The LOD (logarithm of odds) score is a metric by which the evidence for linkage can 
be calculated. The LOD score provides a logarithm (base 10) of the probability the 
genotyped marker is linked to the disease locus compared to the probability of 
observing the co-segregation by chance. A LOD score of 3 corresponds to p=0.001, 
meaning the loci are 1000 times more likely to be linked than inherited together by 
chance suggested as a minimum cut off for declaring linkage [189]. A LOD score of < 
-2 excludes linkage 
A small pedigree, with few meiotic events, results in low resolution for detection of 
the causative gene. On the other hand, large pedigrees with multiple meiotic events 
can be very powerful, and disease genes can be mapped with a single affected 
family. However, even with large pedigrees, the areas of linkage will often extend for 
10-20cM (approximately 10-20million bases, or approximately 60-120 genes). Fine 
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mapping within the region or genotyping candidate genes within that region can 
identify the causative genes.  
 
Figure 1.2  Linkage within a family 
 
 
 
Inheritance of causative locus (red) within an ancestral chromosome (blue) over 
three generations. With each meiosis, the region linked with the causative locus 
decreases as recombination occurs. 
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1.5.1.1   Linkage analysis in MODY1-RW prdigree 
The RW pedigree consisting of more than 360 members over six generations, 
including 74 with diabetes, was studied prospectively from 1958 and provided one of 
the breakthroughs in MODY research [49, 50]. The first breakthrough occurred in 
1991, when Bell et al. identified segregation of MODY with a polymorphism in the 
ADA gene on the long arm of chromosome 20. This was identified after assessing 75 
DNA markers, separated by approximately 20cM. At first, assuming all diabetes in 
this pedigree was due to MODY, the region on chromosome 20q provided a LOD 
score of 1.9. However, on closer examination, it was realised that several individuals 
had a different phenotype with older age of onset of diabetes and insulin resistance 
with hyperinsulinism as opposed to insulin deficiency as seen in other members. 
When linkage analysis excluded family members with an age of onset >25 years, 
linkage between MODY and the ADA locus provided a LOD score of 5. This 
highlights the importance of an accurate phenotype even within families, especially 
when an alternative diagnosis (e.g. T2DM as opposed to MODY) is possible. By 
1996, an area of 13-cM (approx. 7mB) was identified as in linkage with the causative 
mutations. At the same time, HNF1A was identified as the causative gene for MODY 
3. HNF4A was known to regulate HNF1A expression, the gene for which (HNF1A) 
was located in the area of linkage for MODY1, and a mutation (c.802C>A, 
p.Gln268X) was identified as the causative mutation in the RW pedigree, nearly 40 
years after the family was originally identified. 
1.5.1.2   Linkage analysis in MODY3 
A number of families with a clinical diagnosis of MODY were identified that did not 
segregate with the ADA locus on chromosome20q, nor with the newly identified 
GCK-MODY (MODY2 [190, 191]), demonstrating the heterogeneity among MODY 
subjects. Using 97 microsatellite markers, Vaxillaire studied twelve families with 
MODY not genetically linked to GCK or the ADA locus [192]. A marker on 
chromosome 12q exhibited significant linkage with MODY, and a pairwise analysis of 
this marker and surrounding markers identified a region spanning 7cM. Later that 
year, Menzel et al. identified a further three families and localised the region to a 
5cM interval on 12q [193]. The following year Yamagata et al. undertook a 
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systematic search for the causative gene within this region, testing known genes 
within this region, and identified HNF1A as the causative gene for MODY3 [32].  
 
1.5.2   Difficulties with linkage analysis 
The most fundamental aspect to powerful linkage studies is the ability to analyse a 
large pedigree, whose phenotype can be accurately assessed. Conditions with a late 
age of onset can limit the number of participants and generations available for 
genotyping. Unaffected younger family members will not be able to provide any 
useful genotype information to map linkage. Whilst MODY typically has an age of 
onset of <25 years, many develop diabetes at a later age and thus unless an 
individual has diabetes, their affection status cannot be determined with certainty. An 
estimate of disease penetrance at particular ages can be included in many of the 
linkage algorithms. Similarly, conditions affecting reproductive fitness will restrict the 
number in the pedigree. Incomplete penetrance may cause incorrect attribution of 
disease status, impacting on the ability to map by linkage. De novo mutations will 
also not be able to be mapped using linkage studies. 
Diseases with multiple possible genetic causes also affect the ability for a disease 
locus to be mapped. There are currently thirteen known MODY genes, many of 
which are indistinguishable clinically. Combining linkage information from families 
with various underlying MODY subtypes will reduce the power of any study. In 
addition, the more common T1DM and T2DM can both co-exist in a family with 
MODY. Using less stringent phenotypic criteria diminishes the power of the study, 
and will cause a false negative result. As discussed above in the RW pedigree, once 
it was realised that one branch of the family had a phenotype more consistent with 
T2DM than MODY and were no longer classified as MODY, the causative region 
achieved statistical significance.  
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1.5.3   Other methods of gene discovery 
Candidate gene studies 
Candidate gene studies are undertaken based on functional studies, biological 
hypotheses or as a follow up to regions of interest in genome-wide association. 
There have unfortunately been few successes using this approach. Candidate gene 
approaches have only been successful in MODY following linkage studies to restrict 
the region of interest. 
MODY 2 was mapped to the long arm of chromosome 7 by linkage studies. 
Glucokinase (GCK) was identified as a key enzyme in insulin secretion and was 
located within the linked region on 7p. Candidate gene linkage analyses of GCK 
were performed simultaneously by two groups – one involving 16 French families 
[194] and on a large five-generation pedigree in Oxford [190]. Close linkage was 
noted between the GCK locus and the MODY phenotype. Later that same year, a 
nonsense mutation in GCK was identified in one of the French families [191].  
HNF4A was sequenced in the RW pedigree after a gene for a closely related 
transcription factor (HNF1A) was identified as causative in MODY3. HNF4A was 
located within the 13cM interval previously identified through linkage studies.  
Isolated candidate gene approaches, uninformed by previous linkage studies, have 
not proven successful in MODY. In searching for a new susceptibility gene for 
MODY, a number of genes potentially implicated in insulin secretion or action were 
tested for linkage with MODY in a number of families [195]. These genes included 
glucokinase regulatory protein, hexokinase II, insulin receptor substrate 1, fatty acid-
binding protein 2, glucagon-like peptide-1 receptor, apolipoprotein C-II, glycogen 
synthase and phosphoenolpyruvate carboxykinase. None of these showed linkage 
with MODY. 
Candidate gene approaches in MODY have been woefully inadequate; indeed most 
identified disease genes were completely unsuspected on the basis of previous 
knowledge. This highlights the benefits of a hypothesis-free, non-candidate driven 
genome-wide strategy. 
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Association studies 
Genetic association studies aim to detect association between one or more genetic 
variants and a trait or disease. It compares the allele and/or genotype frequencies 
between affected and unaffected individuals. In both linkage and association studies, 
the identified marker may be inherited with the causative variant (which may not 
have been genotyped directly, in which case further genotyping may narrow the 
genetic region). 
Association studies can be performed on candidate regions or genome-wide. 
Candidate gene association studies involve genotyping a set of markers within a 
gene in a sample of disease cases and controls to look for a statistically significant 
difference in allele frequency between the two groups. Genome wide association 
studies generally detect differences in allele frequency between a large number of 
diseased individuals and population controls. These are not designed for rare 
Mendelian conditions with limited numbers of affected unrelated individuals. The 
reasons include 1. Rare variants do not have much linkage disequilibrium (LD) and 
are not well represented in SNP databases; 2. Genome-wide association studies 
relies on LD; 3. Phenocopies within the MODY population will dilute association 
signal; 4. The numbers of cases required are not possible for rare Mendelian 
conditions 
  
1.5.4   Advances in sequencing technologies 
Sanger sequencing, developed by Frederick Sanger in 1977, was the most widely 
used sequencing method for the next four decades [196]. Sanger sequencing works 
on the principle of chain termination, whereby the growing DNA strand is terminated 
by the incorporation of fluorescently-labelled dideoxy nucleotides (ddNTPs), A, T, G, 
and C, in different reactions. The fragments of different lengths are then run on a gel 
in different lanes (in capillary gels) to determine the sequence. The fluorescence is 
read through a laser light source at unique wavelengths to determine the sequence 
of bases. 
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While sequencers with multiple capillaries enable multiple samples to be sequenced 
simultaneously, Sanger sequencing is still many orders of magnitude slower than 
newer sequencing methods. In addition, the read length is limited to approximately 
1000 bases, and the accuracy of the first 40 and last 100 bases is reduced. 
Therefore sequencing large regions (e.g. whole genes with multiple exons) or many 
different regions require multiple reactions, which are time-consuming and ultimately 
expensive. 
Sanger sequencing technology was used to sequence the first human genome, the 
first draft of which was completed in 2001. Substantial progress has been made in 
the decade and a half since the publication of the draft sequence of the human 
genome. As a result of which, Sanger sequencing has been supplanted by MPS 
methods, which is a paradigm shift from that of Sanger sequencing and has allowed 
scaling-up by orders of magnitude. 
1.5.4.1   Massively parallel sequencing technology   
There are multiple platforms in use for MPS. The common feature of these methods 
is that they are ‘massively parallel’, meaning that the number of reads sequenced 
simultaneously in a single experiment is vastly greater than the 96 obtained with 
modern capillary electrophoresis-based Sanger sequencers. 
Traditionally MPS utilised short read sequencing. These approaches were further 
divided into sequencing by synthesis (SBS) or sequencing by ligation (SBL). The 
Illumina systems currently have the largest market share and employ SBS (as 
discussed Chapter 1.4). Long-read sequencing (as used by Pacific Biosciences 
[PacBio]) do not rely on amplification of DNA fragments, enabling repetitive regions 
and structural variations to be more accurately genotyped.  
1.5.4.2   Data analysis and annotation 
MPS is only possible because of the publication of the human genome [174, 175]. 
DNA fragments can be mapped to this reference genome and variants identified. 
There will be a large number of variants identified compared to the single reference 
genome; thus comparing any variant to a variety of published databases (such as 
NCBI dbSNP, 1000genomes, UK10K, the HapMap project) can determine population 
36 
 
frequencies of each variant. Population frequencies of some variants will also vary 
according to ethnicity, thus population-specific reference databases are important. 
1.5.4.3   Data interpretation 
Each human genome contains several million common (i.e. >5% population minor 
allele frequency [MAF] frequency), low-frequency (i.e. MAF of 1-5%) and rare (MAF 
<1%) variants. Studies of WES data have identified approximately 12000 - 17000 
SNPs per person [181, 197, 198].  
When considering sequence data for pathogenic variants, these large numbers of 
variants require filtering to identify the likely pathogenic variants: 
• Quality of read:  is determined by coverage – coverage for a project can be 
defined as “average coverage per base” or “percent of bases covered to depth n”. 
Coverage at each SNP can also be determined. Quality assessment metrics can 
also be determined by the ratio of most probable genotype to the coverage at any 
given variant [199]. 
• Coding regions: variants within the coding region (or splice site) for a gene are 
more likely to demonstrate a larger effect than from intronic variants on protein 
production and thus on the clinical phenotype, required for Mendelian disorders.  
• Non-synonymous mutations: These are mutations within the coding region that 
alter the amino acid produced and thus the protein sequence. The effect of this 
mutation, and likelihood of it being damaging can be predicted using software 
programmes e.g. Polyphen [199, 200], SIFT [201]  
• According to predicted inheritance pattern if familial data is available: e.g. de 
novo, autosomal dominant or recessive, compound heterozygote etc. 
• Published mutation databases, e.g. ClinVar, HGMD, LOVD or condition-specific 
databases 
1.5.4.4   Limitations 
The ability to detect a variant is in part determined by the coverage of that region. 
WGS and WES do not provide uniform coverage of the regions sequenced. There 
will be “gaps” that are poorly covered. These regions may not be targeted by the 
capture platform or there may be difficulties in sequencing particular regions, such as 
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segments with a high GC content, or difficulty with unique mapping, such as 
repetitive regions.  
Structural variation is more difficult to determine using WES and requires further 
bioinformatic analysis. This can either be performed using programmes that assess 
for breakpoints (e.g. CREST), which is possible if the breakpoints occur within the 
region sequenced, or using tools that assess differences in depth of coverage (e.g. 
ExomeDepth) 
Irrespective of the sequencing technology, the ability to determine pathogenicity for 
any variant identified is not straightforward. This is discussed in more depth in 
Chapter 3. Even variants in the above mentioned databases may not be pathogenic 
in each individual subject. This may be a result of incorrect ascertainment of 
pathogenicity in the original subject, or reduced penetrance of the condition. For 
example, sequencing of seven MODY genes in 4003 individuals from the 
Framingham and Jackson cohorts revealed reportedly causative mutations in MODY 
genes in 1.5% and novel variants predicted to be damaging by protein prediction 
algorithms in a further 0.5%. However, despite comprehensive longitudinal clinical 
follow-up (mean follow-up age in late 50s for both cohorts), the vast majority 
remained euglycaemic; and only one individual fulfilled clinical criteria for MODY 
[202]. These data illustrate the difficulty in allocating causality to rare variants in 
autosomal diseases, even when such variants may be highly plausible [203]. 
1.5.4.5   MPS in gene discovery 
MPS has accelerated the pace of new gene discovery in Mendelian disorders, and 
WES has most commonly been used for this purpose. The exome represents about 
1% of the human genome with approximately 30 million base pairs [181] but 
accounts for over 85% of all mutations identified in Mendelian disorders [182]. As a 
result, WES is currently an attractive and practical approach for investigation of 
coding variations. Exome capture allows an unbiased investigation of the complete 
protein-coding regions in the genome. The goal of this approach is to identify the 
functional variant that is responsible for diseases without the high costs associated 
with WGS while maintaining high coverage in sequence depth. 
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The success of MPS in gene mapping is due to: 
a) The ability to generate sequence data for millions of reads simultaneously 
b) The development of a robust reference genome to identify variants 
c) The development of large databases of human variability to characterise 
observed variation. 
Subsequent empiric analysis includes assessing the variant for segregation with 
disease according to the genetic architecture of the disease in question. 
1.5.4.6    MPS in MODY 
WES was used to identify KCNJ11 as the thirteenth MODY gene [102]. A four 
generation family, including 12 members with a clinical diagnosis of MODY was 
identified. WES was performed on four family members: the proband, his affected 
father, unaffected mother and affected cousin. A total of 324 possible variants were 
identified and these variants were assessed in the remainder of the family. Only one 
mutation was present in all affected individuals, c.679G>A (p.Glu277Lys) in KCNJ11. 
Linkage analysis resulted in a LOD score of 3.68 at this site. WES provided a much 
more rapid and cost-efficient method of gene discovery in this instance than 
traditional linkage analysis, and requires fewer family members.  
In 2015 APPL1 was suggested as a new MODY genes, identified in two families, 
having sequenced two individuals from each family by WES [104]. In 2017 RFX6 
was identified in two families using targeted MPS.  
 
1.5.5   Conclusions 
If I have seen further it is by standing on the shoulders of giants (Isaac Newton, 
1676). 
This is no truer for the laws of physics than for genetic discovery. The introduction of 
Sanger sequencing facilitated the publication of the first human genome. The 
publication of the human genome project was essential to the introduction of MPS. 
The pace of change in sequencing technology is unprecedented. The majority of the 
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“low hanging fruit” of Mendelian gene discovery has been achieved either using 
Sanger sequencing with linkage analysis or now with MPS. Certainly for MODY, the 
genes causing the majority of the clinical phenotype appear to have been identified. 
Each subsequent identified gene has been attributed to fewer and fewer cases of 
MODY. However, there still remains a percentage of cases with a clinical diagnosis 
of MODY for which there is no mutation in a previously identified MODY gene. MPS, 
or its next iteration, will undoubtedly be used to identify the next MODY gene in 
weeks - instead of decades needed for the identification of MODY1. 
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1.6   Thesis Outline 
This thesis uses two forms of massively parallel sequencing while investigating 
monogenic disorders of insulin secretion. Chapters 3-5 use targeted MPS. 
Specifically chapter 3 uses targeted MPS to determine the prevalence of MODY in a 
paediatric diabetes population. Chapter 4 establishes the cost-effectiveness of 
targeted MPS for MODY in this population. Chapter 5 reports a novel MODY variant 
identified with targeted MPS. Chapters 6-8 use WES for MODY and CHI. Chapter 6 
is a proof of concept study of WES for MODY and CHI in individuals with a known 
genetic mutations. Chapter 7 uses WES to identify variants in known MODY and CHI 
genes in subjects without a genetic diagnosis. Chapter 8 uses WES for new gene 
discovery in MODY and CHI.  
 
1.7   Aims of the Thesis 
1. To use targeted MPS to determine the prevalence of genetically-confirmed 
MODY in children and adolescents with diabetes mellitus  
2. To determine the cost-effectiveness of targeted MPS for MODY in a paediatric 
diabetes population 
3. To validate the accuracy of WES compared to traditional Sanger sequencing 
in patients with MODY and CHI caused by a known genetic mutation. 
4. To use WES to identify the genetic cause of MODY and CHI 
 
1.8   Significance 
MODY is frequently mis-diagnosed as T1DM or T2DM. This may be due to the lack 
of awareness of MODY and the lack of referral for genetic testing as well as the 
expense of genetic testing. No study to date has sequenced an entire diabetes 
population to determine the prevalence of variants in all MODY genes, in all 
individuals, irrespective of clinical features. With the introduction of MPS, the cost of 
sequencing all MODY genes has decreased rapidly. From a population perspective, 
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this study provides a unique opportunity to determine the prevalence of MODY in an 
Australian population of children and adolescents with diabetes, with essentially 
complete capture of the population at risk. 
Targeted MPS is rapidly becoming more widely available, moving from 
predominantly research laboratories into clinical laboratories. After determining the 
prevalence of MODY in a population, this thesis will determine whether routine MPS 
for all individuals with suspected MODY or T1DM is cost-effective and results in 
improved quality adjusted life years. 
This project will demonstrate the utility of WES for gene identification in MODY and 
CHI, and will provide a rapid means of identifying both known and novel genes 
causing this condition. This will provide important patient benefits including definitive 
diagnosis with timely best-practice management; in CHI this may lead to timely and 
appropriate surgery.  
The use of MPS in monogenic conditions is increasing [181, 204]. This method of 
sequencing has demonstrated sufficient power using small numbers of unrelated 
individuals or families. With the ability to sequence multiple genes at once in a cost-
effective manner, it is conceivable that more patients will undergo next generation 
sequencing. Currently 45-55% of infants with CHI have no identifiable genetic 
aetiology [154]. Over 70% of referrals for genetic testing for MODY fail to identify a 
mutation [20]. Whole exome sequencing offers the possibility for new gene discovery 
for these patients. These may involve new mechanisms of disease, which may open 
up the possibility of new treatments. 
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2.0   Methods 
2.1   Ethics 
Ethics approval was obtained for all subjects and samples in the study.  
For the targeted sequencing study of MODY prevalence, ethics was obtained 
through the Princess Margaret Hospital for Children (PMH) human research ethics 
committee (HREC) [HREC reference 2013074EP]). Every patient of the PMH 
diabetes clinic consents to have their clinical data stored on the Western Australian 
childhood diabetes database (WACDD), with ethics approval for its use in this study 
and other similar projects (HREC reference 2013051EP). 
All other studies described in this thesis were covered under ethics approval 
HREC/12/QPAH/109 (for gene identification for disorders of glucose-stimulated 
insulin secretion using next-generation resequencing.  
2.2   Recruitment 
2.2.1   Subject recruitment for targeted sequencing 
Recruitment of children and adolescents of the PMH diabetes is described in 
Chapter 3.1. 
2.2.2   Subject recruitment for WES 
I was made aware of potential recruits when they were referred for genetic testing for 
MODY or CHI at the Mater Health Services pathology department (currently the only 
centre in Australia that sequences MODY and CHI genes). I contacted the referring 
clinician of any potential recruit; they then discussed the study with their patient and 
invited them to contact me. Some clinicians contacted me directly as they were 
aware of the study. I consented individuals, collected samples and obtained medical 
and family history. 
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Family members were invited to participate in the study by the proband in the family. 
Family members then contacted me and were recruited as described above.  
2.3   DNA extraction 
2.3.1   DNA extraction from blood 
DNA was extracted from peripheral venous blood in EDTA stored at -20°C. 
Extraction was performed using the standard phenol-chloroform method. Leukocyte 
nuclei were lysed using cold lysis buffer (sucrose 109.4g, 1mL 1M Tris-HCL, pH 7.8, 
1.2mL 4.9M MgCl2, 1L distilled water and 10mL Triton X-100). The mixture was 
centrifuged at 2500 r.p.m. for 10 minutes and the supernatant discarded. 25mL cold 
lysis buffer was added to each tube and the pellet re-suspended by vortexing and 
centrifuged at 2500 r.p.m. for 10 minute, after which the supernatant was again 
discarded. The pellet was re-suspended in 750mcL of 5M Sodium Perchlorate and 
heated to 65°C for a minimum of 30 minutes. After cooling to room temperature, 3mL 
of Chloroform was added, mixed by inversion and centrifuged at 3500 r.p.m. for 7 
minutes. The upper phase was collected into a clean Falcon tube and DNA was 
precipitated by the addition of 7mL cooled 100% ethanol. DNA was transferred to 
another Eppendorf and re-suspended in TE buffer. Spectrophotometric analysis was 
performed for DNA quantification (aiming for a 260:280 absorbance ratio of 1.8-2.0).  
2.3.2   DNA extraction from saliva 
Saliva was collected using the Oragene®·DNA salivary collection kit (DNA Genotek 
Inc, Ottawa, Canada). The Oragene®·DNA/saliva sample was mixed by inversion 
and transferred to a falcon tube and incubated at 50°C for at least 1.5 hours. 160mcL 
or Oragene® DNA purifier (for each 4mL sample) was added and vortexed, 
incubated on ice for 10 minutes, then centrifuged at room temperature for 10 minutes 
at 4000 x g. The supernatant was transferred to a fresh tube and equal volume of 
100% ethanol was added and kept at room temperature for 10 minutes to allow the 
DNA to precipitate. The supernatant was discarded and washed with 1mL 70% 
ethanol, which was discarded. The pellet was dissolved in 0.2-0.5mL TE buffer and 
vortexed. The contents were transferred to a fresh 1.5mL Eppendorf tube. This was 
centrifuged for 15 minutes at room temperature for 15 minutes and the supernatant 
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transferred to a fresh tube. Spectrophotometric analysis was performed for DNA 
quantification (aiming for a 260:280 absorbance ratio of 1.8-2.0).  
2.4   Sequencing 
2.4.1   Sanger sequencing 
Primers were designed to amplify 200-1000 base pair (bp) stretches of DNA 
containing candidate variants. A reference sequence is obtained from The National 
Centre for Biotechnology Information (NCBI) database for the genomic DNA and 
mRNA sequences and uploaded into Genalys programme (White Head Institute for 
Biomedical Research, Cambridge MA USA). The nucleotide of interest +/- 500bp 
either side was entered into Primer3 and custom oligonucleotides primers are 
designed.  
50ng (10 µL) of DNA was amplified by polymerase chain reaction (PCR) with 
2.5µL10X Immolase buffer, 2.5µL of 10mM dNTP, 0.75µL MgCl2 (50mM), 1µL of 
forward and reverse primers and 0.05µL Immolase Taq (5U/µL). PCR cycling 
conditions include pre-cycle step of 96°C for 10 minutes, then 35 cycles of 
denaturing at 96°C for 45 seconds, annealing at 60°C for 45 seconds and extension 
at 70°C for 60 seconds. The PCR products were run on an agarose gel to confirm 
product size, in comparison to a DNA ladder with DNA fragments of known size.  
The PCR product was purified using AmpPureXP beads (Beckman Coulter, CA) 
(1.8x volume of product) incubated at room temperature and separated using a 
magnet. The supernatant was removed and the remaining pellet was washed twice 
with 200µL 80% ethanol to remove impurities. The bead pellet was re-suspended 
with 30µL dH2O incubated at room temperature and placed back on the magnetic 
stand, and the supernatant containing the purified PCR product removed. 
A “master mix” including 4 µL Bid Dye sequencing buffer (5X), 1 µL Big Dye, forward 
or reverse primer, PCR product (1-50ng depending on the size of the PCR product) 
and H2O to a volume of 20µL. PCR conditions include pre-cycle step of 96°C for 5 
minutes, the 25 cycles of denaturing at 96°C for 10 seconds, annealing at 50°C for 5 
seconds and extension at 60°C for 4 minutes. 2 µL 125mM EDTA and 2 µL 3M 
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sodium acetate were added to each samples and sequencing products were then 
purified using 100 µL of 100% ethanol. The pellet was resuspended in 10 µL H2O 
and 10 µL HiDi Formamide and capillary electrophoresis performed on Genetic 
Analyser 3130 (Applied Biosystems, Foster City, CA) as explained in more detail in 
Chapter 1.5.4.  
2.4.2   Massively parallel sequencing  
2.4.2.1   Targeted massively parallel sequencing 
Primers were designed for each exon (plus a selected distance either side to include 
splice-sites) of all regions of interest, using the Illumina Design Studio primer design 
tool (http://designstudio.illumina.com) (Illumina, San Diego, CA USA). Amplicon 
length was selected as 425bp. Overlapping amplicons were used as necessary to 
obtain complete capture of regions of interest. 
Genomic DNA was quantified on the Qubit V2 using Qubit high sensitivity (Thermo 
Fisher Scientific, Waltham, MA) reagents to access their quantity. 250ng was used 
for library preparation using the Illumina TruSeq Custom Amplicon Library Prep kit 
(Illumina, San Diego, CA) as per the manufacturer’s instructions.  
Briefly, DNA was enzymatically fragmented and custom designed oligo capture 
probes were hybridised to their region of interest. The unbound oligonucleotides 
were filtered from the genomic DNA. Indices and sequencing primers were added 
and regions of interest amplified in a PCR reaction. (more detail in Chapter 1.4) 
The PCR product was purified using AmpPureXP beads (Beckman Coulter, CA). 
Libraries were quantified on the Perkin Elmer LCGXII (Perkin Elmer, Waltham, MA) 
to access the library quantity and size. Samples passing QC were normalized, 
pooled into batches of up to 96 samples as per Illumina’s pooling guidelines and 
sequenced on an Illumina MiSeq using MiSeq (Illumina, San Diego, CA).  
2.4.2.2   Whole exome sequencing  
WES used a very similar workflow to targeted sequencing. Rather than custom 
designing primers, for WES the capture technology utilises “off the shelf” capture 
technology. Two capture technologies were used – Nimblegen SeqCap EZ 3.0 
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Exome enrichment kit (Basel, Switzerland) and Illumina NexteraTM Rapid Catpure 
Exome (Illumina, San Diego, CA, USA), each with slightly different workflows. 
However, for Chapter 6, other platforms (Nimblegen SeqCap EZ v2.0 (Roche, Basel, 
Switzerland), Illumina TruSeqTM (Illumina, San Diego, CA, USA), and Illumina 
NexteraTM Rapid Capture Expanded Exome (Illumina, San Diego, CA, USA) were 
used by laboratory technicians to generate data. 
The Illumina TruSeq v2 sample preparation kit was used to construct libraries. 
1.6mcg DNA was mechanically sheared using the Covaris E220 to create fragments 
of approximately 200bp in size. Fragments were purified using AmpPureXP beads to 
remove fragments <100bp. The remaining fragments were end-polished, A-tailed 
and adaptor ligated (with sequence-specific primer recognition sequences and 
barcodes for multiplexing samples) according to the manufacturer’s protocol. 
Samples underwent minimal PCR cycling. 
Other samples were prepared using the Illumina NexteraTM Rapid Capture Exome 
library preparation kit. 50ng of DNA was “tagmented” (simultaneously enzymatically 
fragmented adaptors ligated) using transposons. Samples underwent minimal PCR 
amplification during which barcodes were added.  
All samples were quantified using Agilent High Sensitivity DNA assay (Santa Clare, 
CA) on the Bioanalyser 2100 and by qPCR using KAPA library quantification kit 
(Kapa Biosystems, Wilmington, MA). Exome capture was performed using the 
Nimblegen SeqCap EZ v3.0 exome enrichment kit (Roche, Basel, Switzerland), or 
Illumina Nextera Rapid Capture Exome. Libraries were combined into pools of six 
and massively parallel sequencing was performed with six samples per flow lane 
using an Illumina HiSeq 2000 (Illumina, San Diego, CA, USA), generating 100-base 
pair paired-end reads. 
 
2.5   Bioinformatic processing 
Data were demultiplexed using Illumina Data Analysis Pipeline software and aligned 
to the current reference human genome (hg19, released February 2009) using the 
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Novoalign alignment tool. Sequence alignment files were converted using Picard 
tools. Variants were called using the Genome Analysis Toolkit and annotated using 
ANNOVAR. Further analysis of sequence data was performed using custom scripts 
employing R and Bioconductor.  
After exclusion of artefact, good quality (i.e. passing GATK algorithm, which 
incorporates sequence depth, quality scores at the SNP position, maximal length of 
the homopolymer run and strand bias) variants were retained. Samples were 
simultaneously genotyped with a large control cohort to increase GATK sensitivity 
and specificity. Samples are “group called” for these quality reasons. Furthermore, 
the frequency of any alternate allele can be compared with “in house” data of 
currently >3000 exomes to eliminate platform-related artefact.  
The nature of the mutations (splice site, nonsynonymous, synonymous, frameshift, 
stop-loss and stop-gain variants etc) was annotated for transcripts in each reference 
databases (Ensembl, RefSeq and UCSC). The MAF was determined from reference 
databases (NCBI dbSNP (release 147), 1000 Genomes, and ExAC) and from 
internal exome data. Variants were further annotated according to their genomic 
evolutionary rate profiling (GERP) score, which is a measure of evolutionary 
conservation of the genetic sequence across species. The likelihood of a variants 
deleteriously affecting protein structure and function was calculated using protein 
prediction algorithms PolyPhen [200], SIFT [201] and MutationTaster [205].  
Samples without an identified variant were also analyzed for copy number variants 
using ExomeDepth [206] 
 
2.6   Data analysis 
2.6.1   Sanger sequencing 
Raw data (.ab1 files) generated from the ABI3130 (Applied Biosystems, Foster City, 
CA) for each sample were analysed using Genalys software (White Head Institute for 
Biomedical Research, Cambridge MA USA). Raw data files were aligned and 
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compared to the reference sequence for the required transcript for each gene, 
obtained from NCBI. Sequence chromatographs were reviewed manually for 
sequencing quality and base calling accuracy. After artefact was removed, remaining 
variants were interrogated for possible pathogenicity (discussed below).  
2.6.2   MPS data 
WES and targeted MPS data were summarised in a text-delimited file which was 
converted to an Excel file for data manipulation and filtering. Information pertaining to 
each variant included information about the gene location and associated disease 
phenotypes (if any) from Online Mendelian Inheritance in Man® (OMIM), genotype 
call for the variant (0/1 for heterozygotes and 0/0 for homozygotes for the reference 
allele and 1/1 for homozygotes for the alternate allele), depth of coverage, MAF in 
reference databases, allele frequency in internal exome data, and in silico protein 
prediction algorithms  PolyPhen [200], SIFT [201] and MutationTaster [205]. Only 
variants with MAF <5% are included in the spreadsheet. 
Data were then filtered according to desired parameters: 
1. Good quality variants (those that pass the GATK threshold) 
2. Those not commonly observed in internal exome data (to exclude platform 
related artefact) 
3. Genes of interest 
4. Predicted mode of inheritance – for dominant inheritance 0/1 (heterozygous 
mutation); or recessive – (either 1/1 for homozygous, or 0/1 for two variants in 
the same gene for compound heterozygous inheritance; with one variant 
inherited from each parent, if data available) 
5. Variants predicted to have potentially damaging consequence 
("nonsynonymous SNV", "splicing", "frameshift substitution", "stop-gain SNV", 
"stop-loss SNV") using both RefSeq and UCSC transcripts  
6. MAF below a designated threshold, depending on the expected population 
frequency of the variant  
7. Likely pathogenicity of the variant. This was considered using: 
a. GERP score – a base with a high GERP score has been conserved 
through species  
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b. protein prediction algorithms, predicting the likely functional 
consequences of the variant, including PolyPhen, SIFT and 
MutationTaster. For splice-site variants, additional tools such as 
Human Splicing Finder 3.0 [207] were used 
8. Variant frequency in ExAC [208], a database of >60000 exome data, with 
detailed population frequencies, alternative allele counts and genotype quality 
measures. Other databases were also interrogated to determine if a variant 
has been previously observed in association with a clinical phenotype – these 
include the Human Gene Mutation Database (HGMD) [209], Leiden open 
variation database (LOVD) [210] and ClinVar [211]. 
 
2.7   Cost-effectiveness modelling 
The cost-effectiveness analysis presented in Chapter 4 estimated the expected costs 
and outcomes associated with routine targeted MPS screening for MODY at 
diagnosis for all patients thought to have T1DM or MODY. Methodology is presented 
in detail in Chapter 4. However, in brief, prevalence of MODY was based on data 
from Chapter 3.1. The comparator group was defined as ‘standard care’, which 
accounted for ad hoc sequencing for MODY on clinical grounds as directed by 
physicians and based on published data. Modelling for cost-effectiveness used a 
Markov cohort model (based on the structure of the Sheffield Type 1 Diabetes Model 
[212]). The probabilities of transitioning through health states and developing 
complications of diabetes were based on the individual’s age, duration of diabetes, 
and HbA1c; and were based on formulae from the Sheffield Type 1 Diabetes Model. 
These were modelled over a 10 year and 30 year simulation, starting with 1000 
individuals in each cohort. Utilities for each health state was obtained from published 
data. Resource use items were valued using current Australian prices listed on the 
Medicare Benefits Schedule (MBS) [213] and Pharmaceutical Benefits Schedule 
(PBS) [214]. Costs associated with long term diabetes complications were derived 
from the literature and inflated to 2016 dollars [203]. 
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3.0   Targeted Massively Parallel Sequencing to Determine 
the Prevalence of Maturity-Onset Diabetes of the Young 
MODY is a heterogeneous subtype of diabetes with at least thirteen causative genes 
(reviewed in [47]). MODY was originally thought to be a subtype of type 2 diabetes 
(T2DM) but with young age of onset and milder phenotype [7-10]. However, MODY 
is now recognised to be a monogenic disorder of insulin secretion, with a phenotype 
distinct from T2DM.  
Initial estimates of MODY prevalence used clinical features alone: Panzram et al. 
reported a prevalence based on a young age of onset and no insulin requirement for 
five years [17]; in 1995 Ledermann et al. reported prevalence based on young age of 
onset, no insulin requirement for five years and an autosomal dominant inheritance 
[13]. In the last 10 years, prevalence studies have included a genetic diagnosis in 
their criteria. The majority of these have used traditional Sanger sequencing and as 
a result have only assessed a limited number of genes: Schober et al. [18], Kropff et 
al. [19] and Pihoker et al. [215] assessed three genes (HNF4A, GCK, HNF1A), Eide 
et al. assessed one gene only (HNF1A) [15], and Hameed et al. assessed the five 
most common monogenic diabetes genes (HNF4A, GCK, HNF1A, ABCC8, KCNJ11) 
[22]. Further, studies for MODY prevalence have, to date, only sequenced a subset 
of the diabetes cohort – e.g. only those without islet antibodies, or those who have 
evidence of endogenous insulin production (as measured by serum or urinary C-
peptide) [15, 16, 22, 215]. These limitations are not difficult to understand: the 
expense of sequencing multiple genes by Sanger sequencing and/or sequencing 
multiple individuals (whether by Sanger sequencing or MPS) meant that 
parsimonious selection of genes and samples was appropriate.  
More recently MPS has dramatically decreased the cost of sequencing. MPS can 
simultaneously sequence all MODY genes, and by barcoding samples, they can be 
multiplexed to simultaneously sequence multiple samples. MODY is thus an ideal 
condition for MPS. During the course of my PhD, targeted MPS panels have been 
developed for MODY and monogenic diabetes in general [216-219].  
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In this chapter, I designed a targeted MPS panel for MODY using the Illumina 
TruSeq custom amplicon kit, which sequenced the thirteen confirmed MODY genes 
for $80 per samples (reagent costs only). I then used the targeted MPS panel to 
determine the prevalence of MODY variants in a paediatric diabetes cohort. The 
population used for this study is the Princess Margaret Hospital for Children (PMH) 
diabetes clinic. It is unique within Australia, and possibly internationally, as it is the 
only referral hospital for all cases of Type 1 diabetes (T1DM) for an the extremely 
large population – in this case, the entire state of Western Australia (population 2.6 
million). I was able to sequence all available individuals with diabetes from the PMH 
cohort, irrespective of any clinical features: antibody status, family history or 
evidence of endogenous insulin production. 
Although I identified variants in MODY genes in this population, the main difficulty 
proved to be establishing pathogenicity of these variants. Although I identified MODY 
variants, I cannot state the carriers have the clinical diagnosis of MODY. I used the 
American College of Medical Genetics and Genomic criteria for ascribing 
pathogenicity [220]. However, most MODY mutations are private mutations [221]; 
therefore unless the variant has previously been described in association with MODY 
I could not  ascribe likely pathogenicity definitively. Indeed, it was evident that some 
variants published as associated with MODY would not fulfil criteria for pathogenicity 
using these guidelines. As I have also not sequenced family members to assess 
segregation with diabetes nor performed functional studies, the vast majority of 
identified variants were classified as variants of unknown significance. Even those 
with a variant in a known mutational locus do not necessarily have the clinical 
diagnosis of MODY, given the known incomplete penetrance in this condition. For 
example, variants at HNF1A, c.872delC or c.872insC (one of the only “hotspots” in 
MODY [222]) are reported in 184/44217 individuals in the ExAC database (0.42% of 
the population [184/88434 = 0.21% of all alleles]) who underwent exome sequencing 
[208]. Clearly, the prevalence of MODY, let alone MODY with this particular variant, 
is much less than 0.42% of the general population. This suggests that many 
(possibly the majority) of individuals with variants at this locus might not have MODY. 
This issue is not unique to MODY. Minikel et al. recently examined the prevalence of 
variants in PRNP, responsible for prion disease in the ExAC database compared to 
the number of cases of prion disease in the international databases [203]. The 
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prevalence of variants in PRNP was 30-fold high than the prevalence of prion 
disease itself. It is evident many variants are either incorrectly classified as 
pathogenic, or have reduced penetrance.  
 
In this project, I was responsible for obtaining ethics and governance. I selected all 
available samples for sequencing and liaised with collaborators at PMH for sample 
acquisition. I performed sample QC prior to sequencing. I performed the majority of 
the library preparation for the targeted MPS, and performed some of the Sanger 
sequencing validation. After the sequencing data had been processed through our 
laboratory’s bioinformatic pipeline, I analysed the data for variants of interest and 
examined the various databases for variant information. I wrote the first draft of the 
manuscript.  
The following work reports the prevalence of MODY in a paediatric diabetes 
population and has been submitted for publication. 
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3.1   Comprehensive genetic testing of a population-based 
Australian paediatric diabetes cohort reveals a high 
prevalence of pathogenic/likely pathogenic MODY gene 
variants.  
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Abstract  
Objective 
Maturity-onset diabetes of the young (MODY) is caused by autosomal dominant 
mutations in one of thirteen identified genes. A MODY diagnosis profoundly alters 
diabetes management. Estimates of MODY prevalence vary widely, with no 
comprehensive genetic screening of an entire pediatric diabetes population 
previously reported. We aimed to determine prevalence of MODY variants in a 
complete pediatric diabetes cohort. 
Research Design and Methods 
MODY gene variants were assessed using massively parallel sequencing in a 
population-based pediatric diabetes cohort (n=1363) of the sole tertiary pediatric 
diabetes service for Western Australia (population 2.6million) which captures >99% 
of children with type 1 diabetes (T1DM) in the state. All individuals were screened, 
irrespective of clinical features. MODY variants were also assessed in a control 
cohort (n=993). 
Results 
DNA and signed consent were available for 821 children. Seventeen children had 
pathogenic/likely pathogenic variants in MODY genes – two diagnosed with type 2 
diabetes, four with antibody-negative T1DM, three with antibody-positive T1DM, and 
eight previously diagnosed with MODY. Prevalence of MODY variants in the 
sequenced cohort was 2.1%. An additional nine children not part of the sequenced 
cohort had MODY variants previously identified. The minimal prevalence of 
pathogenic/likely pathogenic MODY variants in the Western Australia pediatric 
cohort is therefore 26/1363 (1.9%), compared to 0.3% in controls. 
Conclusions  
This is the first comprehensive study of MODY variants in a population-based 
pediatric diabetes cohort. Given the prevalence of MODY variants, and the 
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enormous advantages of diagnosis, MODY genetic testing should be considered in 
all cases of pediatric diabetes. 
 
Introduction 
Maturity-onset diabetes of the young (MODY) is the commonest form of monogenic 
diabetes and arises from heterozygous mutations in one of thirteen currently 
identified genes, all of which regulate beta-cell function (HNF4A, GCK, HNF1A, 
PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8 and KCNJ11 
(reviewed in [223]). Although some forms of MODY have distinct clinical features 
(e.g. HNF1B-MODY, associated with renal malformations, pancreatic atrophy, 
genital malformations and abnormal liver function tests [80]), most are 
indistinguishable without genetic testing. Further, many cases of MODY are 
misdiagnosed as either type 1 diabetes (T1DM) or type 2 diabetes (T2DM) [20]. The 
International Society of Pediatric and Adolescent Diabetes (ISPAD) currently 
recommend MODY testing in cases of diabetes with family history of diabetes in a 
first-degree relative, an absence of islet autoantibodies and evidence of preserved 
beta-cell function [24]. ISPAD also recommends considering MODY in children 
diagnosed with T2DM who are neither obese nor have acanthosis nigricans, come 
from an ethnic group with low prevalence of T2DM, and who have a strong family 
history of diabetes without obesity [24]. However, most children, including those who 
fulfil the above criteria, are not tested, resulting in estimates that >90% of MODY 
cases are missed [20].  
The overarching rationale for MODY testing is that many MODY subtypes (HNF1A, 
HNF4A, KCNJ11, and ABCC8) may be manageable with oral hypoglycemic agents 
(sulphonylureas) and discontinuation of insulin [224]. This is cost-effective, improves 
metabolic control, with less hypoglycemia, and, most importantly, dramatically 
improves quality of life [28]. In particular, a diagnosis of the GCK subtype leads to 
lifelong cessation of unnecessary insulin treatment [225].  
Previous estimates of MODY prevalence in pediatric diabetes populations have 
varied widely, in part due to differences in selection criteria of cases, number of 
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genes assessed, and method of genetic screening. The development of massively 
parallel sequencing (MPS) has meant that MODY can now be comprehensively 
assessed efficiently and cost-effectively [226]. Two recent studies have used MPS to 
screen a clinic-based diabetes population. Both used targeted sequencing of all 
currently known MODY genes but also only sequenced antibody negative (Ab−) 
cases [23, 227]. Thus, to date, there has not been comprehensive screening of a 
complete pediatric diabetes population. 
The aim of our study was to use targeted MPS to determine the prevalence of 
variants in all known MODY genes in an entire pediatric diabetes population. We 
also compared the prevalence of MODY variants in this population with sequence 
data from a general population control cohort. 
 
Methods 
Study population 
The Princess Margaret Hospital for Children (PMH) provides the only pediatric 
tertiary diabetes service for Western Australia (WA) and includes both Perth-based 
and outreach clinics. WA has a large (2.6 million) and dispersed population; 
however, PMH has previously demonstrated near complete (>99%) case 
ascertainment for all pediatric T1DM in WA [228]. The Western Australian Childhood 
Diabetes Database (WACDD) captures data from all patients seen by PMH diabetes 
service. At diagnosis, each patient has DNA collected (stored at the Western 
Australia DNA Bank), and undergoes antibody testing (glutamic acid dehydrogenase 
antibodies [GAD], islet cell antibodies [ICA], and/or islet antigen-2 antibodies [IA2]). 
Subjects are declared antibody-positive (Ab+) if at least one is positive; and Ab− if 
negative for all antibodies tested. Clinical diagnosis of diabetes type (e.g. T1DM, 
T2DM, MODY, secondary, etc.) is determined by the treating pediatric 
endocrinologist. WACDD is updated after each clinical visit, allowing for revision of 
diabetes classification if appropriate. Consent is obtained separately for use of 
clinical data vs. genetic testing. 
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All patients seen at PMH between December 2013 and December 2015 who had 
both DNA and consent were recruited to this study (PMH Human Research Ethics 
Committee approval number 2013074EP).  
Targeted Sequencing 
Platform Design  
Primers were designed for each exon (plus 20 base pairs [bp] either side) of all 
known MODY genes, using the Illumina Design Studio primer design tool 
(http://designstudio.illumina.com) (Illumina, San Diego, CA USA). Amplicon length 
was selected as 425bp. Overlapping amplicons were used as necessary to obtain 
maximal capture. 
Sequencing 
Genomic DNA samples were received from the WA DNA Bank. All samples were 
quantified on a Qubit 2.0 using Qubit high sensitivity DNA reagents (Thermo Fisher 
Scientific, Waltham, MA) to assess their quantity. 250ng was used for library 
preparation using the Illumina TruSeq Custom Amplicon Library Prep kit (Illumina, 
San Diego, CA) as per the manufacturer’s instructions. Following PCR amplification 
and clean up, libraries were quantified on the Perkin Elmer LabChip GXII (Perkin 
Elmer, Waltham, MA) to assess the quantity and size. Following quality control (QC), 
samples were equalized, pooled into batches of 96 as per Illumina pooling 
guidelines, and 2x250bp paired end sequencing performed on an Illumina MiSeq 
using 500 cycle V2 reagent kits (Cat # MS-102-2003; Illumina, San Diego, CA). 
Sequencing QC metrics all passed Illumina’s specifications, and read quality was 
assessed using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) for each sequencing 
lane.  
Data analysis 
Data were aligned with Illumina’s TruSeq Amplicon workflow (Isis 2.5.1.3) to the 
human genome reference (hg19), and all samples were group called with the 
Genome Analysis Toolkit (GATK) HaplotypeCaller module (v3.5). Single nucleotide 
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polymorphisms (SNPs) and small insertions and deletions (INDELs) were annotated 
with ANNOVAR, and potential damaging effects were predicted using protein 
prediction/splice-site algorithms PolyPhen [200], SIFT [201], MutationTaster [205] 
and Human Splicing Finder 3.0 [207]. 
Variant filtering 
Variants were retained if they passed initial quality control (GATK variant quality 
recalibration score) and had ≥3 alternative alleles and a ratio of alternative to wild-
type allele of ≥20%. Subsequently, coding variants with MAF of <0.1% in conserved 
bases (genome evolutionary rate profile ≥2.4) predicted to be damaging/deleterious 
by at least one protein prediction algorithm were assessed. A conservative MAF was 
used based on: a) prevalence of pediatric diabetes of 0.2% in the Australian 
population [229]; b) prevalence estimates of 2% of MODY in a diabetes population 
[23]. Further, most MODY mutations are private with few mutational hotspots 
reported [221]. Platform-related artefact was eliminated by excluding variants seen in 
>3 samples (either in the diabetes cohort or in the control samples) or those with an 
allele count of >20 in Exome Aggregation Consortium [ExAC].  
Variant Classification 
Each variant was assessed against existing literature and databases (including 
ClinVar, Human Gene Mutation Database, Leiden Open Variation Database, 
UniProt, and PubMed). Likely pathogenicity was determined according to criteria 
recently published by the American College of Medical Genetics and Genomics 
(ACMG) [220]. These criteria use the type of mutation (e.g. frameshift, nonsense, 
essential splice site variants, etc.), population frequencies (e.g.1000Genomes, 
ExAC, dbSNP) and available data from published reports and databases, to classify 
variants into five categories: 1. pathogenic; 2. likely pathogenic; 3. variant of 
unknown significance (VUS); 4. likely benign; 5. benign. 
All data were assessed blinded to diabetes categorization. 
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Sanger sequencing 
All pathogenic/likely pathogenic variants were validated by Sanger sequencing, 
except for two samples with insufficient DNA. Samples with alternate allele read 
depth ≤2 were also assessed, to validate the quality control cut-off (i.e. ≥3 alternate 
alleles).  
Control Data 
An unrelated population cohort drawn from the Anglo-Australian Osteoporosis 
Genetics Consortium (AOGC) was used to assess prevalence of MODY variants, 
using exome data [230] and similar analysis steps. Libraries were constructed using 
the Illumina TruSeq DNA sample preparation and TruSeq Exome capture kits, with 
2x100bp paired end sequencing on the Illumina HiSeq2000. Data were aligned to 
the human genome reference (hg19) with Novoalign (v2.07.18, Novocraft 
Technologies Sdn Bhd, Selangor Malaysia), and GATK base quality score 
recalibration and INDEL realignment were applied. SNPs were identified with 
GATK’s (v1.5) UnifiedGenotyper and INDELs were identified with GATK’s 
HaplotypeCaller. Variant quality score recalibration was applied to both SNPs and 
INDELs. The resulting genotypes were annotated with ANNOVAR. 
Statistical analysis 
Frequencies of MODY variants in WACDD sequence data as a whole and by 
subgroups (Ab− T1DM, Ab+ T1DM or T2DM) and AOGC control data were 
compared using Chi-squared analysis in SPSS for Windows v.24.0.  
 
Results 
Clinical cohort 
There were 1363 patients registered on the WACDD during 2013-15. 1242 children 
(91.1%) were classified as T1DM. 1026 children were defined as Ab+ T1DM (1% 
had three antibodies tested, 78% two, 12% one, and 9% no antibody testing), with 
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120 diagnosed with Ab- T1DM and 96 with unknown antibody status. Eighty-nine 
children (6.5%) were classified as T2DM. The remaining 32 children included six 
children with other forms of monogenic diabetes (immunodysregulation 
polyendocrinolopathy, enteropathy X-linked syndrome [MIM 304790], or neonatal 
diabetes), nine children with diabetes secondary to steroids, pancreatectomy, cystic 
fibrosis or sickle cell disease; and 17 children classified as MODY, all confirmed by 
Sanger sequencing prior to this study.  
Informed consent and DNA were available from 821 children comprising 63% of the 
entire T1DM cohort (65% of Ab+ T1DM, 76% of Ab− T1DM and 17% of unknown 
antibody status T1DM), 43% of the T2DM cohort, and 47% of previously clinically 
diagnosed MODY cases. (Figure 3.1). 
 
Figure 3.1 Numbers of patients in each clinical category of the Western 
Australian Childhood Diabetes Database, as determined by the treating clinician, 
numbers of subjects with consent and DNA available to be sequenced in this study, 
and number of pathogenic/likely pathogenic (P/LP) variants detected. 
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Table 3.1 Baseline characteristics of the sequenced PMH diabetes cohort.  
Category n age at diagnosis 
Gender 
(% male) 
Positive 
family 
history (%) 
DKA at 
diagnosis 
(%) 
HbA1c at 
diagnosis 
HbA1c 
mean 
Ab- T1DM 91 7.09 60.44 14.7 46.91 11.4 7.7 
Ab+ T1DM 667 7.83 51.57 15.1 38.22 11.4 7.8 
unknown Ab 
T1DM 16 5.3 56.25 6.3 25 9.8 8.1 
T2DM 39 13.09 46.15 50 8.33 9.1 7.5 
MODY 8 8.02 62.50 100 0 7.4 6.2 
     
 
 
 
Total 821 7.95 52.50 15.6 38.29 11.2 7.8 
Positive family history indicates diabetes in a first generation relative. Mean HbA1c includes 
all HbA1c after 3 months of diabetes duration. DKA at diagnosis is defined by pH <7.3 or 
bicarbonate <15mmol/L.  
Sequencing Results 
Coverage statistics 
Mean depth of coverage across the thirteen genes was 489-fold. 92% of bases had 
>10x coverage (Supplementary Data Table S3.1 and S3.2). 93% of HNF4A, GCK, 
HNF1A and HNF1B (the genes which account for >95% of identified MODY cases 
[20]) had average coverage depth >10x.  
Sanger sequencing validated the QC threshold of alternate allele read depth ≥3 
reads and alternative allele ratio of >20%. All variants with read depth ≥3 were 
validated with the exception of one sample with good overall read depth (184x) but a 
skewed ratio between alleles (34 alternative allele vs. 150 wildtype, 18% of total 
reads). 
Variants identified in MODY genes 
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Seventeen individuals in the sequenced cohort of 821 individuals had a 
pathogenic/likely pathogenic variant in a MODY gene (Table 3.2). These included all 
eight children previously diagnosed with MODY (based on clinical suspicion and 
previously confirmed genetically) and nine additional children not previously 
diagnosed with MODY (two with a diagnosis of T2DM, four with Ab− T1DM, and 
three with Ab+ T1DM). The prevalence of pathogenic/likely pathogenic MODY 
variants in the sequenced cohort was 2.1%. 
An additional nine cases diagnosed clinically with MODY and with prior genetic 
confirmation were not re-sequenced (absent consent and/or DNA at WA DNA Bank; 
Supplementary Table S3.3). Considering the entire WACDD cohort, and adding 
these nine children to the 17 cases in the sequenced cohort, 26 of 1363 children had 
pathogenic/likely pathogenic variants in MODY genes, giving a minimum prevalence 
of pathogenic/likely pathogenic MODY variants of 1.9%.  
Variants in GCK accounted for the majority of MODY cases in the cohort overall (15 
of all 26 cases). Most of these children (12/15) had been diagnosed clinically, but 
three were only identified as part of this study (two previously diagnosed with T2DM 
and one with Ab- T1DM).  
An additional six subjects in the WACDD cohort had genetically-confirmed neonatal 
or other monogenic forms of diabetes (two ABCC8 mutations, one KCNJ11 mutation, 
two with uniparental disomy at 6p24 and one FOXP3 mutation; Supplementary Table 
S3.3). None of these six subjects were sequenced as part of this study. 
52 children had VUS in MODY genes. Of these, 31 were in PAX4, NEUROD1, 
PDX1, CEL, BLK, and KLF11. Fewer than 100 variants have been described 
collectively for these six genes (either in MODY or in other conditions) and thus there 
were little data in the literature to inform variant classification using ACMG criteria. 
21 variants were in HNF4A, GCK, HNF1A, HNF1B, INS, ABCC8 and KCNJ11, for 
which there are more comprehensive published data. If VUS are included in the 
prevalence calculations, 4.6% of the sequenced cohort (38 of 821) had category 1-3 
variants in the seven most studied MODY genes. 
64 
 
Table 3.2 Pathogenic/likely pathogenic variants in MODY in the sequenced 
cohort 
Gene Transcript allele Protein 
Presumed 
diabetes 
type 
reference/ 
comment 
INS NM_000207 c.308A>G p.Try103Cys Ab- T1DM [231] 
KCNJ11 NM_000525 c.85delC p.Arg29fs Ab- T1DM Novel 
ABCC8 NM_000352 c.638T>C p.Leu213Pro Ab- T1DM [232] 
HNF1A NM_000545 c.475C>T pArg159Trp Ab+ T1DM [222] 
HNF1A NM_000545 c.872C>T p.Pro291Leu Ab+ T1DM [222] 
“mutation hotspot” 
HNF4A NM_000457 c.406C>T p.Arg136Trp Ab+ T1DM [233] 
GCK NM_000162 c.208+1G>A 
 
T2DM 
[234] 
Note same variant observed 
in two individuals (known to 
be related) 
GCK NM_000162 c.208+1G>A 
 
T2DM 
[234] 
Note same variant observed 
in two individuals (known to 
be related) 
GCK NM_000162 c.203G>A p.Gly68Asp Ab- T1DM [234] 
GCK NM_000162 C.214G>A p.Gly72Arg MODY [234] Previously identified 
GCK NM_000162 c.214G>A p.Gly72Arg MODY [234] Previously identified 
GCK NM_000162 c.214G>A p.Gly72Arg MODY [234] Previously identified 
GCK NM_000162 c.449T>C p.Phe150Ser MODY [234] Previously identified 
GCK NM_000162 c.544G>A p.Val182Met MODY [234] Previously identified 
GCK NM_000162 c.556C>T p.Arg186X MODY [234] Previously identified 
HNF4A NM_175914 c.569C>T p.Pro190Leu MODY Previously identified 
HNF4A NM_175914 c.805G>C p.Ala269Pro MODY Previously identified 
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Number of variants in different diabetes clinical subgroups 
Table 3.3 shows the number of pathogenic/likely pathogenic variants and VUS 
according to clinically diagnosed diabetes subtypes, and the proportion of each 
clinically diagnosed cohort sequenced as part of this study. The prevalence of 
pathogenic/likely pathogenic variants in sequenced Ab+ T1DM cases was 0.45% 
and in sequenced Ab− T1DM was 4.4%. Two of 39 T2DM subjects carried the same 
GCK variant, and were siblings. Of note, both were obese (BMI 29.3kg/m2 [+2.0SDS) 
and 27.3kg/m2 [+1.96SDS]) and had acanthosis nigricans.  
The T1DM Ab− group was enriched with pathogenic/likely pathogenic variants 
compared to the Ab+ cohort (P <0.001) and compared to the total sequenced cohort 
(P <0.001). The T2DM group was also enriched with pathogenic/likely pathogenic 
variants compared with the total sequenced cohort (P <0.001). Enrichment for 
pathogenic/likely pathogenic variants remained significant when considering results 
for the entire WACDD cohort (P <0.001). 
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Table 3.3 Number of subjects with MODY variants according to previously allocated diabetes subtype 
Diabetes 
subtype 
Subjects in 
database 
Number 
sequenced 
(proportion 
of clinical 
category) 
Subjects with P/LP 
variant in MODY 
genes 
(% of sequenced 
cohort) 
Subjects 
with VUS 
(overall) 
Subjects with 
VUS in 
common 
MODY genes* 
Category 1 to 3 variants 
in common MODY 
genes* 
(% of sequenced cohort) 
Ab+T1DM 1026 667 (65%) 3 (0.45%) 40 13 16 (2.4%) 
Ab- T1DM 120 91 (76%) 4 (4.4%) 8 5 9 (9.9%) 
T1DM 
Unknown Ab 
status 
96 16 (17%) 0 0 0 0 
T2DM 89 39 (44%) 2 (5.1%) 4 3 5 (12.8%) 
 
MODY 17 8 (47%) 8 (100%) 0 0 8 (100%) 
Control 
cohort 
993 993 3 (0.3%) 34 18 21 (2.1%) 
*HNF4A, GCK, HNF1A, HNF1B, INS, ABCC8, and KCNJ11.
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P/LP: pathogenic/likely pathogenic; VUS: variant of unknown significance; Category 
1-3 variants include pathogenic/likely pathogenic and variants of unknown 
significance 
 
Variants in control cohort 
Three pathogenic/likely pathogenic variants were identified in the control population 
(0.3%) (all in HNF1A). Additionally, 34 subjects had VUS when considering all 
MODY genes, 18 of which were in the seven most studied MODY genes. Thus 3.7% 
of all subjects have variants classified as categories 1-3 in all MODY genes (2.1% in 
the most studied MODY genes). Diabetes status was not known in the control 
population. 
Pathogenic/likely pathogenic variants were significantly enriched in the sequenced 
cohort compared to the control population (P <0.005). Enrichment remained 
significant when considering the entire WACDD (1363 children) compared with the 
control population. Considering each clinical subgroup individually, enrichment was 
seen in Ab− T1DM cases (P <0.001) and T2DM cases (P <0.001) but not Ab+ T1DM 
cases.  
VUS within MODY genes were also significantly enriched in the diabetes cohort 
overall compared to the control cohort (P <0.05), and, in subgroup analysis, were 
enriched specifically in Ab− T1DM and T2DM cases but not Ab+ T1DM cases.  
 
Discussion 
This is the first study to determine the prevalence of MODY variants in all known 
MODY genes in a population-based pediatric diabetes cohort. Every child with DNA 
and consent had their DNA sequenced, regardless of antibody status, family history 
or endogenous insulin production. The prevalence of pathogenic/likely pathogenic 
MODY variants in the sequenced cohort was 2.1%.  
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Although the entire WACDD cohort was recruited for this study, only two thirds had 
both DNA and consent and could be sequenced; and, as shown in Table 3.3, there 
were substantial differences between ascertainment for each diabetes subtype. If the 
proportion of pathogenic/likely pathogenic variants observed in the sequenced cohort 
held for all cases within each diabetes subtype for the entire dataset, 2.3% of 
WACDD would have pathogenic/likely pathogenic MODY variants. Further, although 
WACDD has near-complete ascertainment (>99%) for cases of T1DM in WA [228], 
children with milder hyperglycemia and/or non-ketosis – most of whom will be 
presumed to have T2DM – are more likely to be managed locally and not referred for 
tertiary care. In this context, hyperglycemia in MODY is typically mild, particularly 
when due to mutations in GCK. Thus, there is the potential – both because a lower 
proportion of T2DM within WACDD were sequenced compared to other diabetes 
subtypes, and because fewer cases of T2DM in WA are referred to WACDD – for 
our data to underestimate the true prevalence of MODY in the entire pediatric 
diabetes population. We found two of 39 presumed T2DM cases had a previously 
reported pathogenic variant in a MODY gene, both of whom were obese and had 
clinical signs of insulin resistance. With increases in childhood obesity, the traditional 
metabolic features used to distinguish T2DM from MODY [24] may prove less 
discriminatory. Given the prevalence of MODY variants shown here, and the 
increased ease of screening, it may prove both clinically advantageous and cost-
effective to screen all pediatric T2DM diabetes cases even if current guidelines 
would not recommend testing. However, the generalizability of our results given both 
our small numbers and rapid increase in prevalence of pediatric T2DM driven by 
obesity remains unknown. 
Importantly, the presence of a variant in a MODY gene does not necessarily equate 
to a clinical diagnosis of MODY. Sequencing of seven MODY genes in 4003 
individuals from the Framingham and Jackson cohorts reported causative mutations 
in MODY genes in 1.5% and novel variants predicted to be damaging by protein 
prediction algorithms in a further 0.5%. However, despite comprehensive longitudinal 
clinical follow-up (mean follow-up age in late 50s for both cohorts), the vast majority 
remained euglycaemic; and only one individual fulfilled the clinical criteria for MODY 
[202]. These data illustrate the difficulty in allocating causality to rare variants in 
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autosomal diseases, even when such variants may be highly plausible and/or 
segregate appropriately within families [203]. 
Several previous studies of MODY prevalence have been performed with marked 
differences in results. Initial studies relied solely on clinical criteria (family history, 
young age of onset, low/no insulin requirement five years after diagnosis), and 
reported prevalence of 0.14-1.8% for pediatric diabetes [13, 235, 236]. Later studies 
performed Sanger sequencing of a limited number of MODY genes (usually HNF1A, 
HNF4A and GCK)  in restricted patient cohorts (autoantibody-negative cases with 
evidence of endogenous insulin production and/or family history of diabetes) and 
reported prevalence of 0.18% - 1.2% [19, 215]. More recently, two groups have 
reported results from MPS. Shepherd et al. reported a prevalence of monogenic 
diabetes (including both MODY and neonatal diabetes) of 2.5% [23]. In that study, 
the denominator was the entire diabetes population of two clinics; however, only Ab− 
cases were sequenced. Johannson et al. reported that 4.1% of Ab− cases had 
pathogenic/likely pathogenic variants in MODY genes [227]. Although sequenced, 
the Ab+ population was not included in these prevalence calculations but instead 
was used as control data. 
Within the sequenced cohort itself, and in comparison with the control cohort, there 
was enrichment for pathogenic/likely pathogenic MODY variants in children 
diagnosed with T2DM, with Ab− T1DM and in T1DM with unknown antibody status. 
Yet three cases of Ab+ T1DM carried pathogenic/likely pathogenic variants (0.3% of 
entire Ab+ T1DM cases); to express this alternatively, 3 of 17 cases (18%) with 
pathogenic/likely pathogenic MODY variants were positive for one or more 
antibodies. At present we can only report the rate of MODY variants in the Ab+ 
population, and not whether or not they have a clinical diagnosis of MODY given the 
available clinical data. We would need to determine if this variant segregated with 
diabetes throughout an extended pedigree. Other studies have identified MODY 
variants among their Ab+ population, and conversely, positive antibodies among 
their MODY population. Johansson et al. identified one pathogenic/likely pathogenic 
variant in their 469 Ab+ T1DM cases; however, this case was thought to be T1DM 
clinically and not MODY. Two studies have assessed the presence of antibodies in 
the MODY population. McDonald et al. reported the prevalence of GAD and IA-2 
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antibodies in MODY to be the same as the general population (< 1%), and 
suggested that the presence of antibodies, especially IA-2, makes the diagnosis of 
MODY unlikely [237]. However, these conclusions were predicated on data drawn 
from a cohort referred for genetic testing for MODY which a priori is biased towards 
Ab− subjects as Ab+ diabetes cases are not usually screened. In contrast, Schober 
et al. studying the German-Austrian Diabetes-Patienten-Verlaufsdokumentation 
(DPV) database which includes all children with diabetes in Germany and Austria, 
found 17% of the MODY cases were positive for GAD, ICA, IA2 and/or insulin 
autoantibody (IAA) [18]. The significance of specific auto-antibodies in cases with 
MODY is unclear. It may be that antibodies result from beta-cell damage rather than 
having a direct pathogenic role. The pathogenicity of autoantibodies is unclear even 
in T1DM [238], and there are other examples of antibody induction in non-immune 
illness resulting in immune-mediated damage (e.g. immune-mediated destruction of 
the contralateral eye following trauma or surgery [239], and autoimmune pericarditis 
following ischemic necrosis of the heart [240]). 
We have been very conservative in categorizing MODY variants and included only 
pathogenic/likely pathogenic variants in prevalence calculations, using the 
classification guidelines of the ACMG. It was not possible to assign pathogenicity 
status to all variants, with 52 categorized as VUS. Most MODY mutations are private 
mutations [221] and many VUS in MODY genes will require functional studies to be 
categorized further with confidence. Additionally, sequencing additional family 
members to determine if the variant segregates with diabetes in the family is 
necessary to determine pathogenicity. However, enrichment of pathogenic/likely 
pathogenic variants and the VUS in the diabetes cohort compared to the control 
population is consistent with at least some of these variants being associated with 
disease risk. 
One previous study has specified their criteria for variant classification. Johansson et 
al. [227] used a similar classification system to ACMG (as we have used here), 
although pathogenicity was determined using a system developed for cancer 
susceptibility genetic testing [241]. Other papers have not explicitly defined their 
criteria for allocating pathogenicity, which may contribute to the varying prevalence 
rates reported for MODY [23, 242].  
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Supporting our use of ACMG criteria, we demonstrated enrichment of 
pathogenic/likely pathogenic variants and VUS in the overall diabetes population, 
and individually in the Ab− T1DM and T2DM populations, when compared to an 
unselected control population. Controls and cases were sequenced using different 
methodologies; however, coverage of MODY genes in both groups was comparable 
(data for control group not shown). 
Our study did not assess structural variation in MODY genes in this population. 
Structural variation, including copy number variants (CNVs), is generally uncommon 
in MODY with the exception of HNF1B. Mutations in HNF1B typically account for 
fewer than 5% of MODY cases, however approximately 40% of these are gene 
deletions [82]. Structural variants have also been described rarely in HNF1A and 
GCK [243]. If a mutation in HNF1B was suspected clinically (e.g. presence of 
genitourinary abnormities), assessing for CNV (e.g. multiplex ligation-dependent 
probe amplification) may be appropriate.  
Finally, we would reiterate that although we have identified the presence of a 
pathogenic/likely pathogenic MODY variant in these children, we cannot say 
definitively that these children have MODY. Further clinical investigation of each 
subject, and clinical and genetic characterization of their family, is required to 
determine the clinical significance of these findings. 
In conclusion, 2.1% of children and adolescents with diabetes recruited for this study 
from a large pediatric cohort had pathogenic/likely pathogenic MODY variants. 
MODY variants were more likely in children previously diagnosed with T2DM or with 
Ab− T1DM, than in children with Ab+ T1DM. The high prevalence, rapidly falling cost 
of genetic diagnosis, and significant clinical implications all suggest that genetic 
screening for MODY should be considered in all children and adolescents with 
antibody-negative type 1 diabetes or type 2 diabetes. 
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Supplementary Table S3.1 Quality control data for targeted sequencing. Average capture of each exon to a depth of 10x  
 
Gene Transcript ID Chromosome Start End Exon 
Average capture 
(minimum depth 10x) in 
cohort* 
KLF11 NM_003597 2 10183682 10183885 1 0 
KLF11 NM_003597 2 10186277 10186546 2 99.88 
KLF11 NM_003597 2 10187777 10188722 3 99.67 
KLF11 NM_003597 2 10192354 10194963 4 99.87 
NEUROD1 NM_002500 2 182545157 182545392 1 85.55 
NEUROD1 NM_002500 2 182540833 182543598 2 84.05 
GCK NM_000162 7 44228508 44229022 1 96.9 
GCK NM_000162 7 44192900 44193062 2 98.06 
GCK NM_000162 7 44191870 44192024 3 94.24 
GCK NM_000162 7 44190555 44190674 4 99.7 
GCK NM_000162 7 44189568 44189663 5 99.64 
GCK NM_000162 7 44189359 44189458 6 99.64 
GCK NM_000162 7 44187249 44187432 7 80.63 
GCK NM_000162 7 44186062 44186217 8 86.9 
GCK NM_000162 7 44185096 44185329 9 95.94 
GCK NM_000162 7 44183870 44184879 10 93.68 
PAX4 NM_006193 7 127255455 127255780 1 99.83 
PAX4 NM_006193 7 127254934 127255149 2 99.88 
PAX4 NM_006193 7 127254536 127254611 3 99.88 
PAX4 NM_006193 7 127253810 127253935 4 99.88 
PAX4 NM_006193 7 127253504 127253586 5 99.88 
PAX4 NM_006193 7 127253076 127253145 6 99.88 
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PAX4 NM_006193 7 127251999 127252054 7 99.88 
PAX4 NM_006193 7 127251589 127251730 8 90.75 
PAX4 NM_006193 7 127250346 127251260 9 97.86 
BLK NM_001715 8 11351521 11352100 1 99.42 
BLK NM_001715 8 11400733 11400856 2 97.22 
BLK NM_001715 8 11403561 11403612 3 99.76 
BLK NM_001715 8 11405541 11405634 4 99.76 
BLK NM_001715 8 11406533 11406631 5 97.83 
BLK NM_001715 8 11407668 11407771 6 99.88 
BLK NM_001715 8 11412252 11412398 7 33.36 
BLK NM_001715 8 11412841 11412993 8 98.28 
BLK NM_001715 8 11414167 11414346 9 99.64 
BLK NM_001715 8 11415471 11415547 10 99.76 
BLK NM_001715 8 11418811 11418961 11 99.88 
BLK NM_001715 8 11420488 11420619 12 99.88 
BLK NM_001715 8 11421412 11422108 13 78.11 
CEL NM_001807 9 135937365 135937455 1 99.88 
CEL NM_001807 9 135939791 135939941 2 99.67 
CEL NM_001807 9 135940027 135940149 3 78.12 
CEL NM_001807 9 135940427 135940624 4 98.39 
CEL NM_001807 9 135941917 135942047 5 99.88 
CEL NM_001807 9 135942225 135942332 6 99.59 
CEL NM_001807 9 135942475 135942592 7 94.33 
CEL NM_001807 9 135944059 135944245 8 99.88 
CEL NM_001807 9 135944443 135944646 9 9.48 
CEL NM_001807 9 135945848 135946045 10 99.88 
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CEL NM_001807 9 135946374 135947250 11 30.28 
ABCC8 NM_000352 11 17498176 17498449 1 28.49 
ABCC8 NM_000352 11 17496433 17496574 2 99.88 
ABCC8 NM_000352 11 17491648 17491769 3 99.88 
ABCC8 NM_000352 11 17484985 17485151 4 99.64 
ABCC8 NM_000352 11 17483130 17483372 5 99.88 
ABCC8 NM_000352 11 17482035 17482223 6 99.88 
ABCC8 NM_000352 11 17474666 17474830 7 99.88 
ABCC8 NM_000352 11 17470063 17470218 8 99.88 
ABCC8 NM_000352 11 17464725 17464859 9 99.88 
ABCC8 NM_000352 11 17464267 17464429 10 99.76 
ABCC8 NM_000352 11 17453751 17453791 11 99.88 
ABCC8 NM_000352 11 17452361 17452506 12 99.88 
ABCC8 NM_000352 11 17450112 17450217 13 99.76 
ABCC8 NM_000352 11 17449836 17449952 14 99.84 
ABCC8 NM_000352 11 17449414 17449489 15 99.64 
ABCC8 NM_000352 11 17448596 17448701 16 99.88 
ABCC8 NM_000352 11 17438477 17438509 17 99.28 
ABCC8 NM_000352 11 17436851 17436886 18 99.64 
ABCC8 NM_000352 11 17436059 17436157 19 99.76 
ABCC8 NM_000352 11 17434941 17435025 20 99.88 
ABCC8 NM_000352 11 17434213 17434293 21 99.88 
ABCC8 NM_000352 11 17432063 17432200 22 99.88 
ABCC8 NM_000352 11 17429939 17430064 23 99.67 
ABCC8 NM_000352 11 17428901 17429000 24 99.88 
ABCC8 NM_000352 11 17428435 17428676 25 99.8 
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ABCC8 NM_000352 11 17428169 17428335 26 99.88 
ABCC8 NM_000352 11 17427041 17427110 27 99.88 
ABCC8 NM_000352 11 17426059 17426216 28 99.88 
ABCC8 NM_000352 11 17424208 17424300 29 99.76 
ABCC8 NM_000352 11 17419886 17419988 30 99.76 
ABCC8 NM_000352 11 17419231 17419344 31 99.88 
ABCC8 NM_000352 11 17418740 17418860 32 99.88 
ABCC8 NM_000352 11 17418463 17418593 33 99.88 
ABCC8 NM_000352 11 17417399 17417477 34 96.63 
ABCC8 NM_000352 11 17417157 17417265 35 96.08 
ABCC8 NM_000352 11 17416719 17416822 36 99.76 
ABCC8 NM_000352 11 17415813 17415946 37 99.88 
ABCC8 NM_000352 11 17415244 17415306 38 66.94 
ABCC8 NM_000352 11 17414432 17414675 39 99.64 
INS NM_000207 11 2182398 2182439 1 99.76 
INS NM_000207 11 2182015 2182218 2 96.56 
INS NM_000207 11 2181009 2181227 3 95.2 
KCNJ11 NM_000525 11 17406795 17410206 1 92.04 
HNF1A NM_000545 12 121416549 121416897 1 60.29 
HNF1A NM_000545 12 121426636 121426835 2 99.88 
HNF1A NM_000545 12 121431323 121431509 3 99.88 
HNF1A NM_000545 12 121431967 121432208 4 99.88 
HNF1A NM_000545 12 121434065 121434216 5 94.06 
HNF1A NM_000545 12 121434344 121434545 6 99.74 
HNF1A NM_000545 12 121435277 121435468 7 10.25 
HNF1A NM_000545 12 121437071 121437192 8 98.11 
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HNF1A NM_000545 12 121437286 121437430 9 60.93 
HNF1A NM_000545 12 121438868 121440315 10 98.39 
PDX1 NM_000209 13 28494168 28494681 1 28.81 
PDX1 NM_000209 13 28498393 28500451 2 57.09 
HNF1B NM_000458 17 36104532 36105096 1 99.69 
HNF1B NM_000458 17 36099431 36099630 2 99.76 
HNF1B NM_000458 17 36093550 36093814 3 99.88 
HNF1B NM_000458 17 36091586 36091821 4 77.13 
HNF1B NM_000458 17 36070511 36070671 5 99.81 
HNF1B NM_000458 17 36064924 36065056 6 99.64 
HNF1B NM_000458 17 36060988 36061182 7 99.57 
HNF1B NM_000458 17 36059082 36059200 8 99.88 
HNF1B NM_000458 17 36046434 36047395 9 99.79 
HNF4A NM_175914 20 42984441 42984493 1 99.76 
HNF4A NM_175914 20 43034698 43034872 2 99.88 
HNF4A NM_175914 20 43036021 43036115 3 99.88 
HNF4A NM_175914 20 43042334 43042440 4 99.4 
HNF4A NM_175914 20 43043147 43043302 5 99.8 
HNF4A NM_175914 20 43047065 43047152 6 99.88 
HNF4A NM_175914 20 43048361 43048516 7 99.88 
HNF4A NM_175914 20 43052658 43052894 8 99.73 
HNF4A NM_175914 20 43056975 43057127 9 99.72 
HNF4A NM_175914 20 43058163 43061485 10 91.93 
 
*Percent of exon with at least 10x depth of coverage, averaged over sequenced cohort.
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Supplementary Table S3.2  Quality control data for targeted sequencing. Average capture of each gene to a depth of 10x  
 
Gene Transcript ID 
Percentage of gene 
captured (minimum 
depth of coverage 
10x) 
Number of exons captured >99% 
KLF11 NM_003597 99.81 3/4 
NEUROD1 NM_002500 84.80 0 
GCK NM_000162 94.53 3/10 
PAX4 NM_006193 98.64 7/9 
BLK NM_001715 92.52 8/13 
CEL NM_001807 82.67 6/11 
ABCC8 NM_000352 96.96 35/39 
INS NM_000207 97.17 1/3 
KCNJ11 NM_000525 92.04 0/1 
HNF1A NM_000545 82.14 4/10 
PDX1 NM_000209 56.79 0/2 
HNF1B NM_000458 97.24 8/9 
HNF4A NM_175914 98.99 9/10 
 
*Percent of each gene with at least 10x depth of coverage, averaged over sequenced cohort. 
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Supplementary Table S3.3: Individuals in WACDD with genetically confirmed MODY or other monogenic diabetes but were 
not part of the sequencing cohort (missing DNA and/or consent). 
Gene transcript allele protein 
Presumed diabetes 
type 
comment 
GCK NM_000162 c.685G>A p.G229S MODY  
GCK NM_000162 c.1232_1244del p.S411fs MODY  
GCK NM_000162 c.781G>A p.G261R MODY  
GCK NM_000162 c.183C>A p.Y61Ter MODY  
GCK NM_000162 c.544 G>A P.V182M MODY  
GCK NM_000162 c.718G>A p.G261R MODY  
HNF4A NM_175914 c.805G>C p.A269P MODY  
PAX4 NM_006193 c.555_557dup p.Y186fs MODY  
HNF1B NM_000458 c.1136C>A p.S279fs MODY  
FOXP3 NM_014009 c.1040G>A p.R347H IPEX  
KCNJ11 NM_000525 c.601C>T p.R201C NDM  
ABCC8 NM_000352 c.4139G>A p.R1380H NDM  
ABCC8 NM_000352 c.627C>A p.D209E NDM Transient diabetes 
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UPD6q24    NDM Transient diabetes 
UPD6q24 
   
NDM Transient diabetes 
 
MODY maturity-onset diabetes of the young; NDM neonatal diabetes; IPEX immunodysregulation polyendocrinopathy, enteropathy 
X-linked syndrome 
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4.0 Cost-effectiveness of Targeted Massively Parallel 
Sequencing for Maturity-Onset Diabetes of the Young 
In Chapter 3, I determined the prevalence of MODY variants in a paediatric diabetes 
population. There are many advantages in accurately identifying MODY, both to the 
individual and to the health service. Individuals with particular subtypes of MODY can be 
treated with sulphonlyurea instead of insulin, which is not only cheaper then insulin, but 
improves quality of life. In this chapter, I examined the cost-effectiveness of targeted MPS 
for MODY (Chapter 4). I elected to model the cost-effectiveness of MPS for MODY in 
individuals with presumed T1DM or MODY and did not include T2DM in the model. This 
was because a) T2DM remains a rare diagnosis in paediatric population; and b) as all 
individuals with assumed T1DM are managed with insulin, they would have the greatest 
benefit from a diagnosis of MODY and the possibility of cessation of insulin.  
Similar cost-effectiveness analysis for neonatal diabetes (another subtype of monogenic 
diabetes) has shown genetic testing not only benefited quality-adjusted life years as well as 
being a cost-saving. This has changed clinical management for neonatal diabetes, and it is 
now recommended all cases of diabetes presenting aged <6 months are screened for 
mutations in ABCC8 and KCNJ11. With the rapidly reducing cost of MPS and its increasing 
availability, screening for MODY may become standard practice in cases of T1DM also. 
In this project, I was responsible for obtaining ethics and governance. I was primarily 
responsible for the study design. I provided data from my original prevalence study 
(Chapter 3), researched all available models for diabetes complications, and obtained the 
relevant parameters from the literature required for the model. The Markov model was 
constructed by Dr Hannah Carter. Dr Carter and I jointly wrote the first draft of the 
manuscript.  
The following chapter reports the cost-effectiveness of targeted MPS for in a paediatric 
diabetes population; and a paper has been submitted for publication. 
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Abstract  
Background 
Maturity onset diabetes of the young (MODY) is an autosomal dominant form of diabetes, 
with thirteen established causative genes. Some MODY subtypes can be treated with oral 
hypoglycaemic agents instead of insulin, improving glycaemic control, complication rates, 
quality of life, and costs. Massively parallel sequencing (MPS) enables comprehensive 
genetic screening for MODY, at lower cost than traditional methods. We recently used 
targeted MPS to determine prevalence of MODY variants in an Australian paediatric 
diabetes cohort. Here these data are used in a cost-effectiveness analysis of routine MPS 
screening for MODY in paediatric diabetic cases, compared with standard practice of only 
sequencing individuals with specific clinical features. 
Methods 
A Markov decision model was developed to estimate incremental costs and quality-adjusted 
life years (QALYs) of targeted MPS screening, modelled over 10 and 30 years. We used 
our observed prevalence of pathogenic/presumed pathogenic variants in MODY genes of 
2.14% for routine MPS screening. A prevalence of 0.7% for standard practice was based on 
published data. The probabilities and utility weightings of long-term complications of 
diabetes were based on HbA1c, and were estimated from published data and population 
statistics. A series of one-way sensitivity analyses were performed using the net monetary 
benefit (NMB) framework. 
Results 
Routine MPS screening for MODY was more effective and less costly than standard care 
screening, with 26 QALYs gained and AU$1016000 (US$781696) saved per 1,000 patients 
tested. The cost of screening was fully offset within 10 years. Routine MPS screening 
produced a positive NMB across all one-way sensitivity analyses and remained dominant 
until the MODY prevalence fell below 1.1%. 
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Conclusions 
Routine MPS screening for MODY in the paediatric diabetes population would reduce 
health system costs and improve patient quality of life. Our results make a compelling 
argument for routine genetic screening in all children with presumed T1DM. 
 
Introduction 
Maturity onset diabetes of the young (MODY) is the most common form of monogenic 
diabetes and can arise from heterozygous mutations in one of thirteen identified genes 
(HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8 
and KCNJ11; reviewed in [223]). Individuals with four MODY subtypes (HNF4A, HNF1A, 
KCNJ11, ABCC8) may be able to use oral sulphonylureas (SU) to achieve glycaemic 
control instead of insulin. This results in improved metabolic control and fewer 
complications of diabetes (e.g. retinopathy,  renal failure), lowered risk of hypoglycaemia, 
lowered cost, and improved quality of life (QoL) [244]. Further, the GCK subtype is a non-
progressive form of diabetes and requires minimal follow up [59]. MODY is not an 
autoimmune condition, thus affected individuals do not require annual screening for 
autoimmune diseases as is standard in Type 1 diabetes mellitus (T1DM). Conversely, 
identification of MODY subtypes that are associated with additional clinical features (e.g. 
urogenital abnormalities, liver dysfunction and renal carcinoma in HNF1B-MODY) allows for 
early identification and treatment of these complications.  
MODY is frequently under-recognised and misdiagnosed as T1DM or type 2 diabetes 
mellitus (T2DM) [20]. Currently, MODY screening is recommended based on clinical 
grounds alone i.e. individuals with diabetes who lack classical features of T1DM (e.g. 
diabetes antibodies) or T2DM (e.g. obesity and insulin resistance) who have an autosomal 
dominant family history of diabetes [24]. However, diabetes antibodies may occur in MODY 
[18]; and the increasing prevalence of paediatric obesity means that BMI alone is less 
useful in distinguishing between T2DM and MODY. Thus screening for MODY on clinical 
grounds alone may underestimate the true prevalence, as is evident from differences 
between prevalence rates of MODY in databases where testing was prompted by clinical 
criteria [18] compared to comprehensive population screening (Johnson et al. [submitted]).  
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Screening for MODY using Sanger sequencing is expensive and inefficient, and costs 
AU$750-2500 per gene, depending on gene size. Thus screening of all thirteen genes by 
Sanger sequencing is rarely performed. In contrast, massively parallel sequencing (MPS) 
enables simultaneous sequencing of all known MODY genes, at a fraction of the cost; and 
thus comprehensive genetic screening for MODY is now viable in clinical practice. Recently, 
we screened an entire paediatric diabetes population using targeted MPS, and showed the 
minimum prevalence of pathogenic/likely pathogenic MODY variants (defined by the 
American College of Medical Genetics and Genomics [220]) to be 2.10%. If considering 
only cases identified as T1DM or obvious monogenic cases, the prevalence was 2.14% 
(Johnson et al. [submitted]). In contrast, the prevalence rate of MODY was 0.7% in a 
German and Austrian paediatric diabetes database (German-Austrian Diabetes-Patienten-
Verlaufsdokumentation database [DPV]), published in 2009 [18]. In this population, 
screening appears to have been instigated based on clinical features rather than as routine 
practice, with Sanger sequencing of only three MODY genes [18].  
The aim of the current study is to model the long-term cost-effectiveness of targeted MPS 
screening for MODY in children presenting with diabetes, using population-based Australian 
prevalence data.  
 
Methods 
This cost-effectiveness analysis estimates the expected costs and outcomes associated 
with routine targeted MPS screening for MODY at diagnosis for all patients thought to have 
T1DM, using data obtained from comprehensive MODY screening of all available cases of 
the diabetes service of the Princess Margaret Hospital for Children (PMH), Western 
Australia. This centre captures >99% of children with T1DM in Western Australia (state 
population 2.5 million [245]). The comparator group was defined as ‘standard care’, with ad 
hoc sequencing for MODY on clinical grounds as directed by physicians. Prevalence was 
determined using published data of the DPV database, which includes all children with 
diabetes in Germany and Austria (40,757 patients diagnosed <18 years of age). The 
standard care arm was not drawn from PMH data as our previous research demonstrably 
resulted in a high local awareness of MODY (1.2% identified through clinical suspicion in 
the PMH cohort, compared to 0.65% in the DPV database). 
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Costs were estimated based on the Australian health care system and included treatment 
costs as well as costs associated with complications of diabetes over a 30 year time frame. 
The net effectiveness of each strategy was valued in terms of quality-adjusted life years 
(QALYs). Incremental cost-effectiveness was measured in terms of cost per QALY gained 
(cost-effectiveness analysis). A discount rate of 3% was applied to all future cost and QALY 
outcomes. 
We performed a series of one-way sensitivity analyses to explore the impact of varying the 
modelled assumptions within plausible ranges of uncertainty. 
Model structure, cohort and assumptions 
The decision tree to map the initial diagnosis and treatment pathways for a cohort of 
paediatric patients with presumed T1DM is shown in Figure 4.1. We assumed that MPS 
was 100% specific and 100% sensitive in identifying pathogenic variants in MODY genes 
[246], and that the presence of a pathogenic variant was diagnostic of MODY. 
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Figure 4.1: A decision model for genetic testing 
 
SU: sulphonylurea; MODY 1: HNF4A-MODY; MODY 2: GCK-MODY; MODY 2: HNF1A-MODY; MODY 12: ABCC8-MODY; MODY 
13: KCNJ11-MODY 
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The characteristics of the modelled cohort were based on 1,257 paediatric diabetes 
patients presumed to have T1DM and those already diagnosed as MODY (by Sanger 
sequencing, as directed by their treating clinician) at the Princess Margaret Hospital for 
Children (PMH), Western Australia, between December 2013 and December 2015. Patient 
data were collected prospectively at each visit and formed the Western Australian 
Childhood Diabetes Database (WACDD).  
The key model parameters include clinical features and MODY prevalence (Table 4.1). The 
mean age at diagnosis (8 years) and HbA1c (7.8%) were based on data from WACDD. The 
underlying prevalence of MODY was taken from a previous study of this cohort whereby 
targeted MPS screening detected that 2.14% of patients with T1DM (or a known variant in a 
MODY gene) had a pathogenic/likely pathogenic variant (defined by ACMG criteria [220]) in 
a MODY gene (Johnson [submitted]). The proportions of MODY subtypes were: 10.3% 
HNF4A, 48% GCK, 10.3% HNF1A, 17.8% ABCC8 and 3.4% each for HNF1B, PAX4, 
KCNJ11 and INS. For the benefit of this study, it is assumed all pathogenic/likely 
pathogenic MODY variants will result in the clinical phenotype of MODY. 
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Table   4.1 Clinical characteristics of the modelled cohort: base case, lower and upper estimates  
Variable Base case Lower Upper Source 
MODY prevalence (as detected by MPS) 2.14% 1% 6.5% 
[227] 
Johnson et al. 
(submitted) 
MODY prevalence (as detected by standard care) 0.7% 0.1% 1.5% [18] 
Proportion of MODY that is MODY 2 (MPS) 48% 20% 83% 
[227, 247] 
Johnson et al. 
(submitted) 
Proportion of MODY that is MODY 2 (standard care) 62% 20% 83% [18, 227, 247] 
Proportion of MODY that is MODY 1,3,12,13 (MPS)  41.4% 4.4% 53% 
[23, 227] 
Johnson et al. 
(submitted) 
Proportion of MODY that is MODY 1,3,12,13 (Standard care) 35% 4.40% 53% [18, 247] 
Rate of successful conversion to SU in MODY 1,3,12,13  80% 50% 100% [244, 248] 
Lifetime HbA1c for of insulin-treated individuals#  7.8% 7.3% 8.9% 
Data from WACDD and  
[249] 
Lifetime HbA1c for of SU-treated individuals  6.9% 5.5% 7.0% [244] 
Health utility of insulin-treated individuals# 0.86 0.69 0.96 [248] 
Health utility of SU-treated individuals and MODY 2 0.96 0.86 1.00 [248] 
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Discount rate 3% 0% 5%  
Cost - MPS test $500 $80 $1,000  
#   Insulin-treated individuals include Type 1 diabetes and MODY subjects for whom sulphonylureas were unsuccessful 
SU: sulphonylurea; MPS: massively parallel sequencing; MODY: maturity onset diabetes of the young; MODY 1: HNF4A-MODY; 
MODY 2: GCK-MODY; MODY 3: HNF1A-MODY; MODY-12: ABCC8-MODY; MODY 13: KCNJ11-MODY
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Neonatal diabetes (NDM) constitutes another clinical subgroup of monogenic 
diabetes. Over 50% of NDM cases are due to variants in MODY genes, most of 
which are amenable to SU treatment [248]. Thus these calculations include subjects 
with neonatal diabetes, as these cases would also be detected by targeted MPS for 
MODY.  
In the standard care arm, we assumed that patients were diagnosed with MODY 
following clinical suspicion and Sanger sequencing. We sourced prevalence figures 
for MODY from the DPV database which reported overall prevalence for MODY of 
0.65%, of which 3.7% were HNF4A, 62.1% GCK, 30.9% HNF1A, and 3.3% other 
MODY subtypes [18].  
MODY cases with mutations in HNF1A, HNF4A, ABCC8 or KCNJ11 may be 
converted from insulin to SU therapy, with successful conversion rates of 80-90% 
extrapolated from studies in neonatal diabetes and limited studies in MODY [244, 
250, 251]. The current study assumed that all patients with treatable mutations 
attempted a conversion to SU therapy with a conservative success rate of 80%. 
Failure of SU responsiveness over time was not modelled, due to a lack of long-term 
data in MODY. However, it was assumed that patients successfully converted to SU 
therapy would maintain a lifetime HbA1c of 6.9% [244, 250, 251],which in turn was 
assumed to contribute to reduced long-term diabetes complications (many of which 
are directly proportional to HbA1c levels [252]).  
A Markov cohort model was developed based on the structure of the Sheffield Type 
1 Diabetes Model [212] to examine the impact of long-term diabetes complications. 
We attached the model to the initial decision tree and characterised the progression 
of disease over time by assigning a relative probability of developing complications in 
any given year to each patient cohort. Modelled complications included nephropathy, 
neuropathy, retinopathy, cardiovascular disease, severe hypoglycaemia, and 
diabetic ketoacidosis. Patients could die from end stage renal disease, 
cardiovascular events, or other (non-diabetes related) causes at any time in the 
model. The probabilities assigned to long-term complications accounted for each 
patient’s age, duration of diabetes, treatment type and HbA1c level. There were 
assumptions and transition probabilities associated with long-term complications 
(Supplementary Table S4.1). 
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Resource use and costs 
We determined the resource use and costs associated with MODY testing and 
ongoing treatment of diabetes (Table 4.2).  
 
Table 4.2  Resource use and costs associated with testing and treatment  
Resource use 
Unit Cost 
($)# 
Source (item 
number) 
Annual Cost 
($) 
Testing costs 
Intervention – targeted MPS 500 Assumption 
 
Standard care  - Sanger sequencing 750 [253] 
 
Type 1 DM 
Glucometer strips - 6 per day 0.53 PBS [1503D] 1,161 
Consultation - 4 per annum 75.6 MBS [116] 302 
Coeliac and thyroid function tests - 1 per annum 49.8 MBS [66716, 71163] 50 
Urine ACR - 1 per annum 20.1 MBS [66560] 20 
Insulin regimen 
   
MDI rate: 52% 
 
WACDD 
 
Glargine insulin dose, daily: weight x 50%^ 0.0541 PBS [9039R] 122 – 636 
Insulin Aspart dose, daily: weight x 50% ^ 0.0190 PBS [8435Y] 42 – 224 
Pump rate: 48% 
 
WACDD 
 
Cost of pump, annualised* 
  
6,516 
Insulin Aspart dose, daily: weight x70%^ 0.0190 PBS [8435Y] 60 – 313 
Total 
  
3,621 - 4,183 
MODY 2 
Nil  
  
0 
Other MODY/SU failure 
Glucometer strips – 6 per day 0.53 PBS [1503D] 1,161 
Consultation - 4 per annum 75.6 MBS [116] 302 
Urine ACR - 1 per annum 20.1 MBS [66560] 20 
Insulin regimen 
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MDI rate: 52% 
 
WACDD 
 
Glargine insulin dose, daily: weight x 50%^ 0.0541 PBS [9039R] 122 – 636 
Insulin Aspart dose, daily: weight x 50%^ 0.0190 PBS [8435Y] 42 – 224 
Pump rate: 48% 
 
WACDD 
 
Cost of pump, annualised * 
  
6,516 
Insulin Aspart dose, daily: weight x 70% ^ 0.0190 PBS [8435Y] 60 – 313 
Total 
  
3,571 - 4,133 
MODY 1,3,12,13 on SU 
Glucometer strips - 3 per day 0.53 PBS [1503D] 580 
Consultation - 4 per annum 75.6 MBS [116] 302 
Urine ACR - 1 per annum 20.1 MBS [66560] 20 
Sulphonylurea (gliclazide) - 80mg per day 0.2194 PBS [2449X] 80 
Total 
  
983 
^ Dosages vary and were derived based on median CDC (Centres for Disease 
Control and Prevention) weights per age [254] 
* Assumes annual cannula and reservoir costs based on current market prices, a 
replacement pump every four years based on current market prices (Medtronic 
Australasia, Macquarie Park, NSW, Australia), one same-day admission every four 
years  
# All costs were varied by 20% in the sensitivity analysis except for the MPS cost 
which was varied between AU$80 to AU$1000 to reflect greater uncertainty 
surrounding this figure. 
Abbreviations: MBS Medical Benefits Schedule; PBS Pharmaceutical benefits 
schedule; PMH Princess Margaret Hospital for Children; WACDD Western Australian 
Childhood Diabetes Database; MDI multiple daily injections; ACR albumin creatinine 
ratio; SU sulfonylurea. 
 
 
The cost of MPS genetic testing for reagents is currently AU$80 per sample 
(assuming batching of 96 samples). We have estimated MPS laboratory costs as 
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AU$500 (allowing for labour and bioinformatics time, and lower throughput). Sanger 
sequencing costs were based on average per-gene sequencing costs ($750). We 
assumed that only one MODY gene was sequenced per case, and that all 
sequenced cases had a mutation identified.  
Ongoing treatment protocols were based on current Australian clinical practice. 
Specifically, individuals with MODY do not require annual screening for coeliac 
and/or thyroid disease because MODY is not an autoimmune condition. Additionally, 
those with GCK-MODY require little to no follow up (except during pregnancy) as it is 
non-progressive. The 48% rate of insulin pump use was obtained from WACDD. 
Resource use items were valued using current Australian prices listed on the 
Medicare Benefits Schedule (MBS) [213] and Pharmaceutical Benefits Schedule 
(PBS) [214]. Costs associated with long-term diabetes complications were derived 
from the literature and inflated to 2016 dollars [203] (Supplementary Table 4.2). 
Quality of life (QoL) effects 
We assumed that increased QoL with routine MODY testing was due to the 
immediate effect of ceasing insulin therapy (when possible) and ongoing effects on 
longer term benefits of reduced complications. Quality-adjusted life years (QALYs) 
were derived by weighting the time spent in a given health state by the utility value 
associated with that state (where a utility of zero is equivalent to death and a utility of 
one is equivalent to full health). 
We assigned a base case utility for a life with complication-free T1DM requiring 
insulin of 0.86 [255]. This improved to 0.96 for patients who did not require insulin 
therapy, which included those individuals with MODY successfully converted to SU 
therapy [255] and those with GCK-MODY who were able to cease all therapies. 
Utility decrements associated with various diabetes complications were subtracted 
from these base case values accordingly (Supplementary Table S4.3). 
Sensitivity analyses 
We conducted a series of one-way sensitivity analyses to examine the uncertainty 
around the base case parameters (Table 4.1). We considered the impact of testing in 
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a population with MODY prevalence ranging from 1% to 6.5%, which reflects the 
prevalence of MODY in an antibody-negative T1DM population [227]). We used 
estimates from the published literature for ranges around the proportions for each 
MODY subtype, based on reports from two population-based studies, one using 
traditional sequencing, and one using MPS [227, 247]. Given the paucity of data on 
the percentage of individuals with MODY successfully converted to SU, an arbitrary 
range of 50-100% was chosen. The range of HbA1c in the insulin treated group was 
taken from different cohorts in the Hvidore study [249] and the HbA1c in the MODY 
cohort treated with SU was taken from various case reports and small case series 
[223, 244]. 
MPS is not currently commercially available through our laboratory. To reflect the 
uncertainty in pricing, the testing cost was varied from a lower limit of AU$80 (the 
laboratory reagent cost price assuming batching) to an upper limit of AU$1,000 
(base case AU$500).  
The range of pump use in insulin treated patients was 14% to 65%, reflecting 
different clinic practice [256, 257]. Utility values for insulin treated patients were 
varied from 20% below the base case of 0.86 (i.e. 0.69) up to the point where utility 
was equivalent to non-insulin treated patients (0.96). Similarly, the utility value for 
non-insulin treated patients ranged from a lower limit equivalent to that of insulin 
treated patients (0.86) to an upper limit of 1.00 (i.e. full health). The discount rate 
was tested over a range between 0% and 5%. All other costs, utilities and transition 
probabilities were varied by 20% above and below base case values. 
The results of the sensitivity analyses are presented in terms of their net monetary 
benefits (NMB; Figure 4.2). The NMB is a summary statistic that represents the 
value of an intervention in monetary terms when a willingness-to-pay [WTP] 
threshold for a QALY is known (NMB = [WTP threshold*incremental effectiveness] – 
incremental costs). A positive NMB indicates that a strategy is cost-effective while a 
negative NMB indicates that the costs outweigh the benefits. We adopted a WTP 
threshold of AU$64,000 per QALY, based on a recent published estimate 
representing a standard WTP in the Australian context [258].  
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Results 
The base case model estimated that routine targeted MPS screening for MODY 
would result in an average increase of 0.026 QALYs per patient over a 30 year time 
period (Table 4.3), translating to an additional 26.3 QALYs per 1,000 patients tested. 
The main drivers were the QoL improvements in MODY subjects able to cease 
insulin therapy, and modest reductions in the proportion of patients experiencing 
long term complications. 
In addition to producing health benefits, routine screening reduced total health 
system costs by an average of AU$1016 per patient over 30 years, translating to 
AU$1,016,390 in savings per 1,000 patients tested. This translated to an incremental 
cost effectiveness ratio of AU$2702 per QALY gained and was considered highly 
cost-effective. The costs of routine screening were fully offset within 10 years. 
Savings increased each year due to the lower ongoing costs of SU therapy relative 
to insulin therapy and the lower risk of long-term complications. 
Routine MPS screening for MODY was dominant (i.e. the intervention costs less and 
is at least as effective as the comparator) at both 10 years and 30 years. It was the 
dominant strategy for all the one-way sensitivity analyses except for that of the 
underlying MODY prevalence. A threshold analysis revealed that routine targeted 
MPS was dominant at a prevalence of 1.1% and above.  
When we adopted a willingness-to-pay of AUD $64,000 per QALY, the NMB of 
routine MPS screening was AU$2702. This result was robust and remained positive 
across all the one-way sensitivity analyses (Figure 4.2). The costs and QoL benefits 
of the change from insulin to SU therapy accounted for 78% of the total NMB, far 
outweighing the benefits of reduced diabetes complications. 
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Table 4.3 Base case cost-effectiveness analysis results 
 After 10 years After 30 years 
Modelled cohort 
outcomes 
Routine 
MPS 
testing 
Testing 
based on 
clinical 
suspicio
n only 
Differenc
es 
Routine 
MPS 
testing 
Testing 
based on 
clinical 
suspicio
n only 
Differenc
es 
Microalbuminuria 
(%) 
16.20 16.33 -0.13 42.93 43.26 -0.33 
Macroalbuminiura 
(%) 
1.87 1.89 -0.02 13.36 13.50 -0.13 
ESRD (%) 0.18 0.19 0.00 6.26 6.32 -0.06 
Death from ESRD 
(%) 
0.03 0.03 0.00 2.63 2.66 -0.03 
Background 
retinopathy (%) 
3.38 3.41 -0.03 10.30 10.40 -0.10 
Proliferative 
retinopathy (%) 
0.40 0.40 0.00 1.99 2.01 -0.02 
Macular oedema 
(%) 
1.24 1.25 -0.01 6.09 6.14 -0.05 
Blindness (%) 0.01 0.01 0.00 0.21 0.22 0.00 
Neuropathy (%) 8.30 8.39 -0.07 24.18 24.39 -0.21 
Amputation (%) 0.76 0.77 -0.01 5.50 5.55 -0.05 
Myocardial 
infarction (%) 
0.00 0.00 0.00 0.82 0.83 -0.01 
Stroke (%) 0.00 0.00 0.00 0.19 0.19 0.00 
Heart failure (%) 0.00 0.00 0.00 0.33 0.33 0.00 
Death from CVD 
events (%) 
0.00 0.00 0.00 0.14 0.14 0.00 
Hypoglycaemia 
(mean episodes 
per person) 
0.55 0.55 -0.01 1.76 1.78 -0.02 
Ketoacidosis 
mean episodes 
0.45 0.46 -0.01 1.44 1.46 -0.02 
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per person) 
Alive (%) 99.97 99.96 0.00 97.30 97.27 0.03 
Total costs ($) 49,904.83 50,427.37 -522.53 147,431.3
0 
148,447.6
9 
-1016.39 
QALYs 7.5137 7.5030 0.0107 17.0793 17.0530 0.0263 
ICER ($/QALY) MPS test is dominant MPS test is dominant 
ICER incremental cost effectiveness ratio; QALY quality adjusted life years; ESRD 
End stage renal disease; MPS massively parallel sequencing; CVD cardiovascular 
disease 
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Figure 4.2: Sensitivity analysis for 30 year net monetary benefit (NMB) 
associated with routine genetic testing.  
0 2,000 4,000 6,000 8,000 10,000 12,000
Cost - MPS test
Discount rate
HbA1c - SU treated patients
HbA1c - insulin treated patients
Utility - SU treated + MODY2 patients
Utility - insulin treated patients
SU success in MODY 1,3,12,13
MODY 1,3,12,13 detected (Std Care)
MODY 1,3,12,13 detected (MPS)
MODY 2 detected (Std Care)
MODY 2 detected (MPS)
MODY prevalence
Net Monetary Benefit ($)
 Ranges for bars: 
• MODY prevalence 1.0 - 6.5%  
• MODY 2 detected by standard care or MPS 20 - 83%; discount rate 0% to 5% 
• MODY 1,3,12,13 detected using MPS or standard care 4% - 53%  
• probability of SU success: 50% - 100% 
• baseline utility for insulin treated subjects 0.69 - 0.86 
• baseline utilities for non-insulin treated subjects: 0.86 - 1.0 
• HbA1c for insulin treated subjects 7.3% - 8.9% 
• HbA1c for non-insulin treated subjects 5.5% - 7.0% 
• Discount rate 0 - 5% 
• cost of MPS AU$80 – AU$1,000 
Base case NMB = AU$2702 based on willingness to pay of AU$64,000. NMB: net 
monetary benefit, MPS: massively parallel sequencing, Std Care: standard care, SU: 
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sulphonylurea, MODY 1: HNF4A-MODY; MODY 2: GCK-MODY; MODY 3: HNF1A-
MODY; MODY 12: ABCC8-MODY; MODY 13: KCNJ11-MODY  
 
Discussion 
This is the first cost-effectiveness analysis of routine screening for monogenic 
diabetes using targeted MPS. Routine genetic testing for MODY by targeted MPS is 
both more effective and less costly than current standard care (a diagnostic 
approach that predicates testing on clinical recognition), over both 10 and 30 year 
follow up periods. The health benefits of routine MPS screening were apparent within 
a year, with costs fully offset within 10 years. These results were robust to the effects 
of uncertainty within the modelled parameters: routine testing remained dominant 
when prevalence was as low as 1.1% and sequencing costs were as high as $1,000 
per patient. 
Most of the reduced cost and QoL benefits resulted from the use of SU rather than 
insulin. The change in health utility for SU use was extrapolated from data in adults 
with T2DM, as health utility data is not available for SU-treated MODY (neither in 
adults nor children). Further, ceasing insulin as a child may have greater QoL 
benefits than ceasing in adulthood because the risk (and associated fear) of severe 
hypoglycaemia with insulin therapy is greater in children [259]. Parents of children on 
insulin greatly fear hypoglycaemia [259]. We did not include any QoL benefits for 
parents and other family members; thus the QoL benefits are conservative 
estimates. 
The first analysis of the benefits of genetic testing in monogenic diabetes was 
performed for neonatal diabetes [248]. Genetic testing was cost saving, with 
increased QALYs. This study used traditional Sanger sequencing of two genes, 
notably at greater cost than targeted MPS. Although a greater proportion of neonatal 
diabetes can be treated by SU than can MODY cases, the benefits of SU treatment 
are similar in both groups. Naylor et al. evaluated the cost effectiveness of genetic 
testing (using Sanger sequencing) for MODY in a young adult population with T2DM 
[260]. They based their assumptions on a theoretical prevalence of MODY of 2% in 
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this population, which estimate is yet to be verified. Routine genetic screening in this 
population was not as cost effectiveness as we have shown here, mainly due to 
lower rates of insulin use in T2DM populations. The cost advantage of MPS over 
traditional Sanger sequencing has also been seen in other monogenic conditions 
(e.g. colorectal cancer [261]). 
This study is based on real world data from a paediatric diabetes clinic with 
essentially complete case ascertainment for T1DM for a large catchment population 
(i.e. the entire of Western Australia). Thus, we provide an accurate estimate of 
benefit to the health services of this state. 
A strength of the Markov modelling approach is the ability to synthesise the best 
available evidence in a systematic and transparent manner to estimate costs and 
benefits associated with alternative treatment protocols across patient subgroups. 
We could also estimate the relative rates of long-term diabetes complications for 
insulin and non-insulin treated patients. When combined with data on patient rated 
preferences and health system costs, we had an evidence-based means of 
projecting the long-term cost effectiveness outcomes of a routine screening program.  
We made a number of assumptions in our model, including prevalence of MODY 
gene variants of 2.14% and complete penetrance. The prevalence figure is likely to 
be an underestimate: two thirds of subjects in WACDD had both consent and DNA to 
allow MPS; but the denominator used for prevalence was the entire T1DM and 
MODY population. Furthermore, only pathogenic or likely pathogenic variants were 
included; variants of unknown significance were excluded. Lastly, segregation in 
family members was not assessed; thus penetrance could not be determined in this 
cohort. The presence of a MODY variant does not necessarily result in a MODY 
phenotype [202]. Until a complete population has been sequenced for MODY genes, 
with subsequent assessment of segregation amongst family members, exact 
penetrance of MODY variants remains unknown.  
The probabilities of successful transfer from insulin to SU therapy were based on 
limited evidence drawn mainly from case reports. There is no large scale study of the 
efficacy of SU in MODY and/or treatment failure over time. Nonetheless, the 
sensitivity analyses suggested that the cost effectiveness result was robust to 
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uncertainty around these parameters (modelled from 50% to 100% success). 
Modelling mainly focused on the benefits of switching treatment regimens. Other 
benefits of identifying MODY include screening for and treatment of clinical features 
associated with specific subtypes (e.g. HNF1B-MODY); improved gestational 
management (particularly for GCK-MODY); and cascade screening for this 
autosomal dominant disease in family members. None of these benefits were 
included in the model.  
We based the long-term outcome data for this study on published T1DM 
complication rates, predicated on HbA1c and time, and based on the Sheffield Type 
1 Diabetes Policy Model), as long-term complication data for MODY are unknown.  
Screening might be of greater cost benefit in populations with higher prevalence of 
MODY e.g. those with antibody-negative T1DM [227]. However, as routine testing is 
so dominant in terms of cost and QALY, it may be unnecessary to assess antibody 
status for routine screening to remain cost-effective (although we have not modelled 
this specifically). We have also not modelled costs and complication rates for a 
paediatric T2DM population. Our previous study in a paediatric population showed 
that prevalence of pathogenic/likely pathogenic variants in MODY genes was higher 
in presumed T2DM than in presumed T1DM (both antibody positive and negative 
cases), acknowledging that far fewer T2DM cases were sequenced. Although 
prevalence of MODY variants may be higher in T2DM, the lower use of insulin in this 
cohort may offset cost-benefits, as most of the benefit in this analysis was derived 
from switching from insulin to SU.  
We assumed that standard care (i.e. genetic testing based on clinical suspicion) 
would result in each clinically-identified case having a mutation detectable by Sanger 
sequencing, of only one gene, at cost of AU$750. There are no data on the 
sensitivity of Sanger sequencing in standard care, nor the average number of genes 
screened before testing is either successful or abandoned. Thus identification of 
MODY cases in standard care is likely to cost much more than we have estimated 
here, further underlying the benefits of routine testing using MPS technology. 
The use of MPS in clinical diagnosis of many conditions has moved from the 
research setting to clinical practice but availability is far from universal and costs vary 
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greatly. We used a base case cost of $500 per MPS test to reflect the likely true 
costs of reagents, bio-informatics and personnel time, acknowledging that these 
costs depend on throughput and expertise and that commercial costs usually build in 
a profit margin. However, MPS testing remained cost saving up to AU$1000 per test.  
The current International Society for Paediatric and Adolescent Diabetes (ISPAD) 
guidelines for MODY recommend genetic testing in three situations: a) a family 
history of diabetes in one parent and one other first degree relative; b) when a 
patient with diabetes lacks characteristics of T1DM (no antibodies, low or no insulin 
requirement) c) when a patient with diabetes lacks characteristics of T2DM (marked 
obesity, acanthosis nigricans). The guidelines were created at a time when testing 
was neither readily available nor inexpensive, and do not take into account the 
possibility of de novo mutations and/or incomplete penetrance [262]) or the 
generalised obesity epidemic. Moreover, the DPV cohort showed 17% of MODY 
cases had antibodies. Our study challenges the restriction of genetic testing based 
on clinical criteria as we have shown that, given the current low costs of sequencing, 
routine MPS in all newly diagnosed presumed T1DM children produces QALY gains 
while reducing health system costs. The adoption of this evidence-based and cost-
effective approach will lead to individualisation of therapy and improved patient 
outcomes - and save some children from a lifetime of insulin therapy. 
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Supplementary analysis 
 
The data was reanalysed with a MPS sequencing cost of AU$1000, to reflect current 
commercial sequencing costs.  Based on a cost of AU$1000, routine targeted MPS 
screening for MODY would still result in an increase of 0.026 QALYs. It continued to 
remain dominant over standard testing based ono clinical features alone. It provided 
a cost-saving of $516 per patient over 30 years. Costs were fully off-set within 20 
years. 
When adopting a willingness-to-pay of AU$64000 per QALY, the net monetary 
benefit of routine MPS was AU$1946. 
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Supplementary Table S4.1  Annual probabilities of diabetes related 
complications for sulphonylurea (SU) and non-SU treated cohorts     
 
Item Non-SU treated 
cohort (HbA1c  
7.84%) 
SU treated 
cohort (HbA1c 
6.9%) 
Source 
Neuropathy module  
  
Healthy to clinically confirmed neuropathy 0.0097 0.0050 [212] 
Healthy to peripheral arterial disease with 
amputation 
0.0003 0.0003 [212] 
Clinically confirmed neuropathy to peripheral 
arterial disease with amputation 
0.0154 0.0154 [212] 
 
Nephropathy  
  
Healthy to microalbuminuria 0.0198 0.0131 [212] 
Healthy to macroalbuminuria 0.0005 0.0002 [212] 
Healthy to ESRD 0.0000 0.0000 [248] 
Healthy to death from ESRD 0.0000 0.0000 [248] 
Microalbuminuria to macroalbuminuria 0.0226 0.0082 [212] 
Microalbuminuria to ESRD 0.0000 0.0000 [248] 
Microalbuminuria to death from ESRD 0.0000 0.0000 [248] 
Macroalbuminuria to ESRD * 0.0042 - 0.074 0.0042 - 0.074 [248] 
Macroalbuminuria to death from ESRD 0.0000 0.0000 [248] 
ESRD to death from ESRD 0.0884 0.0884 [212] 
 
Retinopathy and macular oedema  
  
Healthy to background retinopathy 0.0039 0.0011 [212] 
Healthy to proliferative retinopathy 0.0003 0.0001 [212] 
Healthy to macular oedema 0.0009 0.0008 [212] 
Healthy to blindness 0.0000019 0.0000019 [212] 
Background retinopathy to proliferative 
retinopathy 
0.0128 0.0057 [212] 
Background retinopathy to macular oedema 0.0382 0.0328 [212] 
Background retinopathy to blindness 0.0001 0.0001 [212] 
Proliferative retinopathy to blindness 0.0038 0.0038 [212] 
Macular oedema to blindness 0.0016 0.0016 [212] 
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CVD events  
  
CVD event* <0.0001 - 0.60 <0.0001 - 0.60 [212] 
MI given CVD event 0.53 0.53 [212] 
Stroke given CVD event 0.0700 0.0700 [212] 
Angina given CVD event 0.2800 0.2800 [212] 
Heart failure given CVD event 0.12 0.12 [212] 
Death from MI 0.1860 0.1860 [212] 
Death from stroke 0.2240 0.2240 [212] 
Death from heart failure 0.0570 0.0570 [212] 
 
Hypoglycaemia and ketoacidosis  
  
Hypoglycaemia 0.0620 0.0010 [263] 
Diabetic ketoacidosis 0.051 0.0010 [248] 
 
All-cause mortality* 0.00008 - 0.0057 0.00008 - 
0.0057 
[264] 
 
* Variables are time and/or age dependent 
CVD cardiovascular disease; ESRD end stage renal disease; MI myocardial 
infarction; SU sulfonylurea. 
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Supplementary Table S4.2  Base case health state and transition costs   
 
 
Mean costs 
(AU$) Source 
Transition costs (first year with 
complication)  
 
Neuropathy 3,048 [265] 
Amputation 31,680 [266] 
MI 17,217 [266] 
Angina 4,596 [265] 
Heart failure 8,460 [265] 
Stroke 26,195 [266] 
Stroke, death within 30 days 21,347 [266] 
Severe vision loss/blindness 37,807 [265] 
Major hypoglycaemic event 754 [265] 
Ketoacidosis 3,603 [265] 
 Annual costs (ongoing costs of 
complications)  
 
Microalbuminuria 66 [267] 
Macroalbuminuria 66 [267] 
End stage renal disease 84,418 Weighted average from [268] 
Neuropathy 359 [265] 
Amputation 17,346 [266] 
Background retinopathy 266 [267] 
Proliferative retinopathy 1,214 [267] 
Macular oedema 1,214 [267] 
Severe vision loss/blindness 55,985 [265] 
Myocardial infarction 10,828 [266] 
Angina 8,641 [266] 
Heart failure 1,033 [265] 
Stroke 9,954 [266] 
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Supplementary Table S4.3  Base case utility parameters 
 
Health state or event Utility 
Value 
Source 
Baseline utility values  
 
T1DM with no complications  0.86 [248] 
T1DM with no complications and SU treated 0.96 [248] 
 
Utility decrements  
 
Blindness -0.208 [212] 
Macroalbuminuria -0.017 [212] 
End stage renal disease -0.023 [212] 
Clinically confirmed neuropathy -0.055 [212] 
Peripheral arterial disease with amputation -0.116 [212] 
Myocardial infarction -0.058 [212] 
Stroke -0.018 [212] 
Revascularisation -0.058 [212] 
Angina -0.090 [212] 
Severe hypoglycaemia -0.071 [212] 
Diabetic ketoacidosis -0.001 [212] 
 
T1DM type 1 diabetes mellitus; SU sulphonylureas 
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5.0   Case Report of a Novel INS Mutation Causing 
Maturity-Onset Diabetes of the Young 
Recently MPS has moved from the research space into clinical practice; and 
targeted MPS has been introduced into many clinical laboratories for clinical 
diagnoses. Many laboratories, including the Mater health services in Brisbane, have 
developed panels for the MODY genes. The following work is a case report of a 
family with INS-MODY identified through targeted MPS. INS is a rare cause of 
MODY, and typically families with INS-MODY were not be identified as this mutation 
in this gene were considered too rare to justify screening. 
I identified this family with MODY in my own diabetes clinic, and recruited the 
proband and family members to my study. The proband was sequenced at the Mater 
Hospital’s internal Illumina TruSeq DNA custom amplicon panel and bioinformatic 
analysis was performed by Mr Ivan McGown, identifying a novel mutation in INS.  
I was responsible for recruiting the family, obtaining all clinical information, 
organising DNA collection, interrogating variant databases and writing the first draft 
of the manuscript. 
The following work reports the case report of this novel INS mutation and has been 
submitted for publication. 
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5.1   A novel INS-MODY mutation associated with insulin-
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Abstract 
Maturity-onset diabetes of the young (MODY) refers to a heterogeneous group of 
autosomal dominant diabetes, with at least thirteen confirmed causative genes. 
Insulin gene (INS) mutations are a rare form of MODY. Here we describe a family 
with MODY due to a novel INS mutation, detected using massively parallel 
sequencing (MPS).  
Subjects: The proband presented aged 11 years with mild diabetic ketoacidosis, was 
negative for IA2 and GAD antibodies and had an autosomal dominant pedigree for 
diabetes. Both siblings and her mother, none of whom had ketosis, were considered 
to have type 1 diabetes and managed on insulin; while her grandfather was 
managed for decades on sulfonylureas. Of note, her younger sister had an elevated 
fasting proinsulin:insulin ratio of 76% (ref 5-30%) as well as insulin deficiency. 
Sanger sequencing of HNF4A, HNF1A and HNF1B in the proband was negative.  
Methods: The proband underwent targeted MPS using a custom-designed amplicon 
panel and sequenced on an Illumina MiSeq. 
Results A heterozygous INS mutation c.277G>A (p.Glu93Lys) was detected. Sanger 
sequencing confirmed the variant segregated with diabetes within the family. 
Although affected family members had a clinical phenotype consistent with insulin 
deficiency in silico modelling of this variant also suggests disrupted hydrogen 
bonding with the insulin receptor.  
Conclusion: This family has a novel INS mutation and demonstrated variable insulin 
deficiency. MPS represents an efficient method of MODY diagnosis in families with 
rarer gene mutations.  
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Introduction 
Maturity-Onset Diabetes of the Young (MODY) is a heterogeneous group of 
disorders, characterised by autosomal dominant inheritance of beta cell dysfunction. 
The prevalence of MODY is approximately 2% of children with diabetes mellitus [16]. 
However, many cases of MODY are not recognised [20]. To date, at least thirteen 
genes have been associated with MODY, with mutations identified most commonly 
in HNF4A, GCK, HNF1A and HNF1B [20]. Several genes associated with MODY are 
also associated with neonatal diabetes (NDM), usually defined as diabetes 
presenting <6 months of age, including, INS, GCK, PDX1, HNF1B, NEUROD1, 
ABCC8 and KCNJ11. 
Traditionally, genetic confirmation of MODY has involved iterative Sanger 
sequencing, starting with the most common and/or clinically likely genes. 
Consequently, even individuals with compelling clinical histories often have 
incomplete genetic screening. Undoubtedly, this results in mis-classification of 
children with MODY as type 1 diabetes (T1DM) or type 2 diabetes (T2DM) [20]. Until 
recently, comprehensive screening of all MODY-associated genes only occurred 
within the research setting. However, the rapid devolution of massively parallel 
sequencing (MPS) from the research to the clinical setting means comprehensive 
MODY screening can now occur much more efficiently and cost-effectively than 
traditional methods. MPS technologies include agnostic methods (such as whole 
exome or whole genome) and targeted panels for MODY and other monogenic 
diabetes genes [217, 219]. 
Here, we report a family with MODY caused by a novel INS mutation, identified using 
targeted MPS. 
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Case 
Figure 5.1 Pedigree of family with INS variant.  
 
Individuals without diabetes are indicated by white symbols; individuals with diabetes 
by black symbols, males are represented by squares, females by circles. The 
proband is indicated with an arrow. The INS genotype of each individual, if known, is 
indicated below the symbol: WT wild type; c.277G>A variant in INS. Sanger 
sequencing demonstrated beneath each individual. 
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The proband (individual IV:i from pedigree in Figure 5.1) presented aged 11 years 
with mild diabetic ketoacidosis (glucose 15mmol/L, pH 7.25, bicarbonate
 
11mmol/L.) 
and HbA1c 15.2%. Her non-fasting C-peptide at diagnosis was low at 0.14nmol/L 
(fasting reference range 0.3 – 0.7), consistent with insulin deficiency. Testing for anti-
pancreatic antibodies (GAD and IA-2) and insulin antibodies was negative. She was 
commenced on multiple daily injections of insulin aspart and glargine. Initially she 
required insulin doses of 0.6units/kg to maintain an HbA1c of 5.7-6.3% (insulin-
adjusted HbA1c 8.1- 8.7); over the next four years she required a gradual increase in 
insulin to 0.8 units/kg/day to maintain an HbA1C of <6.5%. 
She had a striking family history of autosomal dominant inheritance of diabetes 
spanning four generations (Figure 5.1). Her younger brother (individual IV:ii) was 
diagnosed with diabetes aged 8 years, concomitant with her own diagnosis. At 
presentation, he was non-ketotic, with glucose 19.2mmol/L and random C-peptide 
0.32nmol/L. He also was negative for GAD, IA2 and insulin antibodies. His insulin 
requirement was 0.3 units/kg/day for two years, maintaining an HbA1c between 5.2 – 
5.4% (insulin adjusted HbA1c 6.4-6.6), with a gradual dosage increase over time 
(four years post diagnosis - insulin requirement 0.7 units/kg/day). Their sister 
(individual IV:iii) subsequently presented also aged 8 years, with polyuria and 
polydipsia associated with nonketotic hyperglycaemia. Her oral glucose tolerance 
test revealed a fasting glucose of 5.6mmol/L and two-hour glucose of 17.8mmol/L. 
Her serum insulin was reduced in the context of hyperglycaemia (fasting 3.5mIU/L 
rising to only 10 mIU/L at two hours). She had an elevated intact fasting proinsulin of 
18.4pmol/L (reference range <13.3 pmol/L) and an elevated proinsulin:insulin ratio of 
76% (reference range  5-30% [269]). She commenced insulin at diagnosis and was 
managed on 0.2units/kg/day for the first 2 years, maintaining an HbA1c <6%. Three 
years after diagnosis, her insulin requirement was 0.7units/kg/day. Neither sibling 
has developed ketones since diagnosis.  
Their mother (individual III:iii) was diagnosed aged 11 years with presumed antibody-
negative T1DM, and had been on insulin from diagnosis. Their maternal grandfather 
(individual II:i) was diagnosed with presumed T2DM in his 30s. He was initially 
managed with a sulphonylurea for over two decades but subsequently transitioned to 
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insulin. He had recently been diagnosed with a metastatic pancreatic 
neuroendocrine tumour (NET). 
The autosomal dominant nature of diabetes in this family alerted the caring clinician 
to the possibility of MODY.  
Genetic screening 
No mutations in HNF4A, HNF1A or HNF1B were detected in the proband by Sanger 
sequencing. Subsequently, targeted MPS was performed. Sequence libraries were 
constructed using an Illumina TruSeq DNA custom Amplicon panel (Illumina, San 
Diego, CA USA) which included HNF4A, GCK, HNF1A, PDX1, HNF1B, INS, 
KCNJ11 and ABCC8, and sequenced using an Illumina MiSeq. CLC Bio was used to 
demultiplex data, trim and align the data and generate a variant file. Single 
nucleotide polymorphisms and small insertion/deletions were filtered using 
Cartagenia to identify high-quality, non-synonymous variants in coding regions. 
Variants were further filtered to exclude those predicted to be benign. 
A heterozygous variant (NM_000207.2: c.277G>A; p.Glu93Lys) was detected in INS. 
This variant has not been previously reported in Exome Aggregation Consortium 
(ExAC), dbSNP, 1000 Genomes, LOVD, HGMD or PubMed and is predicted to be 
damaging by protein prediction algorithms PolyPhen, MutationTaster and SIFT. The 
variant was confirmed by Sanger sequencing and segregated with disease in all 
family members tested (genotypes shown in Figure 5.1).  
The variant lies in a highly conserved region and affects an amino acid (Glu93) 
located in one of the alpha helices of the insulin protein. Glu93 in insulin makes 
hydrogen bond interaction with Asn711 of the insulin receptor. In silico functional 
studies suggested the alteration of this Glu93 residue to lysine would be expected to 
disrupt this interaction, leading to impaired binding of insulin to its receptor (Figure 
5.2). 
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Figure 5.2. Overview of the structure of insulin protein interaction with insulin 
receptor.  
 
 
 
E93 in insulin (labelled E4)(insulin in light black sticks, backbone and side-chains) 
makes hydrogen bond interactions (distance 2.68 A between O-N atoms) with N711 
of the insulin receptor (thick black). A replacement by a lysine residue would most 
likely disrupt this interaction and lead to impaired binding of insulin to its receptor.  
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Discussion 
Here we have identified a novel heterozygous variant mutation in INS in a family with 
MODY.  
INS mutations cause a heterogeneous group of monogenic diabetes. To date over 
50 mutations have been described in INS, with both recessive and dominant 
inheritance [270-272]. Most INS mutations are associated with NDM (both autosomal 
recessive and dominant disease); indeed, INS mutations are the second most 
common cause of NDM in non-consanguinous families [270]. Dominant INS 
mutations can cause NDM and MODY phenotypes with the same mutation 
associated with both phenotypes even within the same family, suggesting the 
arbritary nature of the definition of NDM. Thus dominant INS mutations can be 
collectively referred to as Mutant INS-gene Induced Diabetes of Youth (MIDY) [272]. 
However, overall, INS mutations are a rare cause of MODY [270], as mutations in 
other MODY genes are much more prevalent in the MODY population [270]. Unlike 
some forms of MODY, mutations in INS have not been associated with congenital 
hyperinsulinism. 
Insulin synthesis in the pancreatic beta cell is complex. Preproinsulin is the first 
translational product of INS and is translocated across the endoplasmic reticulum 
(ER) membrane, after which proteolytic cleavage of the signal peptide cleaves 
proinsulin. Within the ER, proinsulin undergoes oxidative folding forming three 
disulphide bonds, allowing exit from the ER into the Golgi apparatus. Proinsulin 
subsequently undergoes further cleavage to produce C-peptide and mature insulin, 
which are stored in secretory granules.  
Diabetes-associated INS mutations lead to the production of structurally abnormal 
preproinsulin or proinsulin. Many identified mutations impair cleavage of the signal 
peptide and/or proinsulin folding. Thus misfolded proinsulin is retained in the ER, 
causing ER stress that activates the unfolded protein response, ultimately resulting 
in beta cell apoptosis [273]. This mechanism of beta cell apoptosis from ER stress is 
also seen in another monogenic form of diabetes, Wolfram syndrome, caused by 
mutations in WFS1 [274]. Wolfram syndrome is the prototype of ER disease: WFS1 
encodes a transmembrane protein which localises to the ER, and mutations in this 
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gene result in ER stress and apoptosis, particularly of beta cells and neurons [275]. 
Of note, the insulin deficiency seen in the diabetic Akita mouse (resulting from a 
heterozygous Cys96Try INS mutation) predates beta cell apoptosis and is not 
completely accounted for by the degree of apoptosis [276]. This mutation has a 
dominant negative effect, such that wild type insulin folding is directly affected by 
both the mutant gene product and the change in the ER environment. This affects 
trafficking of the wildtype protein in addition to the mutant protein. Thus the 
combination of beta cell loss and blockage of wild type insulin secretion results in 
insulin deficiency.  
Less commonly, INS mutations can affect binding of insulin to its receptor. Defective 
binding of mutant insulins to the insulin receptor can impair insulin clearance, 
increasing the half-life and circulating insulin levels [277].  
Thus the degree of insulin deficiency (either actual or functional) resulting from INS 
mutations can be variable. INS mutations in NDM result in a severe form of insulin 
deficiency, such that affected individuals frequently present with diabetic 
ketoacidosis [272]. INS-MODY can be more variable, both between and within 
families (as seen here), and can present with milder diabetes managed with diet or 
oral hypoglycaemic agents through to diabetes presenting with diabetic ketoacidosis 
requiring full insulin replacement [278]. Thus the phenotype in INS-MODY is 
dissimilar to other forms of MODY. According to the International society for 
paediatric and adolescent diabetes (ISPAD) guidelines, a diagnosis of MODY should 
be considered when there is “low or no insulin requirements five years after 
diagnosis (stimulated C-peptide >200pmol/L)” [279]. This is clearly not the case for 
most cases of INS-MODY; and thus many cases of INS-MODY presenting with a 
more severe phenotype may be misdiagnosed as T1DM. 
The variable phenotype in our family may result from several of these mechanisms, 
which are not mutually exclusive. The elevated proinsulin-to-insulin ratio in the 
youngest sibling (individual IV:iii) may reflect abnormal insulin processing prior to 
complete beta cell apoptosis, at least in this individual. Unfortunately we do not have 
ratios for other members of this family, so whether their insulin deficiency was due to 
impaired secretion or beta cell destruction is unclear. Similarly, we cannot comment 
as to whether any secreted insulin was able to bind normally to the insulin receptor. 
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The in silico modelling of the mutation identified here suggests that if any insulin was 
secreted by the beta cell it would not bind effectively with the insulin receptor. A 
previously reported family with a mutation at the adjacent codon causing a Val92Leu 
mutation (Insulin Wakayama) exhibited both hyperproinsulinaemia and impaired 
binding of insulin to the insulin receptor [280]. However, it is interesting to note the 
very long period without insulin treatment in individual II:i. He was initially managed 
with sulfonylurea treatment, which suggests that he had some residual insulin 
secretion and that his endogenous insulin was to some degree bioactive. However, 
in retrospect the use of sulphonlyureas in INS MODY may exacerbate ER stress and 
cause further beta cell apoptosis. Over time however he needed to be transitioned to 
insulin treatment. Indeed the increasing insulin requirements in the three siblings is 
consistent with progressive insulin deficiency, possibly secondary to ER stress 
induced apoptosis  
The longer honeymoon period experienced by the two siblings of the proband may 
be related to the earlier diagnosis in the disease process. Replacing insulin and 
decreasing demand for endogenous insulin production may lessen the production of 
mis-folded proinsulin and minimise ongoing ER stress and beta cell apoptosis. “Beta 
cell rest” is also responsible for the honeymoon period in T1DM [281]. However, the 
natural rate of progression of beta cell failure for these children is not known, and 
therefore it is impossible to conclusively say whether earlier intervention affected the 
natural history. 
Lastly, a possible association between the INS mutation and neuroendocrine 
pancreatic tumorigenesis in the grandfather is interesting but purely speculative. 
There have been no reported cases of NET or other pancreatic tumours from INS 
mutations; however, ER stress is known to play a role in NET development [282]. 
Further, other MODY genes have been associated with pancreatic adenocarcinomas 
[283].  
One limitation of this study is the lack of biochemical data on the other family 
members. All patients (aside from individual IV:iii) were already established on 
insulin at the time the diagnosis of INS-MODY was made, While individuals III:iii, IV:i 
and IV:ii appear to have a similar clinical picture to IV:iii, it is not possible to confirm 
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this. Insulin levels would have also been able to confirm if the grandfather (II:i) 
demonstrated insulin deficiency or resistance.  
In conclusion, this case highlights the utility of MPS in diagnosing cases of MODY, 
particularly in rarer forms. Unlike some forms of MODY that can be managed with 
sulphonylureas (e.g. HNF4A, HNF1A, ABCC8 and KCNJ11), MODY arising from INS 
mutations usually requires insulin. Further research will be needed to determine 
whether strategies aimed at reducing ER stress, if initiated early in the course of the 
disease, may potentially slow beta cell apoptosis and improve insulin secretion.  
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6.0  Whole Exome Sequencing for Genetic Diagnosis of 
Maturity-Onset Diabetes of the Young and Congenital 
Hyperinsulinism – A Retrospective Proof of Concept Study 
Until recently, the majority of clinical genetic testing was performed using traditional 
Sanger sequencing. Generally this was performed in a step-wise process starting 
with the most likely and/or most common genes. This technique was appropriate for 
conditions where there are a limited number of genes, and/or those where the genes 
themselves are small. However, for conditions with multiple causative genes (such 
as MODY and CHI) sequencing of all possible genes was unusual due to cost and 
time considerations. The consequence of this policy was evident in early studies of 
MODY and CHI. Even when a genetic diagnosis was considered, individuals referred 
for genetic testing did not receive a genetic diagnosis in 15-70% of cases of MODY 
[20, 284] and 45-55% of cases of CHI [154]; possible reasons included incorrect 
phenotyping, lack of screening of known genes or disease arising from a mutation in 
an as yet unidentified gene.  
MPS offers the ability to sequence multiple target regions simultaneously, for a 
fraction of the cost of sequencing multiple genes individually.  
Chapter 6 presents a proof of concept of WES for the genetic diagnosis in MODY 
and CHI. Although I was able to identify all mutations correctly, I also identified a 
number of issues that need to be considered before WES can be used for diagnostic 
purposes. Firstly, each of the commercially available off-the-shelf capture platforms 
targeted different regions. Secondly, not all targeted regions were captured 
adequately for diagnostic purposes. Thirdly, additional bioinformatics tools were 
required if copy number variants were suspected. 
I was responsible for attaining ethics and governance, and identifying and recruiting 
all subjects. After WES had been performed and samples processed through our 
laboratory’s bioinformatics pipeline, I analysed the data for rare, coding, good quality 
variants in the MODY/CHI genes. I also analysed the extent to which all available off-
the-shelf exome capture technologies targeted exons in the genes of interest for 
these two conditions. Finally, I wrote the first draft of the manuscript. 
124 
 
The following work reports the use of WES for mutation detection in MODY and CHI 
and has been submitted for publication.  
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Abstract 
Aims: To assess the utility of whole-exome sequencing (WES) for mutation 
detection in maturity-onset diabetes of the young (MODY) and congenital 
hyperinsulinism (CHI). MODY and CHI are the two commonest monogenic disorders 
of glucose-regulated insulin secretion in childhood, with thirteen causative genes 
known for MODY and ten causative genes identified for CHI. The large number of 
potential genes makes comprehensive screening using traditional methods 
expensive and time-consuming.  
Methods: Ten subjects with MODY and five with CHI with known mutations 
underwent WES using two different exome capture kits (Nimblegen SeqCap EZ 
Human v3.0 Exome Enrichment Kit, NexteraTM Rapid Capture Exome). Analysis was 
blinded to previously identified mutations, and included assessment for large 
deletions. The target capture of five exome capture technologies was also analyzed 
using sequencing data from >2800 unrelated samples. 
Results: Four of five MODY mutations were identified using Nimblegen (including a 
large deletion in HNF1B ). Although targeted, one mutation (in INS) had insufficient 
coverage for detection. Eleven of eleven mutations (six MODY, five CHI) were 
identified using NexteraTM Rapid (including the previously missed mutation). On 
reconciliation, all mutations concorded with previous data; and no additional variants 
in MODY genes were detected. There were marked differences in the performance 
of the capture technologies. 
Conclusions: WES can be useful for screening for MODY/CHI mutations, detecting 
both point mutations and large deletions. However, capture technologies require 
careful selection. 
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Introduction 
Maturity-onset diabetes of the young (MODY) and congenital hyperinsulinism (CHI) 
represent two monogenic disorders of glucose-regulated insulin secretion. MODY is 
the commonest form of monogenic diabetes, and results from a heterozygous 
mutation in any of thirteen identified genes reported to date, all of which regulate 
beta-cell function (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, 
PAX4, INS, BLK, ABCC8 and KCNJ11 [38, 40, 42, 47]). Some forms of MODY have 
distinct clinical features (for example HNF1B-MODY is associated with renal 
malformations, pancreatic atrophy, genital malformations and abnormal liver function 
tests [80]); however, the majority are clinically indistinguishable without genetic 
testing. Some subtypes of MODY (HNF1A, HNF4A, KCNJ11, and ABCC8) can be 
treated with suphonylureas, which are more cost-effective [248], and improve clinical 
outcomes when compared to insulin therapy (lower risk of severe hypoglycemia, 
improved glycemic control and greater quality of life) [28]. Further, individuals with 
MODY do not require screening for other autoimmune conditions associated with 
T1DM. Indeed, the mildest form of MODY, GCK-MODY (MODY2), is typically mild, 
non-progressive, and requires little to no follow up [59]. 
CHI is the commonest cause of persistent hypoglycemia in infancy and childhood, 
and results from dysregulated insulin secretion [285]. The phenotype of CHI is 
variable and, although in many cases the genetic cause is unclear, a number of gene 
mutations have been identified, including many associated with MODY (HNF1A, 
HNF4A, GCK, KCNJ11 and ABCC8), in addition to non-MODY-associated genes 
(GLUD1, HADH, UCP2, HK-1 and SLC16A1 [286]). Further, the same variants may 
cause both MODY and CHI, both within the same pedigree and even within the 
same individual at different times [287]. Focal CHI is associated with a germline 
paternal mutation in ABCC8 or KCNJ11 combined with focal pancreatic loss of 
heterozygosity. A limited pancreatectomy can be curative in such cases. In contrast, 
diffuse CHI requires more extensive surgery and/or continuous intensive medical 
therapy. Decisions regarding investigations and surgery are thus in part predicated 
upon genetic testing.  
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Genetic confirmation of MODY and CHI has traditionally involved iterative Sanger 
sequencing, starting with the most common and/or clinically likely genes. 
Identification of partial/whole gene deletions or duplications requires additional 
assessment, typically involving multiplex ligation-dependent probe amplification 
(MLPA). However, these approaches are expensive with current Australian costs 
estimated at AUD$750 per gene for each of the four most common MODY genes 
(HNF4A, GCK, HNF1A and HNF1B), increasing to AUD$2500 for ABCC8 due to its 
large size (39 exons). Consequently, even individuals with compelling clinical history 
have incomplete genetic screening; with comprehensive sequencing of all 
associated genes only occurring within the research setting. Undoubtedly, this 
results in mis-classification of children with MODY as T1DM or T2DM [20]. 
In contrast, massively parallel sequencing (MPS) allows simultaneous sequencing of 
multiple target regions, more efficiently and cost-effectively than traditional genetic 
testing. Recently, targeted sequencing panels have been designed for MODY and 
other monogenic diabetes genes [217, 219]. Although targeted sequencing can 
provide excellent mutation detection, panels are expensive to design and may 
become rapidly obsolete [288] given the extraordinary pace of new gene discoveries 
in many monogenic conditions [289]. 
An alternative approach is whole-exome sequencing (WES), allowing simultaneous 
assessment of all coding and splice site regions (captured by most exome 
sequencing technologies), as well as detection of exon deletion(s). The same 
technology can also be used for new gene discovery. Costs of WES (currently 
consumable costs <AUD$650) are much cheaper than single gene sequencing. 
Thus WES may prove a rapid, cost-effective technology for genetic confirmation of 
MODY and CHI, as has been shown for other monogenic disorders [290, 291].  
This study evaluated WES in determining the underlying genetic cause of MODY 
and CHI, using two “off-the-shelf” WES capture technologies as a proof-of concept in 
samples with previously identified mutations. We also assess coverage of known 
MODY/CHI genes using five “off-the-shelf” WES technologies in a large cohort of 
unrelated samples, with comparison to manufacturers’ published targets, to illustrate 
important principles in WES technology selection when screening for these clinical 
disorders. 
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Materials and Methods 
Clinical Cohort 
Fifteen unrelated participants (ten with MODY, five with CHI) were recruited. All had 
germline mutations determined previously by Sanger sequencing (Table 6.1). Ethical 
approval was obtained from The University of Queensland Human Research Ethics 
Committee (UQ 2013000017); all individuals and/or their guardians gave informed 
consent.
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Table 6.1 Summary of Identified Variants using Nimblegen SeqCap EZ v3.0 or Illumina NexteraTM Rapid Capture Exome   
Sample 
Capture 
technology 
Number of 
variants 
MAF<5% 
Remaining coding 
variants of good 
quality after 
removal of 
platform-related 
artefact 
Variants in 
MODY/ CHI 
genes with 
MAF <0. 1% 
Damaging 
varianta 
Exome 
depth 
Mutation as detected 
by Sanger 
sequencing +/– 
MLPA 
MODY_01 Nim 8519 409 3 
HNF4A: 
c 976C>T 
NA 
HNF4A: 
c.976C>T 
MODY_02 Nim 8697 1251 1 
GCK: 
c.540T>G 
NA 
GCK: 
c.540T>G 
MODY_03 Nim 8727 379 1 
HNF1A: 
c.475C>T 
NA 
HNF1A: 
c.475C>T 
MODY_04 Nim 8832 459 0 Nil 
Del chr17: 
34848659-
36348667b 
Deletion 
HNF1B 
MODY_05 Nim 11308 509 0 Nil nil 
INS: 
c.277G>A 
MODY_05 NR 9046 668 1 
INS: 
c.277G>A 
NA 
INS: 
c.277G>A 
MODY_06 NR 7359 718 1 
GCK: 
c.781G>A 
NA 
GCK: 
c.781G>A 
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MODY_07 NR 7807 687 1 
HNF1A: 
c.872dupC 
NA 
HNF1A: 
c. 872dupC 
MODY_08 NR 7885 563 1 
GCK: 
c.754T>C 
NA 
GCK: 
c754T>C 
MODY_09 NR 7414 674 1 
HNF4A: 
c.368C>A 
NA 
HNF4A: 
c.368C>A 
MODY_10 NR 7759 1137 1 
HNF1B: 
c.827G>A 
NA 
HNF1B: 
c.827G>A 
CHI_01 NR 7292 620 1 
KNCJ11: 
c.616C>T 
NA 
KNCJ11: 
c.616C>T 
CHI_02 NR 7535 648 1 
GLUD1: 
c.1490T>C 
NA 
GLUD1: 
c.1490T>C 
CHI_03 NR 7259 662 1 
ABCC8: 
c.3807delC 
NA 
ABCC8: 
c.3807delC 
CHI_04 NR 7404 700 1 
ABCC8: 
c.1223C>T 
NA 
ABCC8: 
c.1223C>T 
CHI_05 NR 8339 846 1 
ABCC8: 
c.2015delG/ 
c.2015delG 
NA 
ABCC8: 
c.2015delG/ 
c.2015delG 
 
a
 Damaging variant according to protein prediction algorithms SIFT, Polyphen and/or MutationTaster 
b
 Deletion encompasses entire HNF1B 
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MAF = minor allele frequency; NA = not assessed; MLPA = multiplex ligation-dependent probe amplification; Nim = Nimblegen 
SeqCap EZ v3.0; NR = Illumina NexteraTM Rapid Capture Expanded Exome   
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Laboratory Methods. 
DNA was either received into the laboratory or was extracted by standard means 
from peripheral blood mononuclear cells or saliva. Sequencing libraries were 
constructed according to manufacturers’ instructions. Exome capture was performed 
using Nimblegen SeqCap EZ Human v3.0 Exome Enrichment Kit [Nimblegen] 
(Roche, Basel, Switzerland), for five MODY samples. The NexteraTM Rapid Capture 
Exome kit [NexteraTM Rapid] (Illumina, San Diego, CA, USA) was used for five CHI 
samples and five separate MODY samples plus one MODY sample previously 
sequenced with Nimblegen. Pre- and post-capture quality and yield were assessed 
by Agilent High Sensitivity DNA assay (Santa Clare, CA) on the Bioanalyzer 2100 
and by qPCR using the KAPA Library Quantification Kit (Kapa Biosystems, 
Wilmington, MA) prior to sequencing. Multiplexed MPS was undertaken on all 
samples (six samples per flow lane) using an Illumina HiSeq 2000 (Illumina, San 
Diego, CA, USA), generating 100-base pair paired-end reads.  
Data were demultiplexed using Illumina Data Analysis Pipeline software (Bcl2fastq 
v1.8.4) and aligned to the current reference human genome (hg19, released 
February 2009) using the Novoalign alignment tool (V3.00.02). Sequence alignment 
files were converted using Picard tools (v1.124). Variants were called using the 
Genome Analysis Toolkit (GATK v2.7-2) and annotated using ANNOVAR. Further 
analysis of sequence data was performed using custom scripts employing R and 
Bioconductor. After exclusion of artefact, good quality (i.e. passing GATK algorithm, 
which incorporates sequence depth, quality scores at the single nucleotide 
polymorphism (SNP) position, maximal length of the homopolymer run and strand 
bias) variants were retained. Variants of potentially damaging consequences (splice 
site, nonsynonymous, frameshift, stop-loss and stop-gain variants) with minor allele 
frequency (MAF) of <0.001 (derived from internal data of >2500 exomes, dbSNP, 
1000 Genomes, and ExAC) were assessed, in known MODY/CHI genes. Variants 
were further filtered to include those predicted to be damaging by any of three 
protein prediction programs (Polyphen, SIFT and MutationTaster). Samples without 
an identified variant were also analyzed for copy number variants using ExomeDepth 
[206]. This was not done a priori given the low frequency overall of copy number 
variants in MODY. Coverage of individual MODY or CHI genes was assessed 
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visually using the Integrative Genomics Viewer (IGV) and formally by custom R 
script. Results were reconciled after blinded analysis was complete.  
Capture Technologies 
WES data from >2800 individuals with unrelated conditions were assessed to 
determine coverage of MODY/CHI genes. Data were generated using one of five 
different capture technologies: Nimblegen SeqCap EZ v3.0 (Roche, Basel, 
Switzerland, n=833), Nimblegen SeqCap EZ v2.0 (Roche, Basel, Switzerland, 
n=245), Illumina TruSeqTM (Illumina, San Diego, CA, USA, n=1354), Illumina 
NexteraTM Rapid Capture Exome (Illumina, San Diego, CA, USA, n=392) and 
Illumina NexteraTM Rapid Capture Expanded Exome (Illumina, San Diego, CA, USA, 
n=69), sequenced on either an Illumina HiSeq2000 or 2500 at a minimum of 100bp 
paired-end read lengths. A custom R script using the Bioconductor package 
TxDb.Hsapiens.ICSC.hg19.knownGene compared percentage coverage of each 
exon of the MODY/CHI genes to a depth of 10x with each capture technology, and 
the number of exons completely (i.e. 100%) covered to a depth of 10x. 
The theoretical targets of the same capture technologies were also compared. 
Information was obtained from the Browser Extensible Data (BED) file distributed by 
each manufacturer’s website and analyzed for all eighteen known MODY/CHI genes. 
A customized R script assessed the cumulative percentage target of the exonic 
coding regions of each gene and for each exon individually. 
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Results 
General Coverage 
Mapping and coverage statistics and detailed base calling statistics for all samples 
are presented in Supplementary Table S6.1. Mean coverage overall was 44-fold with 
NexteraTM Rapid and 38-fold with Nimblegen, with 88% of the targeted capture 
region covered to a depth of 10x with NexteraTM Rapid and 80% for Nimblegen.  
Mutation Analysis 
A summary of mutation detection is presented in Table 6.1. Using Nimblegen 
Capture, a point mutation in a MODY gene concordant with previous Sanger 
sequencing results was identified in three of five MODY samples. A large deletion 
encompassing the entire HNF1B gene (chr17:34848659-36348667) was identified in 
one further sample using ExomeDepth, also consistent with previous results.  
One sample did not have a variant or large deletion detected. The sequencing BAM 
files (alignment data in binary format) were visually reviewed using IGV and 
demonstrated poor coverage of INS; other MODY genes were well covered 
(confirmed formally using R script). Re-sequencing this sample with NexteraTM Rapid 
detected a variant in INS, consistent with previous results (see Table 6.1). On 
revisiting the original sequencing, the variant was seen but had insufficient coverage 
(1x) to pass quality control. 
Using NexteraTM Rapid Capture, a mutation was detected in six MODY (including the 
sample with an INS mutation) and five CHI samples, each consistent with previous 
Sanger sequencing results.  
No other MODY or CHI gene mutations were detected in these samples using either 
sequencing technology. 
Coverage of MODY/CHI Genes in >2800 Unrelated Samples 
Coverage of MODY/CHI genes in >2800 unrelated samples sequenced at our 
institution is shown in Table 6.2 (individual exon data are presented in 
Supplementary Table S6.2). The “real life” performance varied considerably both 
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between capture technologies and when each technology was compared with the 
relevant manufacturer’s target capture BED files. For example, each of the five 
capture technologies has probes designed to target >90% of the exons of GCK. 
However, aside from NexteraTM Rapid, achieving 96% coverage at depth >10x, only 
53-77% of the exonic regions were covered to this depth using the other four capture 
technologies. 
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Table 6.2  Actual coverage of MODY/CHI genes attained using different whole-exome sequencing methods, defined as % 
exons of target gene achieving >10x coverage.  
 
Gene 
Name 
 
Number 
of 
Exons 
 
NexteraTM Rapid 
Capture Exome 
(n a = 392) 
 
NexteraTM Rapid 
Capture Expanded 
Exome 
(n = 69) 
 
Nimblegen SeqCap 
EZ v2. 0 
(n = 245) 
 
Nimblegen 
SeqCap EZ v3. 0 
(n = 833) 
 
Illumina TruSeqTM 
(n = 1354) 
HNF4A 13 
94% 
(1 exon captured 
100%) 
80% 
(1 exon captured 
100%) 
62% 
(0 exons captured 
100%) 
55% 
(0 exons captured 
100%) 
69% 
(0 exons captured 
100%) 
GCK 12 
96% 
(5 exons captured 
100%) 
77% 
(1 exon captured 
100%) 
61% 
(0 exons captured 
100%) 
53% 
(1 exon captured 
100%) 
67% 
(0 exons captured 
100%) 
HNF1A 9 
95% 
(2 exons captured 
100%) 
78% 
(0 exons captured 
100%) 
53% 
(0 exons captured 
100%) 
34% 
(0 exons captured 
100%) 
62% 
(0 exons captured 
100%) 
PDX1 2 
59% 
(0 exons captured 
100%) 
60% 
(0 exons captured 
100%) 
9% 
(0 exons captured 
100%) 
17% 
(0 exons captured 
100%) 
17% 
(0 exons captured 
100%) 
HNF1B 9 
98% 
(5 exons captured 
100%) 
76% 
(0 exons captured 
100%) 
81% 
(2 exons captured 
100%) 
84% 
(4 exons captured 
100%) 
81% 
(0 exons captured 
100%) 
NEUROD1 1 
99% 
(0 exons captured 
100%) 
95% 
(0 exons captured 
100%) 
97% 
(0 exons captured 
100%) 
93% 
(0 exons captured 
100%) 
99% 
(0 exons captured 
100%) 
KLF11 4 
85% 
(2 exons captured 
100%) 
72% 
(0 exons captured 
100%) 
78% 
(0 exons captured 
100%) 
78% 
(1 exon captured 
100%) 
77% 
(0 exons captured 
100%) 
CEL 11 
94% 
(3 exons captured 
100%) 
87% 
(1 exon captured 
100%) 
74% 
(0 exons captured 
100%) 
60% 
(1 exon captured 
100%) 
81% 
(0 exons captured 
100%) 
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PAX4 10 
99% 
(6 exons captured 
100%) 
89% 
(2 exons captured 
100%) 
96% 
(1 exon captured 
100%) 
97% 
(4 exons captured 
100%) 
93% 
(0 exons captured 
100%) 
INS 2 
94% 
(0 exons captured 
100%) 
38% 
(0 exons captured 
100%) 
30% 
(0 exons captured 
100%) 
21% 
(0 exons captured 
100%) 
60% 
(0 exons captured 
100%) 
BLK 12 
96% 
(4 exons captured 
100%) 
69% 
(0 exons captured 
100%) 
75% 
(0 exons captured 
100%) 
86% 
(1 exon captured 
100%) 
71% 
(0 exons captured 
100%) 
ABCC8 39 
97% 
(19 exons 
captured 100%) 
92% 
(6 exons captured 
100%) 
85% 
(4 exons captured 
100%) 
76% 
(6 exons captured 
100%) 
90% 
(0 exons captured 
100%) 
KCNJ11 1 
93% 
(0 exons captured 
100%) 
73% 
(0 exons captured 
100%) 
72% 
(0 exons captured 
100%) 
44% 
(0 exons captured 
100%) 
89% 
(0 exons captured 
100%) 
UCP2 6 
93% 
(2 exons captured 
100%) 
89% 
(0 exons captured 
100%) 
93% 
(0 exons captured 
100%) 
88% 
(1 exon captured 
100%) 
94% 
(0 exons captured 
100%) 
SLC16A1 4 
90% 
(2 exons captured 
100%) 
57% 
(0 exons captured 
100%) 
92% 
(1 exon captured 
100%) 
100% 
(4 exons captured 
100%) 
86% 
(0 exons captured 
100%) 
GLUD1 14 
97% 
(12 exons 
captured 100%) 
80% 
(0 exons captured 
100%) 
87% 
(6 exons captured 
100%) 
87% 
(12 exons captured 
100%) 
87% 
(0 exons captured 
100%) 
HADH 10 
99% 
(9 exons captured 
100%) 
64% 
(0 exons captured 
100%) 
77% 
(3 exons captured 
100%) 
90% 
(9 exons captured 
100%) 
68% 
(0 exons captured 
100%) 
HK1 23 
96% 
(19 exons 
captured 100%) 
77% 
(0 exons captured 
100%) 
83% 
(5 exons captured 
100%) 
89% 
(10 exons captured 
100%) 
81% 
(1 exon captured 
100%) 
a
 n = number of samples 
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Comparison of Capture Technologies 
Targeted capture of MODY/CHI genes varied substantially between the five currently 
available off-the-shelf exome capture technologies. Supplementary Table S6.3 
reveals a comparison of manufacturers’ BED files demonstrating the percent of each 
MODY/CHI gene targeted and the number of exons targeted completely; individual 
exon are displayed in Supplementary Table S6.4.  
Targeted regions varied considerably between capture technologies. In general 
Illumina capture technology had either complete or near-complete or very little/no 
target of exons – in other words, an “all or nothing” approach. Although other capture 
technologies might have more exons targeted overall, many were incompletely 
targeted. 
Discussion 
This study demonstrates that WES can accurately detect mutations in MODY and 
CHI, including copy number variability. However, capture technologies vary in their 
targeting of MODY/CHI genes, which can affect mutation detection; and “real life” 
coverage may differ from manufacturers’ published targeted regions. 
All previously identified mutations in our MODY/CHI cases were detected, including 
a whole gene deletion. Structural variants, including copy number variants (CNVs), 
are generally uncommon in MODY and CHI, although deletions accounted for 39% 
of mutations in HNF1B in the largest published case series to date [82] and structural 
variants have also been described in HNF1A and GCK [243]. We did not analyze all 
samples for structural variation a priori, but planned to perform such analysis (using 
ExomeDepth [206]) in any samples negative for point mutations, which approach 
proved efficient in terms of bioinformatics time. ExomeDepth detects differences 
between depth of sequencing of a particular sample compared with other samples 
on the same sequencing run. The program relies on the deleted or duplicated region 
being longer than the length of read (in this case 100 bases); thus the lower limit of 
detection depends on length of indel, length of sequence reads, and depth of 
coverage, which in general means an indel needs to be larger than a single exon for 
detection [206]. Analysis for smaller insertions and deletions (up to several hundred 
bp) within captured regions might need to employ different bioinformatics tools using 
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alternative methodologies such as “soft clipping”, (e.g. using the program CREST 
[292]. Data from whole-genome sequencing (WGS) may prove better for detection of 
structural variation generally, and for CNVs smaller than sequence reads specifically 
[293]. However, our case illustrates that CNV can be detected using WES; and 
analysis should include assessment for larger insertions and deletions in addition to 
the more usual point mutations seen in these disorders, particularly if no point 
mutation is identified. 
Our data illustrates some limitations of WES, specifically variability in capture 
technologies. We were initially unable to detect an INS mutation in a sample 
sequenced using the Nimblegen platform. Coverage of INS (a two exon gene) 
proved very limited (less than 4x across the entire gene), despite predicted 
comprehensive targeting of this gene. Review of in-house data of 833 samples using 
the same capture technology also showed very poor coverage of this region: 57% 
had coverage at depth of ≥1x, but only 21% had coverage depth ≥10x. This gene 
was reported to be captured comprehensively by NexteraTM Rapid and, indeed, this 
mutation was detected using this technology. INS has a relatively high GC content 
(approximately 65%, compared to an average of 38-48% across the genome) [294], 
and a high GC content can have a deleterious effect on sequencing [295]. In general 
NexteraTM is thought to have better coverage for sequences with higher GC content, 
owing to the preference of the transposon technology used [296]. High GC content is 
also a feature of the first exon of many genes; in this context it was notable that the 
first exon of several MODY/CHI genes was more poorly captured with all 
technologies than subsequent exons (e.g. GCK and HNF1A; see Supplementary 
Table S6.2).  
Our experience gained from sequencing >2800 samples on five different capture 
technologies highlighted differences between these technologies, and between 
defined targets and “real life” coverage. The extent to which 100% coverage, at 
sufficient depth, of each exon of every MODY/CHI gene is required is a matter for 
the clinical community to determine, especially as the most common MODY types 
(HNF4A, GCK, and HNF1A) account for 94% of cases to date [20]. Less than perfect 
capture of every MODY/CHI gene may be acceptable, if the most common genes for 
each condition are sufficiently screened and the extent of screening of the remaining 
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genes is provided. If complete coverage is required, missing exons may need 
sequencing using a different technique (e. g. a different WES capture technology, or 
targeted Sanger sequencing).  
In considering these issues, Johansson et al. undertook WES of participants with 
clinically suspected MODY using Agilent SureSelectTM All Exon capture technology. 
Analysis of a predefined set of 111 glycaemia-related genes revealed wide variation 
of coverage for different exons, ranging from 5% to 100% [297]. They report 88-93% 
of the total exome was covered to a depth of 8x. Philippe et al. compared the 
performance of four different sequencing capture technologies: two WES off-the-
shelf panels (Agilent SureSelectTM all Exon and NexteraTM Rapid Capture Expanded 
Exome) and two customized targeted sequencing capture technologies (RainDance 
and HaloPlex) for two samples with a known HNF1B mutation [298]. 100% coverage 
(at depth of 8x) was not achieved with any capture technology, including the targeted 
panels. RainDance had the greatest coverage, and NexteraTM the least. Despite 80% 
coverage to a depth of 100x, HaloPlex missed 20% of all variants detected by the 
other three capture technologies, while NexteraTM missed 10%. 
In contrast, some customized MODY panels have reported good sequencing 
sensitivity [217, 219]. Ellard et al. achieved >30x coverage for 97.5% of all bases for 
29 monogenic diabetes genes [217]. This study had 32 positive controls, including 
samples with SNPs, indels and larger structural variants, all of which were identified. 
Once designed and tested, panel sequencing is significantly cheaper than WES on a 
per sample basis. Panels also generate significantly less data overall than WES with 
fewer variants for consideration, requiring much less computational and analysis 
time. However, targeted panels need to be re-designed and re-tested with each new 
gene discovery for a condition; and cannot contribute to new gene discovery. 
Although most monogenic diseases arise from exonic mutations [299], the rapid 
progress and diminishing costs of sequencing technology mean WGS may soon be 
affordable and a viable alternative to WES. Apart from the previously mentioned 
exceptions, more than 99% of all mutations in MODY and CHI are exonic or splice-
site mutations; thus 99% of WGS data would be superfluous to diagnostic needs and 
not routinely analyzed. However, intronic mutations in ABCC8 and HADH causing 
CHI were recently identified [300], which obviously would be missed by WES; 
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further, structural variation can be more easily detected using WGS. WGS detect a 
much larger number of variants than WES; and determining causality of intronic 
variants is much more complex than for coding variants. 
We did not test sensitivity of mutation detection for each MODY/CHI gene, but only 
assessed mutations within eight genes. However, identified mutations included 
SNPs, small indels and larger deletions, typical in these diseases. Moreover, we 
assessed >2800 unrelated samples to demonstrate sequencing coverage attainable 
for each MODY/CHI gene. We cannot comment on specificity of WES for MODY/CHI 
using these unrelated samples as their diabetes status is unknown. However, no 
other variants in MODY/CHI genes were identified in the 15 known affected 
individuals other than their previously identified mutations. 
In conclusion, WES can be used to make a genetic diagnosis in MODY and CHI. 
Given the large number of genes involved in these conditions, WES appears cost-
effective and efficient; however, careful selection of appropriate technology is critical 
to ensure targeting of relevant genes, and coverage for an individual sample should 
be assessed. Use of bioinformatics tools appropriate to mutation type is important 
also. Transition of WES from the research space into clinical use in patients with 
MODY or CHI will have major benefits for medical practice, particularly in pediatric 
clinics, enabling efficient and low cost genetic screening for these conditions. 
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Supplementary Table S6.1. Summary statistics for MODY and CHI samples using 
Nimblegen v3.0 and NexteraTM Rapid Capture Exome. 
 Capture 
technology 
Total bases % bases 
on target 
exons 
Target 
exon 
median 
base 
coverage 
Target 
exon 
mean 
base 
coverage 
% target 
exon 
bases 
with 
coverage 
>1x 
% target 
exon 
bases 
with 
coverage 
>5x 
% target 
exon 
bases 
with 
coverage 
>10x 
MODY 
_01 
Nim 6334533190 47.56 39.07 45.69 91.78 85.90 81.41 
MODY 
_02 
Nim 6227445840 47.66 38.37 45.04 91.55 85.44 80.80 
MODY 
_03 
Nim 7194491479 43.05 40.65 46.89 91.60 85.79 81.51 
MODY 
_04 
Nim 5921230680 45.66 35.14 41.02 89.01 82.97 78.48 
MODY 
_05 
Nim 5968367967 45.08 34.31 40.79 90.97 84.27 79.04 
MODY 
_05 
NR 5570876064 17.09 22.32 26.05 98.21 91.42 79.29 
MODY 
_06 
NR 4614651359 35.86 38.45 46.52 98.19 92.78 85.53 
MODY 
_07 
NR 5129683381 38.08 45.76 54.84 98.48 94.06 88.08 
MODY 
_08 
NR 7341683881 35.54 57.84 69.14 98.93 96.70 93.32 
MODY 
_09 
NR 5588706453 36.68 48.16 57.27 98.63 94.62 89.13 
MODY 
_10 
NR 5623711895 36.62 48.17 57.97 98.56 94.35 88.59 
CHI 
_01 
NR 5379561655 36.21 45.50 54.74 98.40 93.86 87.75 
CHI 
_02 
NR 5885807450 38.18 51.97 61.47 98.72 95.52 90.97 
CHI 
_03 
NR 5467942099 37.50 47.78 57.35 98.33 94.03 88.35 
CHI 
_04 
NR 4880765025 37.48 41.95 50.62 98.44 93.99 87.80 
CHI 
_05 
NR 4252700329 42.83 32.30 37.33 97.61 93.24 86.96 
Mean 
Nim  6329213831 45.802 37.508 43.886 90.982 84.874 80.248 
Mean 
NR  5430553599 35.64 43.65 52.12 98.489 94.05 87.80 
Mean 
All 
Samples 
 5711384922 38.82 41.73 49.55 95.99 91.18 85.44 
Nim = Nimblegen SeqCap EZ v3.0; NR = Illumina NexteraTM Rapid Capture Exome   
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Supplementary Table S6.2. Actual coverage of each exon of the MODY and CHI 
genes, reported as % of the exon with >10x coverage.  
  
NexteraTM 
Rapid 
Capture 
Exome 
 
NexteraTM 
Rapid 
Capture 
Expanded 
Exome 
Nimblegen 
SeqCap EZ 
v2. 0 
 
Nimblegen 
SeqCap EZ 
v3. 0 
 
Illumina 
TruSeqTM 
 
Number of samples 392 69 245 833 1354 
HNF4A 
chr20:42984445- 
83 97 9 0 34 
42984493 
chr20:43019233- 
83 97 9 0 34 
43019319 
chr20:43030013- 
83 97 9 0 34 
43030127 
chr20:43031194- 
96 0 17 53 1 
43031284 
chr20:43034698- 
96 94 63 6 84 
43034872 
chr20:43036021- 
99 97 93 93 92 
43036115 
chr20:43042334- 
99 97 91 91 90 
43042440 
chr20:43043147- 
99 90 83 57 90 
43043302 
chr20:43047065- 
96 100 68 28 90 
43047152 
chr20:43048361- 
98 74 87 94 88 
43048516 
chr20:43052658- 
97 71 56 47 64 
43053019 
chr20:43056975- 
98 88 85 83 89 
43057127 
chr20:43058163- 
100 94 86 86 76 
43058305 
GCK 
chr7:44184735- 
93 46 6 0 14 
44184879 
chr7:44185096- 
91 59 2 0 6 
44185329 
chr7:44186062- 
94 97 36 1 65 
44186217 
chr7:44187249- 87 97 53 3 73 
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44187432 
chr7:44189359- 
100 91 96 96 89 
44189458 
chr7:44189568- 
98 99 76 26 97 
44189663 
chr7:44190555- 
100 92 98 92 97 
44190674 
chr7:44191870- 
100 86 82 90 83 
44192024 
chr7:44192900- 
97 98 77 57 91 
44193062 
chr7:44197672- 
100 0 36 100 8 
44197713 
chr7:44198672- 
98 100 83 77 97 
44198719 
chr7:44228508- 
100 58 94 92 81 
44228552 
HNF1A 
chr12:121416572- 
94 41 4 2 11 
121416897 
chr12:121426636- 
99 92 79 73 80 
121426835 
chr12:121431323- 
100 98 97 98 99 
121431509 
chr12:121431967- 
92 72 40 15 56 
121432208 
chr12:121434065- 
100 96 97 92 92 
121434216 
chr12:121434344- 
98 45 54 68 50 
121434799 
chr12:121435277- 
92 57 58 50 61 
121435596 
chr12:121437071- 
94 92 38 1 56 
121437430 
chr12:121438868- 
121438995 98 87 62 32 78 
PDX1 
chr13:28494276-    
63 55 6 16 6 
28494681 
chr13:28498393- 
56 65 12 17 28 
28498838 
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HNF1B 
chr17:36047283- 
100 90 98 99 99 
36047395 
chr17:36059082- 
100 87 100 100 99 
36059200 
chr17:36060988- 
94 94 46 6 65 
36061182 
chr17:36064924- 
100 88 100 100 99 
36065056 
chr17:36070511- 
99 90 93 97 93 
36070671 
chr17:36091431- 
98 40 68 92 62 
36091821 
chr17:36093550- 
100 62 78 100 71 
36093814 
chr17:36099431- 
100 82 98 100 95 
36099630 
chr17:36104532- 
93 95 52 0 70 
36104875 
NEUROD1 
chr2:182542517- 
99 95 97 93 99 
182543587 
KLF11 
chr2:10183844- 
31 58 1 0 1 
10183885 
chr2:10186277- 
100 69 99 100 97 
10186546 
chr2:10187777- 
98 78 96 93 96 
10188722 
chr2:10192354- 
100 86 97 98 92 
10192634 
CEL 
chr9:135937381- 
98 100 80 37 88 
135937455 
chr9:135939791- 
96 51 56 17 80 
135939941 
chr9:135940027- 
97 85 60 36 84 
135939941 
chr9:135940427- 
99 94 66 59 75 
135940149 
chr9:135941917- 
98 98 87 63 89 
135940624 
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chr9:135942225- 
99 99 76 63 80 
135942047 
chr9:135942475- 
99 99 77 51 85 
135942332 
chr9:135944059- 
100 95 97 99 98 
135942592 
chr9:135944443- 
100 99 99 100 98 
135944245 
chr9:135945848- 
100 97 94 97 91 
135946045 
chr9:135946374- 
52 38 27 27 30 
135947151 
PAX4 
chr7:127250906- 
99 99 98 100 93 
127251039 
chr7:127251118- 
99 96 95 92 98 
127251260 
chr7:127251589- 
99 96 95 93 92 
127251730 
chr7:127251957- 
100 73 98 93 98 
127252054 
chr7:127253076- 
100 94 100 100 99 
127253145 
chr7:127253504- 
100 98 98 100 98 
127253586 
chr7:127253810- 
100 100 98 99 99 
127253935 
chr7:127254536- 
100 100 98 100 99 
127254611 
chr7:127254934- 
99 67 88 94 81 
127255263 
chr7:127255455- 
100 61 85 96 70 
127255574 
INS 
chr11:2181082- 
94 90 33 1 63 
2181227 
chr11:2182015- 
95 0 2 4 5 
2182201 
BLK 
chr8:11400734- 
100 76 88 90 77 
11400856 
chr8:11403561- 100 89 96 99 98 
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11403612 
chr8:11405541- 
99 82 93 91 92 
11405634 
chr8:11406533- 
100 84 89 99 89 
11406631 
chr8:11407668- 
99 61 89 94 87 
11407771 
chr8:11412252- 
99 0 48 100 47 
11412398 
chr8:11412841- 
99 91 77 78 71 
11412993 
chr8:11414167- 
99 92 94 98 89 
11414346 
chr8:11415471- 
99 87 97 96 96 
11415547 
chr8:11418274- 
96 19 46 91 28 
11418961 
chr8:11420488- 
100 84 62 78 65 
11420619 
chr8:11421412- 
74 45 1 0 1 
11421617 
ABCC8 
chr11:17414538- 
98 99 80 69 88 
17414675 
chr11:17415244- 
99 100 88 64 96 
17415306 
chr11:17415813- 
100 99 96 99 92 
17415946 
chr11:17416719- 
98 98 89 74 98 
17416822 
chr11:17417157- 
97 98 74 8 93 
17417265 
chr11:17417399- 
100 100 96 96 96 
17417477 
chr11:17418463- 
97 100 75 23 93 
17418593 
chr11:17418740- 
97 100 78 43 97 
17418860 
chr11:17419231- 
95 97 61 5 85 
17419344 
chr11:17419886- 
100 93 99 100 97 
17419988 
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chr11:17424208- 
100 99 84 99 84 
17424300 
chr11:17426059- 
100 96 96 96 97 
17426216 
chr11:17427041- 
100 90 100 99 99 
17427110 
chr11:17428169- 
91 98 93 84 98 
17428335 
chr11:17428435- 
95 87 63 2 85 
17428676 
chr11:17428901- 
100 99 100 100 99 
17429000 
chr11:17429939- 
99 95 100 99 98 
17430064 
chr11:17432063- 
100 70 80 98 82 
17432200 
chr11:17434213- 
99 100 94 95 99 
17434293 
chr11:17434941- 
100 92 96 99 97 
17435025 
chr11:17436059- 
100 90 99 100 98 
17436157 
chr11:17436851- 
100 100 94 95 96 
17436886 
chr11:17438477- 
100 82 88 100 90 
17438509 
chr11:17448596- 
95 98 77 66 81 
17448701 
chr11:17449414- 
98 88 99 91 98 
17449489 
chr11:17449836- 
95 98 70 11 84 
17449952 
chr11:17450112- 
93 98 77 34 91 
17450217 
chr11:17452357- 
100 84 89 94 87 
17452506 
chr11:17453751- 
99 86 96 89 98 
17453791 
chr11:17464267- 
98 97 88 72 97 
17464429 
chr11:17464725- 
100 84 99 97 99 
17464859 
150 
 
chr11:17470063- 
100 96 100 100 98 
17470218 
chr11:17474666- 
100 97 100 100 99 
17474830 
chr11:17482035- 
97 92 55 37 62 
17482223 
chr11:17483130- 
100 69 77 90 76 
17483372 
chr11:17484985- 
100 88 98 99 96 
17485151 
chr11:17491648- 
100 88 92 100 89 
17491769 
chr11:17496433- 
99 85 91 99 90 
17496574 
chr11:17498176- 
84 70 2 5 5 
17498323 
KCNJ11 
chr11:17408466- 
93 74 70 22 88 
17409638 
UCP2 
chr11:73686052- 
100 98 97 100 99 
73686166 
chr11:73686536-  
84 88 95 96 95 
73686716 
chr11:73687686- 
100 92 99 96 99 
73687787 
chr11:73687868- 
84 95 82 56 91 
73688062 
chr11:73688931- 
98 80 89 80 82 
73689141 
chr11:73689298- 
100 80 98 99 97 
73689423 
SLC16A1 
chr1:113456513- 
100 57 99 100 97 
113456787 
chr1:113459735- 
99 42 93 100 86 
113460666 
chr1:113464612- 
100 94 100 100 98 
113464755 
chr1:113471714- 
99 47 71 100 60 
113471930 
GLUD1 
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chr10:88811508- 
100 81 100 100 99 
88811627 
chr10:88813099- 
100 96 100 100 99 
88813161 
chr10:88817448- 
100 85 99 100 95 
88817539 
chr10:88818907- 
100 93 99 100 99 
88819030 
chr10:88819918- 
100 93 99 100 98 
88819998 
chr10:88820445- 
100 95 100 100 99 
88820582 
chr10:88820672- 
100 80 100 100 99 
88820809 
chr10:88822413- 
100 89 100 100 99 
88822592 
chr10:88827820- 
100 74 96 100 93 
88827914 
chr10:88834308- 
100 98 100 100 97 
88834371 
chr10:88835725- 
100 90 96 100 94 
88835780 
chr10:88836333- 
100 86 96 100 95 
88836413 
chr10:88853690- 
93 0 0 0 1 
88853735 
chr10:88854082- 
75 65 22 0 43 
88854526 
HADH 
chr4:108911089- 
93 80 2 0 5 
108911220 
chr4:108925930- 
100 0 35 100 1 
108926073 
chr4:108930915- 
100 98 100 100 95 
108931043 
chr4:108935587- 
100 54 98 100 96 
108935744 
chr4:108940696- 
100 86 99 100 98 
108940822 
chr4:108944630- 
100 97 100 100 98 
108944719 
chr4:108948844- 100 94 100 100 99 
152 
 
108948916 
chr4:108953483- 
100 0 35 100 1 
108953533 
chr4:108954332- 
100 91 99 100 95 
108954448 
chr4:108955395- 
100 84 98 100 94 
108955513 
HK1 
chr10:71048500- 
100 92 99 100 97 
71048526 
chr10:71052014- 
36 0 0 0 0 
71052106 
chr10:71055389- 
100 99 100 99 98 
71055436 
chr10:71060591- 
100 68 96 100 92 
71060617 
chr10:71075711- 
100 0 34 99 8 
71075770 
chr10:71078704- 
86 98 1 0 2 
71078766 
chr10:71103583- 
100 88 97 100 94 
71103745 
chr10:71119653- 
100 95 94 99 92 
71119801 
chr10:71124539- 
100 93 97 100 95 
71124658 
chr10:71128292- 
100 99 99 99 99 
71128387 
chr10:71128993- 
100 93 100 100 100 
71129092 
chr10:71129197- 
100 90 100 100 99 
71129380 
chr10:71136690- 
100 91 99 100 97 
71136845 
chr10:71139618- 
100 66 91 98 88 
71139851 
chr10:71142243- 
99 72 59 48 66 
71142547 
chr10:71144089- 
100 99 100 100 99 
71144237 
chr10:71144552- 
100 92 99 99 99 
71144671 
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chr10:71146079- 
100 97 100 100 99 
71146174 
chr10:71148953- 
100 40 66 100 66 
71149153 
chr10:71151881- 
100 76 98 98 97 
71152064 
chr10:71154706- 
100 79 97 99 96 
71154861 
chr10:71158351-  
84 87 90 76 96 
71158584 
chr10:71160747- 
100 99 90 82 85 
71160891 
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Supplementary Table S6.3 Theoretical targeting of each MODY and CHI gene 
according to the manufactures’ BED files. 
Gene 
Name 
Number 
of Exons 
NexteraTM 
Rapid 
Capture 
Exome 
 
NexteraTM 
Rapid 
Capture 
Expanded 
Exome 
 
Nimblegen 
SeqCap EZ 
v2. 0 
 
Nimblegen 
SeqCap EZ 
v3. 0 
 
Illumina 
TruSeqTM 
 
HNF4A 13 
100% 
(13 exons 
targeted 
100%) 
80% 
(9 exons 
targeted 
100%) 
83% 
(10 exons 
targeted 
100%) 
90% 
(7 exons 
targeted 
100%) 
80% 
(9 exons 
targeted 
100%) 
GCK 12 
100% 
(12 exons 
targeted 
100%) 
92% 
(11 exons 
targeted 
100%) 
99% 
11 exons 
targeted 
100%) 
98% 
(10 exons 
targeted 
100%) 
92% 
(11 exons 
targeted 
100%) 
HNF1A 9 
100% 
(9 exons 
targeted 
100%) 
87% 
(6 exons 
targeted 
100%) 
89% 
(4 exons 
targeted 
100%) 
89% 
(6 exons 
targeted 
100%) 
87% 
(6 exons 
targeted 
100%) 
PDX1 2 
100% 
(2 exons 
targeted 
100%) 
100% 
(2 exons 
targeted 
1005) 
83% 
(0 exons 
targeted 
100%) 
78% 
(0 exons 
targeted 
100%) 
100% 
(2 exons 
targeted 
100%) 
HNF1B 9 
100% 
(9 exons 
targeted 
100%) 
96% 
(8 exons 
targeted 
100%) 
94% 
(5 exons 
targeted 
100%) 
95% 
(5 exons 
targeted 
100%) 
96% 
(8 exons 
targeted 
100%) 
NEUROD1 1 
100% 
(1 exon 
targeted 
100%) 
100% 
(1 exon 
targeted 
100%) 
81% 
(0 exons 
targeted 
100%) 
65% 
(0 exons 
targeted 
100%) 
100% 
(1 exon 
targeted 
100%) 
KLF11 4 
100% 
(4 exons 
targeted 
100%) 
100% 
(4 exons 
targeted 
100%) 
92% 
(2 exons 
targeted 
100%) 
91% 
(1 exon 
targeted 
100%) 
100% 
(4 exons 
targeted 
100%) 
CEL 11 
100% 
(11 exons 
targeted 
100%) 
100% 
(11 exons 
targeted 
100%) 
94% 
(8 exons 
targeted 
100%) 
86% 
(3 exons 
targeted 
100%) 
100% 
(11 exons 
targeted 
100%) 
PAX4 10 
100% 
(10 exons 
targeted 
100%) 
92% 
(8 exons 
targeted 
100%) 
86% 
(7 exons 
targeted 
100%) 
86% 
(5 exons 
targeted 
100%) 
92% 
(8 exons 
targeted 
100%) 
INS 2 
100% 
(2 exons 
targeted 
100%) 
50% 
(1 exon 
targeted 
100%) 
100% 
(2 exons 
targeted 
100%) 
100% 
(2 exons 
targeted 
100%) 
50% 
(1 exon 
targeted 
100%) 
BLK 12 
100% 
(12 exons 
targeted 
100%) 
94% 
(11 exons 
targeted 
100%) 
94% 
(10 exons 
targeted 
100%) 
98% 
(10 exons 
targeted 
100%) 
94% 
(11 exons 
targeted 
100%) 
ABCC8 39 
100% 
(39 exons 
targeted 
100%) 
100% 
(38 exons 
targeted 
100%) 
100% 
(38 exons 
targeted 
100%) 
96% 
(29 exons 
targeted 
100%) 
100% 
(38 exons 
targeted 
100%) 
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KCNJ11 1 
100% 
(1 exon 
targeted 
100%) 
100% 
(1 exon 
targeted 
100%) 
77% 
(0 exons 
targeted 
100%) 
71% 
(0 exon 
targeted 
100%) 
100% 
(1 exon 
targeted 
100%) 
UCP2 6 
100% 
(6 exons 
targeted 
100%) 
100% 
(6 exons 
targeted 
100%) 
100% 
(6 exons 
targeted 
100%) 
92% 
(2exons 
targeted 
100%) 
100% 
(6 exons 
targeted 
100%) 
SLC16A1 4 
100% 
(4 exons 
targeted 
100%) 
98% 
(3 exons 
targeted 
100%) 
92% 
(2 exons 
targeted 
100%) 
88% 
(1 exon 
targeted 
100%) 
98% 
(3 exons 
targeted 
100%) 
GLUD1 14 
100% 
(14 exons 
targeted 
100%) 
93% 
(13 exons 
targeted 
100%) 
84% 
(8 exons 
targeted 
100%) 
88% 
(10 exons 
targeted 
100%) 
93% 
(13 exons 
targeted 
100%) 
HADH 10 
100% 
(10 exons 
targeted 
100%) 
80% 
(8 exons 
targeted 
100%) 
80% 
(8 exons 
targeted 
100%) 
96% 
(7 exons 
targeted 
100%) 
80% 
(8 exons 
targeted 
100%) 
HK1 23 
100% 
(23 exons 
targeted 
100%) 
89% 
(20 exons 
targeted 
100%) 
93% 
(17 exons 
targeted 
100%) 
92% 
(16 exons 
targeted 
100%) 
89% 
(20 exons 
targeted 
100%) 
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Supplementary Table S6.4. Theoretical capture of each individual exon 
according to the respective manufactures’ BED files.  
 
NexteraTM 
Rapid 
Capture 
Exome 
NexteraTM 
Rapid 
Capture 
Expanded 
Exome 
Nimblegen 
SeqCap EZ 
v2. 0 
Nimblege
n SeqCap 
EZ v3. 0 
Illumina 
TruSeqTM 
HNF4A 
chr20:42984445- 
42984493 100 100 100 100 100 
chr20:43019233- 
43019319 100 0 0 0 0 
chr20:43030013- 
43030127 100 100 100 100 100 
chr20:43031194- 
43031284 100 0 0 100 0 
chr20:43034698- 
43034872 100 100 100 95 100 
chr20:43036021- 
43036115 100 100 100 99 100 
chr20:43042334- 
43042440 100 100 100 100 100 
chr20:43043147- 
43043302 100 100 100 92 100 
chr20:43047065- 
43047152 100 100 100 100 100 
chr20:43048361- 
43048516 100 100 100 94 100 
chr20:43052658- 
43053019 100 65 79 94 65 
chr20:43056975- 
43057127 100 80 100 100 80 
chr20:43058163- 
43058305 100 100 100 100 100 
GCK 
chr7:44184735- 
44184879 100 100 100 100 100 
chr7:44185096- 
44185329 100 100 100 86 100 
chr7:44186062- 
44186217 100 100 100 100 100 
chr7:44187249- 
44187432 100 100 100 100 100 
chr7:44189359- 
44189458 100 100 100 100 100 
chr7:44189568- 
44189663 100 100 100 90 100 
chr7:44190555- 
44190674 100 100 86 100 100 
chr7:44191870- 
44192024 100 100 100 100 100 
chr7:44192900- 100 100 100 100 100 
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44193062 
chr7:44197672- 
44197713 100 0 100 100 0 
chr7:44198672- 
44198719 100 100 100 100 100 
chr7:44228508- 
44228552 100 100 100 100 100 
HNF1A 
chr12:121416572- 
121416897 100 100 99 78 100 
chr12:121426636- 
121426835 100 100 100 100 100 
chr12:121431323- 
121431509 100 100 100 100 100 
chr12:121431967- 
121432208 100 100 98 100 100 
chr12:121434065- 
121434216 100 100 100 100 100 
chr12:121434344- 
121434799 100 44 48 52 44 
chr12:121435277- 
121435596 100 60 70 100 60 
chr12:121437071- 
121437430 100 74 89 71 74 
chr12:121438868- 
121438995 100 100 100 100 100 
PDX1 
chr13:28494276- 
28494681 100 100 86 75 100 
chr13:28498393- 
28498838 100 100 80 80 100 
HNF1B 
chr17:36047283- 
36047395 100 100 87 100 100 
chr17:36059082- 
36059200 100 100 100 100 100 
chr17:36060988- 
36061182 100 100 100 100 100 
chr17:36064924- 
36065056 100 100 100 92 100 
chr17:36070511- 
36070671 100 100 100 100 100 
chr17:36091431- 
36091821 100 61 69 86 61 
chr17:36093550- 
36093814 100 100 100 89 100 
chr17:36099431- 
36099630 100 100 96 100 100 
chr17:36104532- 
36104875 100 100 96 85 100 
NEUROD1 
chr2:182542517- 
182543587 100 100 81 65 100 
158 
 
KLF11 
chr2:10183844- 
10183885 100 100 100 100 100 
chr2:10186277- 
10186546 100 100 87 93 100 
chr2:10187777- 
10188722 100 100 81 85 100 
chr2:10192354- 
10192634 100 100 100 86 100 
CEL 
     
chr9:135937381- 
135937455 100 100 100 100 100 
chr9:135939791- 
135939941 100 100 100 91 100 
chr9:135940027- 
135940149 100 100 100 64 100 
chr9:135940427- 
135940624 100 100 100 100 100 
chr9:135941917- 
135942047 100 100 100 71 100 
chr9:135942225- 
135942332 100 100 100 100 100 
chr9:135942475- 
135942592 100 100 100 81 100 
chr9:135944059- 
135944245 100 100 73 92 100 
chr9:135944443- 
135944646 100 100 99 96 100 
chr9:135945848- 
135946045 100 100 100 96 100 
chr9:135946374- 
135947151 100 100 65 58 100 
PAX4 
chr7:127250906- 
127251039 100 100 0 100 100 
chr7:127251118- 
127251260 100 100 100 71 100 
chr7:127251589- 
127251730 100 100 94 100 100 
chr7:127251957- 
127252054 100 58 100 100 58 
chr7:127253076- 
127253145 100 100 100 100 100 
chr7:127253504- 
127253586 100 100 100 76 100 
chr7:127253810- 
127253935 100 100 100 40 100 
chr7:127254536- 
127254611 100 100 100 100 100 
chr7:127254934- 
127255263 100 65 64 83 65 
chr7:127255455- 
127255574 100 100 100 88 100 
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INS 
chr11:2181082- 
2181227 100 100 100 100 100 
chr11:2182015- 
2182201 100 0 100 100 0 
BLK 
chr8:11400734- 
11400856 100 100 100 100 100 
chr8:11403561- 
11403612 100 100 100 100 100 
chr8:11405541- 
11405634 100 100 100 100 100 
chr8:11406533- 
11406631 100 100 100 100 100 
chr8:11407668- 
11407771 100 100 100 100 100 
chr8:11412252- 
11412398 100 100 100 100 100 
chr8:11412841- 
11412993 100 100 100 82 100 
chr8:11414167- 
11414346 100 100 100 100 100 
chr8:11415471- 
11415547 100 100 100 100 100 
chr8:11418274- 
11418961 100 22 27 90 22 
chr8:11420488- 
11420619 100 100 100 100 100 
chr8:11421412- 
11421617 100 100 98 100 100 
ABCC8 
chr11:17414538- 
17414675 100 100 100 100 100 
chr11:17415244- 
17415306 100 100 100 100 100 
chr11:17415813- 
17415946 100 100 100 100 100 
chr11:17416719- 
17416822 100 100 100 100 100 
chr11:17417157- 
17417265 100 100 100 100 100 
chr11:17417399- 
17417477 100 100 100 100 100 
chr11:17418463- 
17418593 100 100 100 100 100 
chr11:17418740- 
17418860 100 100 100 84 100 
chr11:17419231- 
17419344 100 100 100 100 100 
chr11:17419886- 
17419988 100 100 100 100 100 
chr11:17424208- 
17424300 100 100 100 100 100 
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chr11:17426059- 
17426216 100 100 100 100 100 
chr11:17427041- 
17427110 100 100 100 99 100 
chr11:17428169- 
17428335 100 100 100 100 100 
chr11:17428435- 
17428676 100 100 90 44 100 
chr11:17428901- 
17429000 100 100 100 100 100 
chr11:17429939- 
17430064 100 100 100 96 100 
chr11:17432063- 
17432200 100 100 100 100 100 
chr11:17434213- 
17434293 100 100 100 100 100 
chr11:17434941- 
17435025 100 100 100 100 100 
chr11:17436059- 
17436157 100 100 100 100 100 
chr11:17436851- 
17436886 100 100 100 100 100 
chr11:17438477- 
17438509 100 100 100 100 100 
chr11:17448596- 
17448701 100 100 100 100 100 
chr11:17449414- 
17449489 100 100 100 100 100 
chr11:17449836- 
17449952 100 100 100 97 100 
chr11:17450112- 
17450217 100 100 100 42 100 
chr11:17452357- 
17452506 100 98 100 100 98 
chr11:17453751- 
17453791 100 100 100 100 100 
chr11:17464267- 
17464429 100 100 100 100 100 
chr11:17464725- 
17464859 100 100 100 87 100 
chr11:17470063- 
17470218 100 100 100 100 100 
chr11:17474666- 
17474830 100 100 100 100 100 
chr11:17482035- 
17482223 100 100 100 93 100 
chr11:17483130- 
17483372 100 100 100 95 100 
chr11:17484985- 
17485151 100 100 100 98 100 
chr11:17491648- 
17491769 100 100 100 100 100 
chr11:17496433- 
17496574 100 100 100 100 100 
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chr11:17498176- 
17498323 100 100 100 100 100 
KCNJ11 
chr11:17408466- 
17409638 100 100 77 71 100 
UCP2 
chr11:73686052- 
73686166 100 100 100 100 100 
chr11:73686536- 
73686716 100 100 100 92 100 
chr11:73687686- 
73687787 100 100 100 93 100 
chr11:73687868- 
73688062 100 100 100 78 100 
chr11:73688931- 
73689141 100 100 100 87 100 
chr11:73689298- 
73689423 100 100 100 100 100 
SLC16A1 
chr1:113456513- 
113456787 100 100 98 95 100 
chr1:113459735- 
113460666 100 93 71 71 93 
chr1:113464612- 
113464755 100 100 100 85 100 
chr1:113471714- 
113471930 100 100 100 100 100 
GLUD1 
chr10:88811508- 
88811627 100 100 100 100 100 
chr10:88813099- 
88813161 100 100 100 100 100 
chr10:88817448- 
88817539 100 100 100 100 100 
chr10:88818907- 
88819030 100 100 100 100 100 
chr10:88819918- 
88819998 100 100 100 100 100 
chr10:88820445- 
88820582 100 100 93 64 100 
chr10:88820672- 
88820809 100 100 100 73 100 
chr10:88822413- 
88822592 100 100 100 100 100 
chr10:88827820- 
88827914 100 100 100 100 100 
chr10:88834308- 
88834371 100 100 55 100 100 
chr10:88835725- 
88835780 100 100 59 100 100 
chr10:88836333- 
88836413 100 100 77 100 100 
chr10:88853690- 100 0 0 0 0 
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88853735 
chr10:88854082- 
88854526 100 100 89 99 100 
HADH 
chr4:108911089- 
108911220 100 100 100 97 100 
chr4:108925930- 
108926073 100 0 0 100 0 
chr4:108930915- 
108931043 100 100 100 100 100 
chr4:108935587- 
108935744 100 100 100 100 100 
chr4:108940696- 
108940822 100 100 100 100 100 
chr4:108944630- 
108944719 100 100 100 100 100 
chr4:108948844- 
108948916 100 100 100 100 100 
chr4:108953483- 
108953533 100 0 0 100 0 
chr4:108954332- 
108954448 100 100 100 91 100 
chr4:108955395- 
108955513 100 100 100 75 100 
HK1 
chr10:71048500- 
71048526 100 100 100 100 100 
chr10:71052014- 
71052106 100 0 0 0 0 
chr10:71055389- 
71055436 100 100 100 100 100 
chr10:71060591- 
71060617 100 100 100 100 100 
chr10:71075711- 
71075770 100 0 100 100 0 
chr10:71078704- 
71078766 100 100 100 100 100 
chr10:71103583- 
71103745 100 100 78 100 100 
chr10:71119653- 
71119801 100 100 100 80 100 
chr10:71124539- 
71124658 100 100 100 100 100 
chr10:71128292- 
71128387 100 100 100 100 100 
chr10:71128993- 
71129092 100 100 100 100 100 
chr10:71129197- 
71129380 100 100 100 83 100 
chr10:71136690- 
71136845 100 100 100 100 100 
chr10:71139618- 
71139851 100 100 91 100 100 
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chr10:71142243- 
71142547 100 100 99 84 100 
chr10:71144089- 
71144237 100 100 100 99 100 
chr10:71144552- 
71144671 100 100 100 100 100 
chr10:71146079- 
71146174 100 100 100 100 100 
chr10:71148953- 
71149153 100 50 69 75 50 
chr10:71151881- 
71152064 100 100 100 100 100 
chr10:71154706- 
71154861 100 100 92 100 100 
chr10:71158351- 
71158584 100 100 100 92 100 
chr10:71160747- 
71160891 100 100 100 100 100 
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7.0   The Prospective Use of Whole Exome Sequencing in 
Undiagnosed Maturity-Onset Diabetes of the Young and 
Congenital Hyperinsulinism: Identification of Novel 
Variants in Known Genes 
This chapter presents comprehensive MODY and CHI screening, using WES, in 13 
individuals who lacked a genetic diagnosis. Three individuals were given a genetic 
diagnosis, with novel variants identified in ABCC8, HNF4A and RFX6 and (includes 
a submitted paper [Chapter 7.6]).  
In this study, I was responsible for attaining ethics and governance, and identifying 
and recruiting all the subjects. Lisa Anderson and Sharon Song performed the WES 
library preparation. I performed Sanger sequencing, with the guidance of Ms Jessica 
Harris. Dr Paul Leo and Ms Mhairi Marshall provided the bioinformatics support. Dr 
Felicity Newell performed the copy number analysis. I was responsible for data 
analysis and first draft of this manuscript. Prof Emma Duncan assisted with 
conceiving this study, study design, analysis of sequencing data and edited the 
manuscript. 
 
7.1   Introduction 
MODY is a heterogeneous group of autosomal dominant diabetes caused by a 
mutation in any of the genes affecting beta cell function. In 2016, there were thirteen 
genes reported to be associated with MODY. In 2017 an autosomal dominant 
mutation in RFX6 was identified in three separate families with MODY. CHI is the 
most common form of persistent neonatal hypoglycaemia. In the past few years 
increasing evidence has also emerged for the role of HK1 in CHI. Thus the number 
of MODY and CHI genes is expanding over time 
The majority of MODY cases are currently undiagnosed [20]. This is mostly due to 
lack of recognition of MODY. However, even when MODY is clinically suspected, 
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between 15-70% of cases will not have a genetic diagnosis [20, 284]. Some forms of 
MODY have distinct clinical features (for example HNF1B-MODY is associated with 
renal malformations, pancreatic atrophy, genital malformations and abnormal liver 
function tests [80], or fasting hyperglycaemia in GCK-MODY [59]); however, the 
majority are clinically indistinguishable without genetic testing. Some MODY 
subtypes can be treated with sulphonylurea tablets which results in improved 
metabolic control, less hypoglycaemia and improved quality of life compared to 
insulin therapy [25-29]. 
Approximately 45-55% of cases of CHI have no identifiable genetic basis [154]. 
Flanagan et al. reported a KATP channel mutation in 88% of their diazoxide-
unresponsive cohort (i.e. those not able to achieve euglycaemia with diazoxide 
alone); no mutation (in KATP or other genes) was detected in the remaining 12%. Of 
the diazoxide responsive cohort, 73% had no identifiable mutation – it is not clear 
how many genes were screened in each patient [154]. A genetic diagnosis is of 
particular importance in the diazoxide-unresponsive cases of CHI, where a 
paternally-inherited KATP channel mutation may suggest focal disease, which can be 
curable with limited pancreatectomy. 
Conventional sequencing was time-consuming and expensive. Thus even those with 
a compelling clinical case may only have a limited number of genes sequenced. 
Massively parallel sequencing (MPS) allowed the simultaneous sequencing of 
multiple target regions (from individual exons or genes through to whole genomes) in 
multiple subjects. Targeted sequencing is currently available clinically for 
identification of mutations in the known MODY/CHI genes. However, even with 
targeted MPS, many cases do not receive a genetic diagnosis.  
We used WES to look for variants in known MODY/CHI genes in subjects with a 
clinical diagnosis of MODY or CHI without an identified genetic cause. Subjects in 
whom we do not identify a mutation in a known MODY gene, were recruited for the 
new gene discovery study (Chapter 8). 
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7.2   Methods 
7.2.1   Clinical Cohort 
Thirteen unrelated probands were recruited (seven with MODY and six with CHI). All 
had a clinical diagnosis of either MODY or CHI, but no genetic diagnosis, having had 
Sanger sequencing of a limited (between one and four) number of genes organised 
by their treating clinician (see Tables 7.1 and 7.2).  
Ethical approval was obtained from The University of Queensland Human Research 
Ethics Committee (UQ 2013000017); all individuals and/or their guardians gave 
informed consent. 
7.2.2   Laboratory Methods. 
DNA was either received into the laboratory or was extracted by standard means 
from peripheral blood mononuclear cells or saliva. Sequencing libraries were 
constructed according to manufacturers’ instructions. Exome capture was performed 
using either Nimblegen SeqCap EZ Human v3.0 Exome Enrichment Kit (Roche, 
Basel, Switzerland) or NexteraTM Rapid Capture Exome kit (Illumina, San Diego, CA, 
USA). Pre- and post-capture quality and yield were assessed by Agilent High 
Sensitivity DNA assay (Santa Clare, CA) on the Bioanalyzer 2100 and by qPCR 
using the KAPA Library Quantification Kit (Kapa Biosystems, Wilmington, MA) prior 
to sequencing. Multiplexed MPS was undertaken on all samples (six samples per 
flow lane) using an Illumina HiSeq 2000 (Illumina, San Diego, CA, USA), generating 
100-base pair paired-end reads.  
7.2.3   Data annotation 
Data were demultiplexed using Illumina Data Analysis Pipeline software (Bcl2fastq 
v1.8.4) and aligned to the current reference human genome (hg19, released 
February 2009) using the Novoalign alignment tool (V3.00.02). Sequence alignment 
files were converted using Picard tools (v1.124). Variants were called using the 
Genome Analysis Toolkit (GATK v2.7-2) and annotated using ANNOVAR. Further 
analysis of sequence data was performed using custom scripts employing R and 
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Bioconductor. After exclusion of artefact, good quality (i.e. passing GATK algorithm, 
which incorporates sequence depth, quality scores at the SNP position, maximal 
length of the homopolymer run and strand bias) variants were retained.  
7.2.4   Data analysis 
Variants of potentially damaging consequences (splice site, nonsynonymous, 
frameshift, stop-loss and stop-gain variants) with MAF <0.001 (derived from internal 
data of >2500 exomes, dbSNP, 1000 Genomes, and ExAC) were assessed. This 
threshold was adopted as: a) prevalence of pediatric diabetes of 0.2% in the 
Australian population [229]; b) prevalence estimates of 2% of MODY in a diabetes 
population [23]. Further, most MODY mutations are private with few mutational 
hotspots reported [221]. 
Variants were further filtered to include those predicted to be damaging by any of 
three protein prediction programs (Polyphen, SIFT and MutationTaster). Samples 
without an identified variant were also analyzed for copy number variants using 
ExomeDepth [206]. This was not done a priori, given the low frequency overall of 
copy number variants in MODY.  
7.2.5   Sanger sequencing 
Sequencing was performed on the GeneticAnalyzer 3130 (Applied Biosystems, 
USA) using BigDye v3.1 reagents, and analysed using the manufacturer’s software. 
Sanger sequencing was performed on family MODY_104 for ABCC8 (as per Chapter 
7.6) 
Sanger sequencing was performed in family MODY_100 for HNF4A exon 5 using 
primers: 
Forwards primer CTGTGCAGGGGACAGAGAGT 
Reverse primer GCCCCAATCTCCTCACCTAT 
168 
 
Sanger sequencing was performed in family MODY_116 for RFX6 exon 5 using 
primers: 
Left primer TCTGTCTTTCCCTTTCATGC 
Right primer ATGCCCAATGCTCTCAAATC 
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7.3   Results 
Table 7.1 Clinical data for probands with MODY  
Family Individual ID age at diagnosis treatment Genes sequenced prior to WES 
MODY_029 MODY_029.3 15 insulin HNF4A, GCK, HNF1A 
MODY_047 MODY_047.3 20 insulin GCK 
MODY_060 MODY_060.3 42 insulin HNF4A, HNF1A 
MODY_100 MODY_100.3 11 insulin HNF1A 
MODY_104 MODY_104.3 27 insulin HNF4A, HNF1A, HNF1B 
MODY_116 MODY_116.3 30 insulin HNF4A, GCK, HNF1A, HNF1B 
MODY_255 MODY_255.3 18 OHG GCK, HNF1A 
OHG: oral hypoglycaemic agent 
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Table 7.2 Clinical data for probands with CHI  
Family Individual ID 
age at CHI 
diagnosis 
Treatment 
 
Genes sequenced prior to WES 
CHI_017 CHI_017.3 10 months Diazoxide ABCC8, KCNJ11, HNF4A 
CHI_042 CHI_042.3 Birth Diazoxide ABCC8, KCNJ11, HNF4A, GCK 
CHI_046 CHI_046.3 Birth Diazoxide ABCC8, KCNJ11, HNF4A, GCK 
CHI_054 CHI_054.3 4 months 
Diazoxide responsive 
80% pancreatectomy for focal 
disease 
ABCC8, KCNJ11 
CHI_067 CHI_067.3 2 years Diazoxide ABCC8, KCNJ11 
CHI_068 CHI_068.3 20 years Diazoxide ABCC8, KCNJ11 
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Coverage statistics 
Mapping and coverage statistics and detailed base calling statistics for all samples are presented in Table 7.3. Mean coverage 
overall was 43-fold, with 81% of the targeted capture region covered to a depth of 10x. 
Table 7.3. Summary statistics for MODY and CHI samples 
Sample Total bases 
% bases 
on 
target 
exons 
Target 
exon 
median 
base 
coverage 
Target 
exon 
mean 
base 
coverage 
% target 
exon 
bases 
with 
coverage 
>1x 
% target 
exon 
bases 
with 
coverage 
>5x 
% target 
exon 
bases 
with 
coverage 
>10x 
% target 
exon 
bases 
with 
coverage 
>30x 
MODY_029.3 5187196181 47.9 32 37.6 91 84.4 79.2 54.6 
MODY_060.3 5462202710 46.2 32.8 38.2 88.9 82.8 78.1 55.5 
MODY_047.3 5641493654 44.5 31.9 38.1 90.7 83.8 78.3 54.3 
MODY_255.3 5951522227 46.2 35.3 41.7 89.1 83.1 78.7 58.6 
MODY_116.3 6872041898 45.5 41.2 47.5 89.9 83.2 78.7 63.2 
MODY_100.3 6042377434 46.1 36.1 42.2 89.2 83.2 78.9 59.5 
MODY_104.3 66684379 45.1 37.5 43.9 90.8 84.5 79.9 61.1 
CHI_017.3 2748162390 47.3 23.5 28.1 95.7 86.4 75.2 36.7 
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CHI_042.3 4060057190 37.5 36 43.1 97.9 91.7 83.8 52.9 
CHI_046.3 4581003392 37.6 40.1 48.8 98.3 92.9 85.7 57.1 
CHI_054.3 6524284873 38.7 59 70.3 98.8 95.6 91.3 72.5 
CHI_067.3 4180832750 46.6 34.4 40.9 97.2 91.9 85 55.2 
CHI_068.3 4051199475 44.5 31.6 37.7 97.1 91.6 84.2 51.9 
Mean 4720696812 44.1 36.3 42.9 93.4 87.3 81.3 56.4 
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Table 7.4 Variants identified in identified MODY/CHI genes in probands 
Proband Number of 
variants 
MAF<5% 
Remaining coding 
variants of good 
quality after 
removal of platform-
related artefact 
Variants in 
MODY/ CHI 
genes with MAF 
<0. 1% 
Damaging 
variant# 
Exome depth Variant 
MODY_029.3 6334 207 0 0 0  
MODY_047.3 6104 216 0 0 0  
MODY_060.3 6614 192 0 0 0  
MODY_100.3 6798 223 1 1 - 
HNF4A 
c. 581A>C, 
p.Q194P 
MODY_104.3 6503 263 1 1 - 
ABCC8 
c.4169C>T, 
p.A1390V 
MODY_116.3 6559 235 1 1 - 
RFX6 
c.1399G>A, 
p.E467K 
MODY_255.3 6666 296 0 0 0  
CHI_017.3 6180 517 0 0 0  
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CHI_042.3 6790 495 0 0 0  
CHI_046.3 7329 632 0 0 0  
CHI_054.3 7725 466 0 0 0  
CHI_067.3 6979 504 0 0 0  
CHI_068.3 10388 472 0 0 0  
#
 Damaging variant according to protein prediction algorithms (SIFT, PolyPhen and/or Human Splicing Finder v3.0) 
MAF = minor allele frequency;  
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Variant identification 
Of the seven subjects with a clinical diagnosis of MODY, a variant in a MODY gene 
was identified in three probands, segregating with disease in each family. 
No variants in CHI genes were identified in the six subjects with CHI. 
MODY_104 Family  
An ABCC8 variant, c.4169C>T, p.A1390V was identified in proband MODY_104.3. 
Further results are presented in Chapter 7.6.  
MODY_100 Family 
Figure 7.1 Pedigree information for MODY_100 family.  
Subjects with diabetes are shown in black. Those with gestational diabetes in grey. 
Females are circle, males are squares. Arrow indicates proband. Age at diagnosis 
and current treatment are listed. * indicated subject who underwent WES, # indicated 
subjects who underwent Sanger sequencing. Individual IDs are listed below. Ins 
insulin; OHG oral hypoglycaemic agent 
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HNF4A 
A heterozygous variant c.581A>C, p.Q194P (according to transcript NM_175914) in 
exon 5 of HNF4A was identified in subject MODY_100.3. This variant was confirmed 
with Sanger sequencing in the proband, the proband’s sister, brother and father, all 
of whom had diabetes (Figure 7.2). The variant is novel and not present in any 
databases (ExAC, LOVD, ClinVar, HGMD). It is predicted to be damaging according 
to protein predication algorithms SIFT, PolyPhen and Mutation Taster. 
 
Figure 7.2 DNA sequence of the HNF4A gene with the heterozygous variant 
c.581A>C by Sanger sequencing 
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MODY_116 Family 
Figure 7.3 Pedigree information for MODY_116 family.  
 
 
 
 
 
 
 
 
 
 
Subjects with diabetes are shown in black. Those with gestational diabetes in grey. 
Females are circle, males are squares. Arrow indicates the proband. Age at 
diagnosis and current treatment are listed. * indicated subjects who underwent WES, 
#
 indicated subjects who underwent Sanger sequencing. 
Ins insulin; OHG oral hypoglycaemic agent 
 
 
 
 
I 
 
II 
 
 
III 
 
 
IV 
 
*# 
30 
Ins 
68 
OHG 
30 
Ins 
24 
diet 
*# 
*# 
30 
Ins 
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RFX6 
A heterozygous mutation in regulatory factor X, 6 (RFX6) c.1339G>A, p.E467K in 
exon 13 was identified in proband MODY_166.3 and was also present in a sister and 
aunt with diabetes. The variant is novel and not present in any databases (ExAC, 
LOVD, ClinVar, HGMD). It is in a conserved region (GERP score 5.19) and is 
predicted to be damaging according to protein predication algorithms SIFT, 
PolyPhen and Mutation Taster. 
 
7.4   Discussion 
We have identified novel variants in three of seven families with a clinical diagnosis 
of MODY. We identified no variants among the CHI probands sequenced.  
7.4.1   Variant identification 
ABCC8  
This is discussed separately in Chapter 7.6. 
HNF4A is the third most common MODY gene [67]; nonetheless, this gene had not 
been previously screened in this family. As the proband and many of the family 
members were diagnosed as adolescents, they were considered to have T1DM and 
commenced on insulin. However, HNF4A-MODY is generally sensitive to 
sulphonylurea. Thus a diagnosis of MODY may enable this individual and indeed all 
affected family members to cease insulin which is life-changing (as discussed 
previously). 
RFX6 has only been recently associated with MODY in 2017 [301]. RFX6 is 
expressed almost exclusively in the pancreas with lower levels in liver and heart 
[302]. Rfx6 belongs to the regulatory factor X family of winged helix transcription 
factors that are essential for islet cell development. Rfx6 controls insulin expression 
and secretion by modulating Ca2+ channel expression [106]. Rfx6 null mice lack all 
endocrine cells, including beta cells and die within a few days of birth [109]. Rfx6 
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loss in adult beta cells leads to glucose intolerance, impaired beta cell glucose 
sensing and defective insulin secretion [303].  
Recessive RFX6 mutations can result in Mitchell-Riley syndrome (OMIM #601346), 
with an absence of pancreatic islet cells, associated with intestinal atresia, 
gallbladder hypoplasia and intractable diarrhoea [304]. To date there have been 
fourteen subjects identified with homozygous RFX6 mutations [106, 109, 110, 304, 
305]. The majority developed diabetes as a neonate, however, four subjects were >2 
years of age [305]. In many of the families, the heterozygous carriers had adult-onset 
diabetes [108, 109].  
In 2015 RFX6 was first reported as a possible MODY gene. Artuso et al. used 
targeted sequencing for all MODY and “candidate” diabetes genes in 30 individuals, 
diagnosed <25 years with a three generation family history and consistent with the 
ISPAD guidelines for MODY screening [306]. They identified three individuals with 
heterozygous RFX6 mutations; the pathogenicity in each case is unclear. One 
individual had a RFX6 and WFS1 mutation, both inherited from her mother, who also 
had diabetes. Case 2, an 18year old male with diabetes, had a heterozygous variant 
in RFX6, however, no segregation of the variant was undertaken. Case 3 was a 10yo 
girl with diabetes in whom they identified a variant in RFX6 and ABCC8, inherited 
from her mother and father respectively, both of whom had diabetes. 
In 2017, Patel et al. identified two probands with novel heterozygous RFX6 variants 
with reduced penetrance using targeted MPS [301]. There was co-segregation of the 
variant in 9/10 individuals with diabetes. There was reduced penetrance of the 
variant, with 27% of heterozygotes developing diabetes by 27years of age, with a 
median age of presentation of diabetes of 15 years. Each individual had diabetes, 
without the other features of Mitchell-Riley syndrome, with significant endogenous 
insulin production, non-sulphonylurea sensitivity.  
We initially did not identify this variant when filtering variants for those in known 
MODY/CHI genes, because this gene was not known to be associated with MODY. 
However, once this gene was identified as a possible new MODY gene this year, I 
was able to review our exome data and identify this variant. This highlights one 
benefit of WES vs. panel sequencing. 
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7.4.2   Gene screening: optimum approaches? 
Sanger sequencing 
All our samples had Sanger sequencing of (between one and four) MODY genes 
prior to this study, as directed by their treating clinician. At a cost of AUD$750 per 
gene for the four most common MODY genes (HNF4A, GCK, HNF1A and HNF1B), 
and up to AUD$2500 for ABCC8 (the most common gene in CHI), very few 
individuals would have any further genes tested. The four most common genes 
account for approximately 95% of MODY cases [20]. Two genes account for 
approximately 45% of CHI cases [307]. Each subsequent gene accounts for fewer 
and fewer cases. Sequencing by traditional methods is time-consuming and costly 
with increasingly diminishing returns for each gene sequenced. WES, on the other 
hand, costs <AUD$1000 per sample. Thus, unless the clinical presentation suggests 
a single gene (e.g. GCK in individuals with fasting hyperglycaemia, or urogenital 
abnormalities in HNF1B), it is likely to be more cost-effective to use WES than 
sequencing multiple genes by Sanger sequencing. .  
Targeted MPS vs. WES vs. WGS 
Targeted MPS has been used clinically to identify variants in MODY genes [217, 
219]. Targeted sequencing has lower costs per run than WES, with good depth of 
coverage across the targeted exons. There is also significantly less data generated 
per run which requires less bioinformatics time and resources, as well as less time 
for data analysis. There is also no risk of “incidental” findings in other genes with 
targeted sequencing. The disadvantage of targeted sequencing is the ability to 
modify the panel with new genes are identified. We were able to review our WES 
data in light of the discovery of the new MODY gene and identify a family with a 
variant in RFX6. WES can also be used for new gene discovery, which is not 
possible with targeted sequencing. Unlike targeted sequencing, WES requires no a 
priori knowledge of candidate genes involved in a condition to sequence these 
individuals using “off the shelf” capture platforms.  
The exome comprises <1% of the genome, but contains 85% of the disease-causing 
mutations [308]. This WES has the potential to be more cost-effective and a viable 
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alternative to whole genome sequencing (WGS). More than 99% of all mutations in 
MODY and CHI are exonic or splice-site mutations; thus 99% of WGS data would be 
superfluous to diagnostic needs and not routinely analyzed. However, intronic 
mutations in ABCC8 and HADH causing CHI were recently identified [300], which 
obviously would be missed by WES; further, structural variation can be more easily 
detected using WGS. WGS would also detect a much larger number of variants than 
WES; and determining causality of intronic variants is much more complex than for 
coding variants  
We failed to identify a variant in a known causative gene in over half the MODY 
samples and all the CHI samples. Further gene discovery was pursued in these 
families with the results are presented in Chapter 8. 
7.5   Conclusion 
We identified variants in known MODY genes segregating with diabetes in three of 
seven families. Both Chapter 6 and Chapter 7 support the premise that WES is an 
efficient and relatively cost-effective method of genetic diagnosis for MODY and CHI, 
where there are multiple possible causative genes. My data also show the 
advantage of being able to reinterrogate WES data in light of new gene discovery, 
and the possibility of new gene discovery (presented in Chapter 8). 
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Abstract 
Background: Maturity-onset diabetes of the young (MODY) is a heterogeneous 
group of disorders caused by a dominant mutation in one of thirteen genes. Whole 
exome sequencing (WES) has improved ease of MODY diagnosis by enabling 
comprehensive and cost-efficient screening of all MODY genes. 
Case report: We identified a non-obese proband with clinical features of MODY 
(autosomal dominant antibody-negative diabetes). He had a history of macrosomia 
and transient neonatal hyperinsulinism. Other family members also had a history of 
macrosomia and later diabetes. Sanger sequencing of the four most common MODY 
genes failed to identify a cause. WES identified a novel ABCC8 mutation 
(c.4169C>T, p.Ala1390Val) segregating with disease in the family (diabetes and/or 
clinical hyperinsulinism). However, penetrance varied, with two carriers having very 
mild/absent disease. 
Discussion: This case demonstrates the clinical utility of WES in determining the 
cause of MODY in a condition with multiple candidate genes; and illustrates the 
phenotype associated with ABCC8 mutations. 
 
Introduction 
Maturity-onset diabetes of the young (MODY) is the most common form of 
monogenic diabetes and results from a dominant mutation in any of thirteen 
identified genes, all of which regulate beta-cell function (HNF4A, GCK, HNF1A, 
PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8 and KCNJ11 
[reviewed in [309]]). MODY accounts for 2 -2.5% of childhood diabetes [16], 
[Johnson et al. (submitted)]. Until recently, MODY genetic screening was uncommon 
even in individuals with suggestive family history and usually limited to the most 
common MODY genes (e.g. HNF1A or GCK which together account for 
approximately 90% of identified cases) [20]. However, massively parallel sequencing 
(MPS) means comprehensive MODY gene testing is now feasible in a cost-and time-
efficient manner [217]. 
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We report a novel ABCC8 mutation identified by whole exome sequencing (WES) in 
a family with MODY in whom previous limited Sanger sequencing had failed to 
identify a mutation. This family highlights the variable phenotype of individuals with 
mutations in genes regulating insulin secretion, with clinical evidence of hyper- and 
hypo-secretion within the family and even within the same individual at different time 
points. 
 
Clinical Case 
A family with a highly suggestive MODY history (Figure 7.4) was recruited to a study 
of WES for disorders of insulin secretion (ethical approval: University of Queensland 
Human Research Ethics Committee [UQ 2013000017]). All individuals gave 
informed consent. 
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Figure 7.4   Pedigree demonstrating dominant inheritance of diabetes 
associated with a ABCC8 mutation 
 
 
Circles represent females, squares indicate males. Diagonal line represents 
deceased individuals. Filled squares/circles indicate individuals with diabetes. 
Hashed squares indicate clinical evidence suggestive of hypoglycaemia and/or 
hyperinsulinism (see text). Age of diabetes onset is indicated below each symbol. 
WT: wild-type. c.4169C>T:  demotes heterozygous ABCC8 mutation 
 
The proband (individual IIIa) is a Caucasian male diagnosed with diabetes aged 27 
years during a routine workplace medical examination. Past history included 
macrosomia at birth (weight 4.96kg) and transient neonatal hyperinsulinaemic 
hypoglycaemia. At diagnosis he had polyuria but no weight loss. There was no 
personal or family history of autoimmune disease. GAD-65 and IA-2 antibodies were 
negative. He required minute insulin doses (0.2 - 0.4 units/kg/day) to achieve 
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excellent glycaemic control (HbA1c <6.5% [48mmol/mol]). He had episodes of mild 
hypoglycaemia with exercise and manual work, and could remove his pump for days 
without developing ketosis. MODY was considered but Sanger sequencing was 
negative for HNF4A, GCK, HNF1A and HNF1B mutations. 
His mother (individual IId) was diagnosed with diabetes during this study, aged 64 
year with weight 62kg; and managed with diet. Glycaemic control had been normal 
throughout three pregnancies and on all previous random glucose readings. 
The proband’s maternal uncle (individual IIc) was also macrosomic at birth (weight 
5.7kg) although postnatal hypoglycaemia was not reported. He also presented with 
diabetes aged 27 years, and similarly required minimal insulin doses (20 units in total 
for sedentary days and no insulin on active days) for several decades, until he 
developed obesity. At the start of this study, individual IIc was aged 56 years, 
weighed 102kg, and required 130 units of insulin to maintain HbA1c <7% 
(53mmol/mol). 
A second maternal uncle (individual IIb) was also diagnosed with diabetes aged 30 
years, and managed with insulin. Further clinical details are not available. 
The proband’s (deceased) maternal grandfather (individual Ib) had frequent 
symptoms suggestive of hypoglycaemia, which were self-treated and never 
investigated. (He had frequent episodes of neuroglycopaenic symptoms including 
confusion, which responded to barley sugar). The proband’s (deceased) maternal 
grandmother (individual Ia) was diagnosed with diabetes in her eighties. She was not 
known to have diabetes in pregnancy. 
The proband’s sister (aged 28 years) was born prematurely but had normal weight 
for gestational age. She had no clinical evidence of hyperinsulinism or diabetes 
(including recent oral glucose tolerance testing). The proband’s brother was also 
clinically well. 
DNA was extracted from peripheral blood mononuclear cells or saliva by standard 
means. The proband underwent WES using the Nimblegen EzCap Human v3.0 
Exome Enrichment kit (Roche, Basal, Switzerland). Multiplexed MPS was 
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undertaken using Illumina HiSeq 2000 (Illumina, San Diego, CA, USA) generating 
100basepair paired-end reads. Demultiplexing, sequence alignment, variant calling 
and annotation were performed as described previously [291]. Good quality, 
damaging variants (defined as splice site, nonsynonymous, frameshift, stop-loss and 
stop-gain variants) in MODY genes with minor allele frequency <0.1% were retained. 
A novel heterozygous missense variant in ABCC8 was identified (NM_000352 
c.4169C>T, p.Ala1390Val). This variant has not been previously reported in Exome 
Aggregation Consortium (ExAC), dbSNP, 1000 Genomes, LOVD, HGMD or PubMed 
and is predicted to be damaging by protein prediction algorithms PolyPhen, 
MutationTaster and SIFT. Sanger sequencing confirmed the mutation, which 
segregated with diabetes +/- clinical hyperinsulinism in all available individuals. 
Additionally, the proband’s unaffected sister was a carrier. 
The proband was commenced on sulphonylureas (glyclazide 160mg daily). Initially, 
his insulin requirement halved, with maintenance of good glycaemic control. 
Subsequently, he was lost to follow-up, precluding further trial of insulin reduction. 
His uncle (Individual IIc) was also commenced on glyclazide 160mg daily; insulin 
was reduced from 130 units to 10 units per day with good glycaemic control, and he 
reported marked improvement in quality of life. 
 
Discussion 
This case shows the clinical utility of comprehensive MODY screening in individuals 
with suggestive history, even if previous screening of common MODY genes has 
been negative. Our family demonstrates the variable penetrance and phenotypic 
variability of ABCC8 mutations. 
ABCC8 encodes the sulphonylurea receptor 1 (SUR1) of the beta cell ATP-sensitive 
potassium (KATP) channel. Mutations in ABCC8 can cause varying phenotypes. Both 
dominant and recessive loss-of-function mutations can cause hyperinsulinism. 
Diabetes (both neonatal diabetes and MODY) results from gain-of function 
mutations, usually with dominant inheritance although recessive inheritance has 
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been reported in neonatal diabetes [140, 310]. Asymptomatic carriers of both gain- 
and loss-of-function have been reported; and dual phenotypes (neonatal 
hyperinsulinism with later adult-onset diabetes) have been reported within the same 
family and within the same individual [310, 311], as seen here also. This switching of 
phenotypes is not unique for ABCC8 mutations, as macrosomia and neonatal 
hyperinsulinism followed by diabetes has also been reported for HNF4A and HNF1A 
MODY [287, 312]. Mouse models of hyperinsulinism due to dominant KATP channel 
mutations have demonstrated increased beta cell apoptosis [313], as have 
pancreatic samples from human cases of congenital hyperinsulinism undergoing 
pancreatectomy [314], which may explain progression from hyperinsulinism to insulin 
insufficiency in some MODY subtypes. 
Our family showed highly variable age of onset of diabetes. Diabetes presented in 
affected males at a slightly older age (27, 27 and 30 years) than is typical for MODY, 
which usually presents <25years [279]. In contrast, the proband’s mother had 
demonstrable normal glycaemic control throughout her child-bearing years and 
beyond, only developing mild diet-controlled diabetes aged 64. The proband’s carrier 
sister (aged 28 years) has normal glucose tolerance. Whether her clinical course 
ultimately resembles her mother’s remains unknown. Neither mother nor sister have 
a history suggestive of hyperinsulinism. The maternal grandfather had a long history 
suggestive of symptomatic hypoglycaemia. The proband’s grandmother had 
diabetes diagnosed at a late age. Without DNA confirmation, any clinical relationship 
with this ABCC8 mutation in either grandparent is speculative. 
Many cases of neonatal diabetes and MODY from ABCC8 mutations have been 
completely or partially responsive to sulphonylureas [315, 316]; and two affected 
individuals in this family similarly had excellent response. Compared to insulin, 
sulphonylureas are not only more cost-effective [248], but also improve clinical 
outcomes, with lower risk of severe hypoglycaemia, improved glycaemic control, and 
greater quality of life [26-29]. Further, individuals with MODY do not require routine 
screening for other autoimmune conditions. 
This case demonstrates the utility of WES in conditions with a large number of 
possible causative genes. Although some forms of MODY have distinct clinical 
features that could direct screening (e.g. HNF1B-MODY) the majority are clinically 
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indistinguishable. The presence of macrosomia and neonatal hyperinsulinism may 
have suggested an ABCC8 mutation; however, these features are also reported for 
HNF1A and HNF4A mutations, both more common causes of MODY than ABCC8. 
Our proband had four genes sequenced at cost AUD$750/gene ($3000) prior to 
WES. ABCC8 is a large gene with 39 exons; had ABCC8 mutations been suspected 
earlier, Sanger sequencing would have cost AUD$2500. At <AUD$1000 per sample, 
WES provided a very cost-effective means of obtaining a genetic diagnosis in this 
family; comprehensive panel MPS would be expected to be similarly cost-effective. 
In conclusion, WES determined a novel ABCC8 variant causing MODY in a family 
with previously negative screening. This family demonstrates the varied phenotype 
associated with ABCC8 mutations, from hyperinsulinism to MODY; and the clinical 
benefits of making a MODY diagnosis. 
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8.0   The Use of Whole Exome Sequencing for New Gene 
Discovery in Congenital Hyperinsulinism and Maturity-
Onset Diabetes of the Young 
 
8.1   Introduction 
WES has revolutionised new gene discovery in the 21st century. The first gene 
discovered using WES was for Bartter syndrome in 2009 [197]. Since then the 
number of new genes has increased exponentially. In 2012, Gilissen et al. reported 
the number of rare monogenic diseases was estimated to be >5000 and for half of 
these the underlying genes were unknown [317]. As of May 2017, OMIM reports 
there are 3734 genes with phenotypes causing mutations; and currently the rate of 
new gene discovery for monogenic conditions is estimated at three per week [289]. 
The reasons for success of MPS in gene mapping are described in Chapter 1.5 
De novo variants can often be identified by sequencing the proband and both 
parents [318]. In recessive conditions, new causative genes have been identified by 
WES even by sequencing the proband alone, where the individual was either 
homozygous for the alternate allele [319], or compound heterozygous with two 
different mutations in the same gene [320]; however, functional studies and/or 
replication in other families is needed to verify such a result. Dominant conditions are 
more difficult to map, as many variants will co-incidentally segregate with disease 
state. First degree relatives (separated by one meiosis) have a 50% chance of 
sharing any given variant; this proportion drops off exponentially with increasing 
distance between relatives (i.e. greater number of meioses). The probability of two 
relatives sharing a common allele is 1/2n, where n refers to the number of meiotic 
events between the two individuals. Thus sequencing distantly-related family 
members can enable causative variants in dominant conditions to be identified. 
The first family (the RW pedigree) with maturity-onset diabetes of the young (MODY) 
was identified in 1958, with over 360 family members spanning four generations 
191 
 
[321]. Sequencing began in 1985 and in 1996 the gene (HNF4A) was identified as 
the cause of diabetes in this family [31]. By comparison, Bonnefond et al. identified 
KCNJ11 as the thirteenth MODY gene using WES in 2012 in a four generation 
family, including 12 members with a clinical diagnosis of MODY [102]. WES was 
performed on four family members: the proband, his affected father, unaffected 
mother and affected cousin. A total of 324 possible variants were identified and 
these variants were assessed in the remainder of the family. Only one mutation was 
present in all affected individuals, c.679G>A (p.Glu277Lys) in KCNJ11. Linkage 
analysis resulted in a LOD score of 3.68 at this site. WES provided a much more 
rapid and cost-efficient method of gene discovery in this instance than traditional 
linkage analysis, and requires fewer family members.  
I previously used WES to identify variants in known MODY/CHI genes in subjects 
with a clinical diagnosis of MODY or CHI (Chapter 7). In those without a mutation in 
a known MODY or CHI gene, I now extended WES to other family members, for 
gene discovery in both MODY and CHI. 
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8.2   Methods 
8.2.1   Clinical Cohort 
Thirteen unrelated probands were recruited (seven with MODY and six with CHI). All 
had a clinical diagnosis of MODY or CHI, but no prior genetic diagnosis. Three 
MODY cases subsequently had a genetic cause identified, as described in Chapter 
7. The remaining ten probands (four MODY and six CHI) were recruited for a new 
gene discovery study, along with their available family members.  
Ethical approval was obtained from The University of Queensland Human Research 
Ethics Committee (UQ 2013000017); all individuals and/or their guardians gave 
informed consent. 
8.2.2   Laboratory Methods and Data Annotation 
This was performed as presented in Chapter 7.2. Relatives within a family were all 
sequenced using the same capture technology. 
Data analysis 
Filtering for known MODY/CHI genes  
Data were first analysed for variants in known MODY/CHI genes, as described in 
Chapter 7.2.  
Filtering for new gene discovery  
Sequence data from probands and their family members were filtered for new gene 
discovery, according to the likely mode of inheritance.  
For MODY families and CHI families with presumed dominant mode of inheritance, 
data were filtered according to the following: 
• seen on ≤5 occasions in my laboratory’s internal exome data from over 3000 
exomes (as a means for excluding platform artefact) 
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• Variants for whom all affected individuals were heterozygous (i.e. 0/1) and all 
unaffected individuals homozygous for the reference allele (i.e. 0/0) – i.e. the 
variant segregated appropriately with disease state. 
• MAF 0 (i.e. novel variants). This stringent threshold was chosen as most 
MODY mutations are private [67].  
• Variants in a conserved region with a GERP score >2 
• Variants predicted to be damaging by any protein` prediction algorithm 
(Polyphen, SIFT and MutationTaster, or Human Splice Site finder for splice 
site variants) 
For CHI families without a clear dominant history in whom there was an unknown 
mode of inheritance (presumed sporadic or recessive), data were filtered according 
to possible de novo dominant inheritance or diallelic (compound heterozygous or 
recessive homozygous) inheritance.  
• De novo dominance was assessed looking for variants that were 
heterozygous in  affected individuals (i.e. 0/1) but not present in the 
(unaffected) parents (i.e. 0/0) 
• For compound heterozygous inheritance, variants in the proband and any 
affected siblings were heterozygous (i.e. 0/1) for two different alleles per 
gene, one variant inherited from each parent. MAF of each observed variant 
had to be <0.001. 
• For homozygous inheritance, variants in the proband were 1/1 for a single 
allele (MAF <0.001) 
In addition to within-family analysis, I also assessed for variants in a common gene 
shared by more than one proband. 
Consanguinity was evaluated during sequencing QC. All remaining candidate genes 
were assessed to identify those implicated in insulin production; previously reported 
in genome-wide association studies of T1DM or T2DM; or associated with known 
insulin-regulating proteins using STRING.  
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Sanger sequencing 
Sanger sequencing was performed for two putative candidate genes. Sequencing 
was performed as described previously. 
Sanger sequencing was performed on family CHI_067 and CHI_068 for AGAP2 
exon 1 using primers: 
Left primer ACCACGAGTGGAGCCAAA, and  
Right primer CCTCCTGTGCTCTTGGTGA.  
Sanger sequencing was performed on family MODY_029 for KCNK16 exon 3 using 
primers: 
Left primer CCAGTCCAACAAAGAGGAACA, and  
Right primer GGTCCTCCCATCTTTCAATG 
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8.3   Results 
8.3.1   Clinical information: MODY 
Family MODY_029 
This pedigree is shown in Figure 8.1. 
The proband (MODY_029.3) was diagnosed with diabetes aged 15 years. She 
presented atypically, when hyperglycaemia (glucose >13mmol/L) was incidentally 
detected during investigations for lethargy. Her fasting glucose was 5.6mmol/L, with 
C-peptide of 0.2nmol/L (reference range 0.3-0.7nmol/L) and HbA1c 6.1% at 
presentation. She was negative for three diabetes autoantibodies (islet cell antibody, 
islet antigen 2, and glutamic acid decarboxylase-65). She was 57kg and 165cm (BMI 
20.9kg/m2). She only required basal insulin, in doses of 1-2 units per day to maintain 
an HbA1c 5.7-6.5%. Recent assessment showed her fingerprick fasting blood 
glucose to be usually 5-6mmol/L but on formal oral glucose tolerance testing a 
fasting glucose of 7.8mmol/L and two-hour glucose of 19.6mmol/L. Sanger 
sequencing for GCK, HNF1A and HNF4A was negative. 
Her maternal aunt (MODY_029.21) presented aged 13 years after a collapse during 
exercise and was found to have hyperglycaemia without ketosis. She was also 
antibody negative, and not overweight. She required 9-10 units of Mixtard® 30/70 
mane only to maintain HbA1c 5-6%. She frequently experiences symptomatic 
hypoglycaemia two hours after breakfast.  
The mother of the proband (MODY_029.2) was diagnosed with non-ketotic 
hyperglycaemia aged 15 years following a brief history of polyuria and polydipsia. 
She was also antibody negative and not overweight. She has required 8-11 units per 
day of isophane insulin, without rapid-acting insulin, to maintain her HbA1c 6-7%.  
The maternal grandmother (MODY_029.98) also had diabetes diagnosed aged 30 
years. She required <10 units/day of basal insulin to maintain HbA1c 6-6.5%. She 
died aged 82 years, without evidence of diabetes complications. 
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Figure 8.1 
Pedigree information MODY_029 family. Subjects with diabetes are shown in black. 
Females are circle, males are squares. Asterisk indicated subjects who underwent 
WES. Arrow indicates the proband. Age at diagnosis, current treatment and 
individual ID are listed below. Ins: insulin.  
 
Other MODY families 
Three other MODY families were recruited to this study. All families had a three 
generation autosomal dominant antibody negative diabetes. The clinical information 
for the proband in each family is presented in Chapter 7 (Table 7.1 and 7.2). 
Pedigree information for all three remaining families is illustrated in Figure 8.2  
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Figure 8.2 Pedigree information for all remaining MODY families. 
MODY_060 Pedigree 
 
MODY_047 Pedigree 
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MODY_255 Pedigree 
 
Subjects with diabetes are shown in black. Females are circle, males are squares. 
Asterisk indicates subjects who underwent WES. Arrows indicate the proband. Age 
at diagnosis (in years) and current treatment are shown. Ins insulin; OHG oral 
hypoglycaemic agent. Individual IDs are listed below each pedigree. 
 
8.3.2   Clinical information for CHI families 
Four CHI probands had apparently sporadic hyperinsulinism (CHI_017.3, 
CHI_042.3, CHI_046.3 and CHI_054.3). Clinical details for CHI_017.3, CHI_042.3, 
CHI_046.3 and CHI_054.3 are shown in Chapter 7 (Tables 7.1 and 7.2). 
Two families (CHI_067 and CHI_068) had autosomal dominant CHI. Pedigrees are 
illustrated in Figures 8.3 and 8.4. 
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Family CHI_067 
The pedigree for this family is shown in Figure 8.3. 
The proband (CHI_067.3) presented with a hypoglycaemic seizure aged 2 years. 
She had a history of frequent early morning drowsiness which resolved with sugary 
drinks. At presentation her blood glucose was 2.1mmol/L, with insulin 5.1 mU/L and 
suppressed ketones. She had a subsequent episode of hypoglycaemia to 2.7mmol/L 
with suppressed insulin of <2mmol/L and beta-hydroxybutyrate 0.4mmol/L. Her 
cousin (CHI_067.41) had also presented with hypoglycaemic seizure aged 4 years. 
Her brother (CHI_067.42) subsequently presented (also aged 4 years) with a 
hypoglycaemia seizure with elevated insulin and suppressed ketones. All three 
children have responded well to diazoxide.  
Their father (CHI_067.4) had an episode of loss of consciousness with 
hypoglycaemia, but has not had further investigations or treatment. Other members 
of the family (Figure 8.3) have type 2 diabetes. 
Samples CHI_067.3, CHI_067.41 and CHI_067.42 were available for WES. 
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Figure 8.3 Pedigree information for family CHI_067 
 
Subjects with hypoglycaemia are shown in black. Those with diabetes in grey. Those 
with unconfirmed hypoglycaemia are hashed. Females are circle, males are squares. 
Asterisk indicated subjects who underwent MPS. Arrow indicates the proband. 
Subject ID and age at diagnosis hypoglycaemia is listed below symbol. 
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Family CHI_068 
The pedigree for this family is shown in Figure 8.4. 
The proband (CHI_068.3) presented with a hypoglycaemia seizure (blood glucose 
un-recordably low on glucometer) at age 20, after consuming alcohol with no food. 
Formal blood glucose was 1.8mmol/L, with insulin 20mU/L (inappropriate for 
hypoglycaemia). He complained of “always being hungry”. He has been well since 
commencing diazoxide. 
His second cousin (CHI_068.61) was born with appropriate birth weight (3.7kg at 
term). He presented with a seizure disorder at 9 months associated with 
developmental delay. At 22 months he presented with an episode of loss of 
consciousness, during which his blood glucose was 1.4mmol/L. He was responsive 
to diazoxide, and remains on diazoxide at age 23 years. He has severe intellectual 
impairment and is unable to live independently. His father (CHI_068.71) also had a 
history of seizures and hypoglycaemia as an adult, but was never formally 
investigated or treated for hyperinsulinism.  
There is no known hypoglycaemia in other family members 
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Figure 8.4  Pedigree information for family CHI_068 
 
Subjects with confirmed hyperinsulinism are shown in black. Those with unconfirmed 
but clinically suggestive hypoglycaemia are hashed. Females are circle, males are 
squares. Asterisk indicated subjects who underwent MPS. Arrow indicates the 
proband. Subject ID and age at diagnosis hypoglycaemia is listed below symbol. 
 
8.3.3   Sequencing Data 
 
Coverage statistics 
Mapping and coverage statistics and detailed base calling statistics for all samples 
are presented in Table 8.1. Mean coverage overall was 40-fold, with 84% of the 
targeted capture region covered to a depth of 10x.
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Table 8.1. Summary statistics for all MODY and CHI samples 
Sample Total bases % bases on target exons 
Target exon 
median 
base 
coverage 
Target exon 
mean base 
coverage 
% target 
exon bases 
with 
coverage 
>1x 
% target 
exon bases 
with 
coverage 
>5x 
% target 
exon bases 
with 
coverage 
>10x 
% target 
exon bases 
with 
coverage 
>30x 
CHI_017.1 5147166017 56.0 52.5 60.8 97.9 94.5 90.2 71.2 
CHI_017.2 3639038253 43.8 27.7 33.3 96.9 90.3 81.5 45.8 
CHI_017.3 2748162390 47.3 23.5 28.1 95.7 86.4 75.2 36.7 
CHI_042.1 5398028834 44.1 42.9 49.1 97.8 94.3 89.8 67.0 
CHI_042.2 3731040197 36.8 22.3 26.9 97.2 91.6 82.5 38.7 
CHI_042.3 4060057190 37.5 36.0 43.1 97.9 91.7 83.8 52.9 
CHI_046.1 3021452218 32.1 17.1 19.2 96.7 90.7 79.1 24.2 
CHI_046.2 2729456248 34.3 17.9 19.5 97.1 89.7 77.4 22.3 
CHI_046.3 4581003392 37.6 40.1 48.8 98.3 92.9 85.7 57.1 
CHI_054.1 2708621596 33.1 16.9 18.5 96.9 89.4 76.3 20.4 
CHI_054.2 2571902578 36.2 17.4 19.2 97.2 89.7 76.9 22.1 
CHI_054.3 6524284873 38.7 59.0 70.3 98.8 95.6 91.3 72.5 
CHI_067.3 4180832750 46.6 34.4 40.9 97.2 91.9 85.0 55.2 
CHI_067.41 2571902578 36.2 17.4 19.2 97.2 89.7 76.9 22.1 
CHI_067.42 4672927706 38.7 42.0 51.4 98.3 93.0 86.2 58.8 
CHI_068.3 4051199475 44.5 31.6 37.7 97.1 91.6 84.2 51.9 
CHI_068.61 4772849669 46.3 36.1 43.3 97.5 97.4 85.9 51.2 
MODY_029.21 5386986408 35.9 44.2 53.5 98.6 94.5 88.7 63.0 
MODY_029.3 5187196181 47.9 32.0 37.6 91.0 84.4 79.2 54.6 
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MODY_029.98 5835073129 38.4 52.9 64.4 98.2 93.6 88.0 65.9 
MODY_029.4 1824158333 35.8 12.8 14.2 95.5 80.4 60.1 9.9 
MODY_047.1 5914670485 36.6 49.6 59.1 98.9 95.8 91.1 68.9 
MODY_047.3 5641493654 44.5 31.9 38.1 90.7 83.8 78.3 54.3 
MODY_047.31 5597490396 36.5 47.2 56.6 98.6 94.7 89.3 65.5 
MODY_060.3 5462202710 46.2 32.8 38.2 88.9 82.8 78.1 55.5 
MODY_060.4 3443352081 42.6 25.8 30.9 96.6 89.6 80.1 42.6 
MODY_060.31 5250262551 37.1 44.1 54.9 98.3 93.4 86.8 60.6 
MODY_060.2 3202031611 41.5 9.5 34.0 91.5 68.2 44.1 6.6 
MODY_255.1 4817661828 37.8 41.8 51.3 98.3 93.3 86.5 59.1 
MODY_255.3 5951522227 46.2 35.3 41.7 89.1 83.1 78.7 58.6 
MODY_255.98 5086069904 37.3 43.5 53.2 98.3 93.5 87.0 60.9 
MODY_255.12 2992573541 35.1 20.2 21.9 97.4 91.0 80.8 28.5 
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8.3.4   MODY gene analysis 
MODY families 
Variant filtering for the MODY families is presented in Table 8.2. 
Variants in two possible genes (KCNK16 and USP42) were identified for 
MODY_029. KCNK16 has a known role in insulin secretion. The only known role for 
USP42 is in spermatogenesis.  
Among the other MODY families, MODY_060 were left with five variants in 4 genes, 
MODY_047 were left with four possible variants and MODY_255 with six possible 
variants. None of these were in strong candidate genes for MODY. There were no 
variant in a shared gene between these families. 
CHI families 
Variant filtering for the CHI families is presented in Table 8.3 (de novo or dominant 
inheritance) and Table 8.4 (compound heterozygous inheritance). There were no 
homozygous variants in any CHI proband. 
Family CHI_067 and CHI_068 each had two variants remaining after filtering 
assuming autosomal dominant inheritance, with one variant (in AGAP2) shared by 
both families. The families are not known to be related, but come from the same 
town and share a family name, although this is a very common name. These two 
individuals had an identity by descent value of 0.03, at which level it is not possible 
to comment further on relatedness. 
No clear candidate gene was identified for the remaining CHI families, under either 
genetic model.
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Table 8.2 Possible candidate genes for MODY families 
Family MODY_029 MODY_060 MODY_047 MODY_255 
No. coding variants with MAF <5% with 
appropriate segregation 
after platform-related artefact removed 
17 14 35 22 
Variants with MAF 0 5 9 8 10 
GERP score >2 4 5 7 9 
Damaging variant# 2 5 4 5 
Candidate genes 
KCNK16 
USP42 
 
ALCAM 
GSR 
SLC45A2 
SYNPO2 
SYNPO2 
 
ATP6V1H 
EML6 
IMPA1 
PKHD1L1 
 
FNDC3B 
MED12L 
PAX7 
RBM33 
ZNF177 
ZNF30 
 
#
 Damaging variant according to protein prediction algorithms (SIFT, PolyPhen and/or Human Splicing Finder v3.0) 
MAF minor allele frequency, GERP genomic evolutionary rating profile. Coding variants include splice-site, non-synonymous, 
frameshift, stop-gain and stop-loss variants
207 
 
Table 8.3 Possible novel variants in candidate genes for CHI families, assuming autosomal dominant or de novo 
inheritance 
Family CHI_017 CHI_042 CHI_046 CHI_054 CHI_067 CHI_068 
No. coding variants with MAF <5% 
with appropriate segregation 
after platform-related artefact 
removed 
119 126 113 63 30 15 
Variants with MAF 0 91 82 57 16 5 2 
GERP>2 52 54 48 13 2 2 
Damaging variant# 23 37 35 9 2 2 
Candidate genes 
ACLY 
ADAMTS3 
AKAP11 
ANKAR 
ANKRD27 
ASB2 
ATXN7L2 
C3orf43 
CASP9 
AGRN 
AKAP6 
BSN 
C1orf68 
C6orf106 
C9orf64 
CDHR4 
CELSR1 
CEP131 
ARHGEF17 
ARID1B 
BRD8 
C10orf71 
C1QTNF6 
CASZ1 
CREB3L4 
DCTPP1 
DENND3 
ACHE 
COL9A1 
GPR37L1 
MAP2K7 
PPM1N 
PTCHD1 
RGSL1 
SLC27A5 
TAS2R19 
 
AGAP2 
SCAMP3 
 
AGAP2 
TMEM2 
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EMID1 
FAM13A 
FAT2 
FHDC1 
GALNT18 
GRM8 
IL20RA 
KCTD1 
KMT2C 
LHFP 
LRP11 
LRWD1 
MAPK8IP3 
MAPKAP1 
MYH13 
MYRF 
POLR3C 
PTCHD2 
PTPN14 
SEMA6B 
SNX33 
 
COL24A1 
CPZ 
DBN1 
DHX37 
ELOVL5 
EML3 
GPBP1 
GTF3C4 
HEATR5B 
KIAA0319 
KIAA1804 
KLHL11 
KMT2D 
LRP12 
MOV10 
MVD 
MYO18B 
MYOM3 
OTOG 
PRLR 
RRP12 
DIS3L2 
DPP9 
DTX3 
GLI2 
GPSM1 
HMG20A 
LRPAP1 
LZTS1 
MEGF11 
NNMT 
NOS3 
NSRP1 
OPCML 
PLEKHH1 
PODXL2 
PRKRIR 
PRR14L 
PTPN5 
SBNO1 
SCNN1A 
SF3B1 
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RTN1 
Sep-05 
SMTN 
STK40 
TMEM131 
TMEM194A 
TUBB 
UMOD 
UNC80 
ZNF710 
IRS4 
 
SLC12A9 
SORL1 
SPRYD7 
TMEM161A 
TMEM194A 
VWA2 
WDR24 
XCR1 
ZDHHC21 
 
#
 Damaging variant according to protein prediction algorithms (SIFT, PolyPhen and/or Human Splicing Finder v3.0) 
MAF minor allele frequency, GERP genomic evolutionary rating profile. Coding variants include splice-site, non-synonymous, 
frameshift, stop-gain and stop-loss variants
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Table 8.4 Possible candidate genes for CHI subjects, assuming compound heterozygous inheritance 
Family CHI_017 CHI_042 CHI_046 CHI_054.3 
Number of coding heterozygous variants in 
proband with MAF<5% 
after platform-related artefact removed 
517 495 632 466 
Variants with MAF 0.1% 268 257 351 236 
≥2 variants per gene with MAF <0.1% 31 27 47 28 
Inherited in compound heterozygous manner 0 0 2 variants (1 gene) 2 variants (1 gene) 
GERP >2.0 0 0 2 variants (1 gene) 2 variants (1 gene) 
Damaging variant# 0 0 1 variant 1 variant 
Candidate genes (with diallelic inheritance) - - - - 
#
 Damaging variant according to protein prediction algorithms (SIFT, PolyPhen and/or Human Splicing Finder v3.0) 
MAF minor allele frequency, GERP genomic evolutionary rating profile. Coding variants include splice-site, non-synonymous, 
frameshift, stop-gain and stop-loss variants 
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8.3.5   Novel candidate gene for MODY: KCNK16 
A heterozygous mutation in potassium channel, subfamily K, member 16 (KCNK16) 
(NM_001135105: c.341T>C, p.Leu114Pro in exon 3) was identified in Family MODY_029 
and segregated with disease. The variant is novel (not present in ExAC, LOVD, ClinVar, 
HGMD). It is in a highly conserved region (genomic evolutionary rating profile [GERP] 
score 5.65) and is predicted to be damaging according to all three protein predication 
algorithms. 
Figure 8.5 Sanger sequencing results for KCNK16 c.341T>C variant in family 
MODY_029  
   
 
 
 
 
 
Individual 
 
 
MODY_029.2  
 
 
 
 
 
MODY_029.3  
 
 
 
 
MODY_029.4  
 
 
 
 
MODY_029.98  
 
 
 
 
MODY_029.21  
 212 
 
8.3.6   Novel candidate gene for CHI: AGAP2 
The same heterozygous mutation in ARF GTPase-activating protein with GTPase domain 
ankyrin repeat, and pleckstrin homology domain 2 (AGAP2) was identified in all subjects 
with familial CHI in two separate families. The variant (NM_001122772) c.820A>G, 
p.Lys274Glu in exon 1 is novel (not present in ExAC, LOVD, ClinVar, HGMD). It is in a 
conserved region (GERP score 4.83) and is predicted to be damaging according to all 
protein predication algorithms. 
 
Figure 8.6 Sanger sequencing results for AGAP2 c.820A>G variant in family CHI_067 
and CHI_068  
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8.4   Discussion 
These data suggest a novel candidate gene for each of CHI and MODY.  
KCNK16 is a member of the 2-pore domain superfamily of background K+ channels, also 
known as TWIK-related alkaline pH-activated K+ channel-1 (TALK-1). TALK-1 is 
exclusively expressed in the pancreas [322]. It is open at all membrane potentials and able 
to drive the resting membrane potential towards the K+ equilibrium, creating an outwardly-
rectifying K+ current. TALK-1 channels are not sensitive to the classical KATP channel 
blockers, and are mildly sensitive to Tetraethylammonium (TEA), Barium, quinine and 
quinidine; and are activated by alkaline pH. 
When glucose enters the beta cell it is phosphorylated to G6P, undergoes further 
glycolysis to pyruvate and enters the TCA cycle, resulting in increased ATP and other 
second messengers. The increased ATP closes the KATP channel, depolarising the cell and 
allowing calcium entry through voltage-dependent calcium channels; which ultimately 
triggers insulin secretion. TALK-1 regulates the electrical activity, calcium entry and insulin 
secretion in beta cells. Increased TALK-1 channel activity polarises the beta cell plasma 
membrane potential by causing K+ efflux, reducing calcium entry, and reducing second-
phase glucose-stimulated insulin secretion [323].  
A KCNK16 SNP, rs1535500, has been identified in multiple T2DM GWAS [324-326]. Site-
directed mutagenesis of this SNP causing insertion of A277E into cloned human TALK-1 
channels in mice resulted in increased surface localisation of TALK-1 and enhanced 
channel activity, which promoted beta cell membrane polarisation with resulting reduced 
calcium influx and reduced insulin secretion [323]. Thus this common variant results in a 
gain-of-function of TALK-1 and a reduction in insulin secretion. Conversely Kcnk16-
deficient mice have beta cell membrane depolarisation, increased islet calcium influx and 
enhanced second phase (but not first phase) glucose-stimulated insulin secretion [323].  
The clinical phenotype in our family fits the predicted phenotype from a gain-of-function 
mutation. A gain-of-function mutation would be predicted to result in increased channel 
density and function, increased K+ efflux, maintaining polarisation and reducing calcium 
entry and subsequent insulin secretion. It appears to affect second-phase insulin secretion 
only; the KATP channel is still functional in response to increased ATP in an increased 
metabolism state and can release insulin on glucose entry into the cell, as occurs after a 
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meal. Our family all required predominantly basal insulin only. Indeed, MODY_029.21 was 
on mixed rapid- and long-acting insulin but frequently experienced hypoglycaemia within 
two hours of administration, suggesting she does not require rapid-acting insulin.  
Thus KNCK16 appears a very strong candidate for a new MODY gene. Functional studies 
of this mutation are now being planned. 
AGAP2 (also known as PI3K enhancer, PIKE) has not been described in association with 
a human phenotype. PIKE isoforms, PIKE-S, PIKE-L and PIKE-A control a diverse number 
of cellular activities, including gene transcription and metabolism, apoptosis, cell migration, 
transformation. PIKE is important in neurodevelopment, and neuroprotection [327]. PIKE-/- 
mice have smaller brains with thinner cortex, fewer cortical neurons and diminished 
dendritic arborisation and more cell death under excitotoxic insults [327]. PIKE is also an 
anti-apoptotic factor and proto-oncogene. Its expression is increased in many tumours, 
especially CNS tumours, including astrocytoma and glioblastoma [328]. 
Its role in metabolism is demonstrated by the PIKE -/- mouse. It has differing functions in 
different tissues. PIKE -/- mice display reduced white adipose tissue as a result of 
defective adipogenesis [329] and are more resistant to weight gain and adipose tissue 
gain during high fat meals. Both muscle and fat are hypersensitive to insulin: PIKE -/- mice 
have lower circulating insulin; require higher glucose infusion rates during 
hyperinsulinaemic euglycaemic clamps; and insulin stimulation triggers higher glucose 
uptake in both soleus muscle and adipocytes. On the other hand the liver appears insulin 
resistant, with enhanced gluconeogenesis and reduced hepatic lipid content [330]. The 
apparent variation in tissue-specific insulin sensitivities may be due to activation of 
different pathways: in muscle and fat, the PI3K/Akt pathway is induced, activated by 
AMPK, however, the PI3K/Akt pathway is significantly reduced in the liver due to 
decreased insulin receptor activation. The phenotype in heterozygous mice has not been 
reported. PIKE is not known to act on the pancreas directly; rather altering insulin 
sensitivity in different tissues. 
Of note, our subjects all had elevated insulin levels, not simply increased sensitivity to 
insulin. Thus a role of this variant remains speculative and will require functional work to 
elucidate.  
 215 
 
Remaining cases 
We were unable to demonstrate a genetic cause in many cases of MODY and CHI in the 
remaining cases.  
There are three families remaining with a clinical diagnosis of MODY, who did not receive 
a likely genetic diagnosis. Possible reasons include: 
1.  Phenocopies within the pedigree or misdiagnosis of MODY. There may be 
individuals with T2DM, even in a family with MODY, and their inclusion will cause 
inaccuracies in the results 
2. Inclusion of unaffected individuals. MODY has incomplete penetrance; and 
penetrance is age-related. For example, the penetrance of HNF1A mutations is 
approximately 63% by 25 years and 93.6% by 50 years [67]. Thus an unaffected 
individual, especially a young individual, may carry an as-yet unpenetrant variant, 
and thus provide a spurious result if included as an unaffected case. 
3. Using a minor allele frequency that was too stringent. As many MODY variants 
display incomplete penetrance, a variant may have been identified in a previously 
sequenced individual who does not (yet) have diabetes. Furthermore, individuals in 
exome databases may have diabetes and are not necessarily ‘healthy’ controls. 
Some databases include clinical information; but this is not universal. 
4. The candidate gene may be present in the list, but as it is not currently known to be 
involved in pathways for insulin secretion. One benefit of WES data is the ability to 
review it in the light of new gene or new mechanistic discoveries; thus some of the 
families may ultimately be ‘solved’.  
Similarly, I did not identify a candidate gene for four CHI families either. CHI can be 
inherited in an autosomal dominant or recessive function. We were not able to 
demonstrate any homozygous or compound heterozygous mutations in the cohort; and the 
number of candidate genes for possible de novo inheritance was too great to be 
informative. De novo mutations have previously been discovered in other conditions using 
proband/parent trios [318], but did not prove possible in this case.  
In both conditions, the lack of large pedigrees with autosomal dominant inheritance 
reduced the chance of identifying a new candidate gene. Additionally, I perhaps did not 
make the most parsimonious selection of samples to sequence, (e.g. sequencing a 
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parent’s DNA, only to later receive a grandparent’s DNA). Many families simply had too 
few individuals.  
8.4   Conclusion 
WES in four MODY families and six CHI families has enabled the discovery of two putative 
novel candidate genes. Finding new genetic causes of disorders of insulin secretion is 
important as it provides new biological insights into human pancreas development and 
function as well as potentially providing novel therapeutic targets - with important treatment 
implications. 
 
 217 
 
9.0   Conclusions and future direction 
The work in this thesis has used two forms of MPS (targeted sequencing and WES) for 
multiple studies into two conditions involving defects in glucose-stimulated insulin 
secretion, MODY and CHI. These have included:  
1. Determining the prevalence of MODY in a paediatric diabetes population;  
2. Estimating the cost-effectiveness of genetic screening for MODY; 
3. Evaluating the robustness of WES for gene screening in CHI and MODY; 
4. Detecting novel variants in known MODY and CHI genes; and  
5. Identifying potential novel genes involved in glucose-stimulated insulin secretion.  
 
Determining the prevalence of MODY in a paediatric diabetes population  
The prevalence of MODY variants in a paediatric diabetes population using targeted MPS 
(Chapter 3) was estimated to be 2.1%. This is the only prevalence study to date that 
includes all cases of paediatric diabetes, including those who would typically be excluded 
from testing (e.g. cases with a presumed clinical diagnosis of T1DM or T2DM). This 
estimate is likely to be conservative as it is likely that some of the variants classified as 
VUS will prove to be pathogenic; indeed VUS were enriched in our diabetes population 
compared to the control cohort, suggesting a role for some/many of these variants. 
Furthermore, only two-thirds of the population were sequenced and there were substantial 
differences in ascertainment for the different cohorts (e.g. percentage of T2DM sequenced 
vs Ab- T1DM sequenced), which could affect the final prevalence.  
The main challenge in this study was to establish pathogenicity of identified variants, both 
for VUS but also for variants classified as pathogenic/likely pathogenic. The ability to 
determine pathogenicity for VUS is problematic, although not specific to MPS.  However, 
the issues related to variants classified as pathogenic/likely pathogenic have some 
difficulties specific to the disease in question. Firstly, variants previously associated with 
MODY may not be pathogenic in each case. Many MODY variants have delayed or 
reduced penetrance. This is clearly demonstrated by the over-representations of some 
MODY variants in exome databases, exceeding the rate of MODY in the general 
community, even for variants with strong functional evidence of pathogenicity. In Chapter 
7.6, I identify varied penetrance of an ABCC8 variant, with two carriers having very 
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mild/absent disease. Secondly, it is possible that individuals with diabetes may have a 
MODY variant that is not penetrant in their particular case, and truly have T1DM or T2DM: 
in such cases insulin withdrawal may be ineffective and dangerous, particularly in T1DM. 
Thirdly, individuals may have both MODY and T1DM or T2DM; the additive effect of the 
additional diabetes subtype on the overall phenotype is an interesting area for future 
research. 
Thus my future plans will be to examine in greater detail patients previously diagnosed as 
T1DM or T2DM but with a MODY variant. Most MODY mutations are private [67] so 
assessing pathogenicity of any particular variant requires a case-by-case approach. Even 
MODY variants known to be pathogenic (according to the ACMGG criteria) may not be 
pathogenic in each individual carrying that variant. Thus I will determine if the identified 
variant segregates with diabetes in the family. This requires a de-novo variant, or 
sufficiently distantly-related family members to be sequenced. Frequently in clinical 
practice, segregation is only assessed in the parent or other first degree relative. However, 
this is insufficient, as an individual will inherit 50% of their variants from that parent. Thus it 
insufficient to prove the variant segregates with diabetes other than by chance. For every 
meiosis separating family members, 50% of the DNA is shared. Thus parents or siblings 
will share 1:2 of their DNA; second cousins share 1:32 of their DNA, which would allow a p 
value of <0.05 if the disease segregated with the variant. Furthermore, adding additional 
relatives can improve the statistical significance.  
The primary reason to diagnose MODY is to recognise individuals who can cease insulin 
and commence sulphonylureas, which is life-changing for the child and their family, but not 
without significant risk if the diagnosis is not robust. The most parsimonious method to 
assess this would be to commence sulphonylurea therapy whilst withholding/reducing 
insulin. This will at the discretion and under the direction of their treating endocrinologist. 
The safest method is likely to involve removing bolus insulin whilst continuing/reducing 
basal insulin. Individuals who respond to sulphonylurea therapy, appear to be very 
sensitive and are obvious fairly soon [331]. However there is a significant risk of worsening 
metabolic control and ketoacidosis if the individual does not respond and is not monitored 
closely. Conversely, there is a risk of hypoglycaemia in those who do respond, in whom 
insulin was not ceased or reduced appropriately. Thus this would only be done under close 
supervision from their clinician, either as an inpatient or an outpatient. 
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In an ideal situation with a novel variant or variant of unknown significance, I would create 
a mutational construct and undertake functional analysis of the variant. However, given the 
proportional of MODY mutations that are private mutations and the number of variants 
without functional data, this is not fiscally viable. Once we have assessed segregation and 
any clinical response in those with a mutation in a gene known to be sensitive to 
sulphonylureas, we will be better placed to assess the prevalence of MODY in this 
population, as opposed to MODY variants. All other studies of prevalence have assessed 
for variants, and not reported whether these variants do segregated with diabetes in their 
families. So this would provide a unique set of follow up data. 
 
Estimating the cost-effectiveness of genetic screening for MODY  
I have also shown that it is cost-effective to screen paediatric patients for MODY using 
targeted MPS (Chapter 4). Our data are based on some assumptions; primarily that the 
pathogenic/likely pathogenic variants identified in the prevalence study all result in a 
clinical diagnosis of MODY, and that no VUS cause MODY. Once we have clinically 
assessed all the individuals in the prevalence study population, we can revise the 
prevalence figure. However, it is important to note our study retained a cost-saving down 
to a prevalence rate of 1.1%, as demonstrated in the sensitivity analysis (Figure 4.2). We 
will also be able to comment more fully on the rate of successful transition to 
sulphonylureas, albeit in a relatively small sample size. 
A cost-effectiveness study for another form of monogenic diabetes, neonatal diabetes, has 
altered clinical management of neonatal diabetes world-wide [25]. Greely et al. found 
genetic testing not only improved quality-adjusted life years, but was cost-saving. Based 
on their study, it is now recommended all children who present with diabetes aged <6 
months have genetic testing for the two most common neonatal diabetes genes. The 
findings from our study support a similar change in practice for MODY as MPS becomes 
more widely available.  
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Evaluating the robustness of WES for gene screening in CHI and MODY  
I demonstrated WES can accurately detect mutations that cause MODY and CHI in a proof 
of concept study (Chapter 6). This study however did highlight some technical aspects that 
need consideration when utilising WES to screen for clinical disorders. Firstly, WES 
technologies do not necessarily target the whole exome. Each “off the shelf” exome 
capture targets different regions of the genome. A priori assessment of the targeted 
regions of the capture technology compared to the genes/exons of interest is required 
before choosing a particular capture technology. Secondly, not all the regions targeted by 
each technology will be captured. Thirdly, in addition to SNPs and indels, WES was able to 
detect copy number variants (CNV) using additional bioinformatic tools. This can be 
performed using programmes that assess differences in depth of coverage (e.g. 
ExomeDepth), as demonstrated in Chapter 6.  
During the course of this thesis, these technologies have moved from purely research 
tools to clinical use. Yet this work demonstrates many potential issues with respect to the 
utility of these technologies, including variable capture, in particular for WES. This has 
implications in the use of WES for diagnostic purposes. While WES capture technologies 
are evolving and improving rapidly, targeted MPS may prove a more reliable technology 
for diagnostic purposes with greater depth of coverage, fewer “gaps” in coverage, and a 
lower cost per sample. With fewer variants to assess, targeted sequencing requires less 
computational and analysis time and generates less data to be stored and analysed than 
WES. However, targeted sequencing panels need to be re-designed and re-tested with 
each gene identified. As of 2016, there were 13 commonly acknowledged genes 
responsible for MODY. In early 2017 Patel et al. reported three families with MODY 
caused by RFX6 mutations [105]. In our prospective proof of concept study (Chapter 7), I 
was able to re-analyse our WES data and identify a family with MODY with a mutation in 
RFX6. This would not have been possible with targeted sequencing. However, target and 
capture of WES have improved in the last few years, and the entire exome may soon be 
more reliably captured using WES. 
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Detecting novel variants in known MODY and CHI genes 
Despite the caveats mentioned above, WES is a useful means of gene testing for MODY 
and CHI, as demonstrated by my identification of novel variants in several families. 
 
Identifying potential novel genes involved in glucose-stimulated insulin secretion  
In addition to mutation screening for diagnostic purposes, WES can be used for new gene 
discovery. WES has accelerated the pace of gene discovery in Mendelian disorders. The 
agnostic approach to data analysis has identified new genes in hitherto unknown 
pathways. The discovery of these new genes has 1) improved understanding of 
pathophysiology, 2) extended the clinical phenotype, and 3) therapeutic implications. I 
identified KNCK16 as a possible new MODY gene in one family. Vierra et al. described a 
mouse model with a gain-of-function variant in this gene that had a similar phenotype to 
our family [323]. We are currently working with a collaborator with experience in KCNK 
channels to assess the structure and function of this channel and the channel with this 
variant. We are also planning to approach other centres with exome data for MODY 
individuals to determine if there are other individuals with MODY and a KCNK16 variant to 
add to the evidence for pathogenicity. This channel does not respond to the usual stimuli 
of the KATP channels of the islet cell. The discovery of a new gene may lead to new 
medications for this specific subtype of diabetes, and may be generalizable to other forms 
of MODY or diabetes.  
I have also identified a possible new gene in CHI, AGAP2. This gene was identified in two 
families, not known to be related, both with a dominant form of CHI. Functional information 
from knock-out mouse models suggest the primary mechanism for this gene is to alter 
insulin sensitivity rather than insulin secretion [329]. If functional work proves this gene is 
pathogenic in CHI, it would suggest a new mechanism for CHI and raise the possibility for 
potential novel therapeutic approaches. 
Final conclusions 
While MPS has translated successfully from a purely research tool onto clinical diagnostic 
laboratories, there remain many challenges. The primary challenge is of interpretation of 
MPS results: specifically with regard to the sensitivity and specificity of the test. 
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Interpretation of negative findings requires understanding of how the test performs with 
respect to robust identification of SNPs and indels, and its ability to detect larger structural 
variants. Interpretation of positive findings requires recognition of the difficulty ascribing 
pathogenicity to any variant; this issue is not unique to MPS but does have some specific 
implications in MODY. Nonetheless, MPS has allowed more cost-effective and efficient 
means of genetic diagnosis which has facilitated the individualisation of management. 
MPS, especially WES, currently provides the most effective and efficient method for new 
gene discovery and has revolutionised genetic discovery in the last decade [332]. 
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10.2   Web resources 
1000 Genomes: http://www.1000genomes.org/ 
46Genomes from Complete Genomics: 
http://www.completegenomics.com/sequencedata/download-data/ 
Agilent SureSelect: https://earray.chem.agilent.com/suredesign/index.htm 
ANNOVAR: http://www.openbioinformatics.org/annovar/ 
 Bcl2fastq: 
https://support.illumina.com/downloads/bcl2fastq_conversion_software_184.html 
Bioconductor package TxDb.Hsapiens.UCSC.hg19.knownGene: 
http://www.bioconductor.org/packages//2.10/data/annotation/html/TxDb.Hsapiens.UCSC. 
hg19.knownGene.html 
Cartagenia: http://www.agilent.com/en/products/software-informatics/bioinformatics-
(cartagenia) 
CASAVA - http://www.illumina.com/software/genome_analyzer_software.ilmn 
CLC bio: https://www.qiagenbioinformatics.com/products/clc-assembly-cell/ 
Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center 
for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: dbSNP137): 
http://www.ncbi.nlm.nih.gov/projects/SNP/ 
 DINDEL: http://www.sanger.ac.uk/resources/software/dindel/  
Exome Aggregation Consortium (ExAC): http://exac.broadinstitute.org/ 
GATK: http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit 
Human Gene Mutation Database: http://www.hgmd.cf.ac.uk/ac/index.php 
Human Splicing Finder: http://www.umd.be/HSF/ 
Integrative Genomics Viewer http://www.broadinstitute.org/igv/ 
Illumina TruSeq: 
http://support.illumina.com/sequencing/sequencing_kits/truseq_exome_enrichment_kit/do 
wnloads.ilmn 
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Leiden open variation database: http://www.lovd.nl/3.0/home 
MutationTaster: http://www.mutationtaster.org/ 
Nextera Rapid Capture Exome Targeted Regions 
http://support.illumina.com/downloads.ilmn 
Nextera Rapid Capture Expanded Exome Targeted Regions 
http://support.illumina.com/downloads/nextera_rapid_capture_expanded_exome_targeted 
_regions_manifest_bed.ilmn 
NHLBI Exome Sequencing Project: http://evs.gs.washington.edu/EVS 
Nimblegen: http://www.nimblegen.com/products/seqcap/ez/v3/index.html 
Novoalign alignment tool: www.Novocraft.com 
Novosort: http://www.novocraft.com/novosort-v1-03-05-released/ 
Online Mendelian Inheritance in Man (OMIM): http://www.omim.org 
Package hapFabia - Bioconductor:  
http://www.bioconductor.org/packages/2.11/bioc/html/hapFabia.html 
Picard tools (v1.42): http://picard.sourceforge.net 
PolyPhen: http://genetics.bwh.harvard.edu/pph/ 
Primer3: http://bioinfo.ut.ee/primer3-0.4.0/ 
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/ 
SAMtools: http://samtools.sourceforge.net 
SIFT: http://sift.jcvi.org/ 
STRING: http://string-db.org 
UCSC genome browser: http://genome.ucsc.edu 
UK10K project: http://www.uk10k.org 
Unigene: www.ncbi.nlm.nih.gov/UniGene/ 
UniProt: http://www.uniprot.org/uniprot/ 
